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Abstract
HBPl (HMG box containing protein 1) is a member of the high mobility group 
chromosomal proteins. The HMG box contained in this protein binds DNA in a 
sequence specific manner and other domains in the protein allow its participation in 
protein-protein interactions that can have profound effects in the regulation of 
chromatin structure and, as a consequence, gene expression, proliferation and 
differentiation programmes. The protein also contains a novel domain called AXH 
that is also present in Ataxin-1 (ATX1), a human protein responsible for 
spinocerebellar ataxia type 1. The function of the AXH domain is unknown.
An initial study to define the function of the AXH domain was to measure its 
structural properties and stability. This was achieved by producing protein constructs 
spanning the AXH modules of ATX1 and HBPl and comparing their properties. This 
led to the identification of the minimal region sufficient for forming independently 
folded units (domains). It was also shown that the AXH of ATX1 contains a 
dimerization domain whereas the AXH of HBPl stays as a monomer.
In order to define the subcellular localisation of HBPl the protein was tagged with 
enhanced yellow fluorescent protein (EYFP) and expressed in HEK293 cells. 
Subcellular localization of the respective fusion proteins was analyzed by direct 
fluorescence microscopy. EYFP-tagged wild type HBPl was located exclusively in 
nuclei, while EYFP alone was equally distributed throughout the cells. To identify the 
NLS, several HBPl deletion mutants were tagged with EYFP. Mutant HBPl that 
contained only the HMG box also localized exclusively in nuclei, while the deletion
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of the HMG box resulted in the loss of preference for nucleus. These results indicate 
that HBPl is a nuclear protein and that the NLS is located within the HMG box of 
HBPl.
To assess the function of HBPl, standard gene-targeting techniques were used to 
produce a mouse in which the exons coding for the HMG box, an essential region of 
HBPl, is flanked by loxP sites (floxed), so that this domain can be deleted specifically 
at will by directing the expression of Cre in a tissue specific manner.
Using the above strategy two mouse lines were generated: one carrying HBPl alleles 
with floxed HMG box coding exons to be used in conditional deletion studies and one 
with a constitutive deletion of these exons (AHMG). Furthermore, we generated two 
Cre transgenic mice lines that allow the deletion of floxed gene segments either only 
in the lymphoid compartment (hCD2-iCre) or in the entire haematopoietic 
compartment (Vav-iCre). Crossing these Cre transgenic lines to mice carrying the 
floxed alleles will allow the inactivation of genes only in certain tissues so that 
biological questions can be answered with increased specificity.
Mice homozygous for the gene deletion (HBPlAHMG/AHMGmice) were viable, fertile, 
and have normal numbers and percentages of haematopoietic lineages. However, T 
lymphocytes from HBP1ahmg/ahmg animals proliferate at a significantly higher rate in 
response to anti-CD3 in vitro. Initial experiments indicate that the increased 
proliferation by HBP1ahmg/ahmgT lymphocytes might be due to the fact that the cells 
are in a "poised for activation" state and, thus, predisposed for immediate response to 
stimulation.
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Introduction
Introduction
Differentiation follows a common path in many different tissues and cell types. 
Expression of early differentiation markers is the first sign that precursor cells are 
undergoing a particular differentiation program. At the time of the cell exit, 
differentiating cells begin to induce expression of late tissue specific genes. 
Morphological changes can follow until fully differentiated phenotype is acquired.
The differentiation process has been described in detail for many tissue types both in 
vivo and in vitro. These descriptions include cascades of gene induction and or 
repression and the morphological changes.
The orderly progression through all the differentiation steps is regulated at the 
molecular level. The early differentiation genes expressed in committed precursors are 
in most cases tissue specific transcription factors required for activation for later 
genes that are essential for full differentiation or repression of genes that were 
essential for the precursor but incompatible with full differentiation. The regulation of 
the factors is a very complex process requiring the coordination of different cellular 
pathways and molecular events. The interaction between trans-acting transcription 
factors and other protein co-factors with cis linked locus regulatory sequences 
represents the final level of gene activation or repression; that is, the assembly of a 
complete transcription or repressor complex. Many other events levels of control
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precede these terminal events in the hierarchy of gene regulation, including cell cycle 
stage, integration of various extra-cellular signalling and signal transduction pathways 
and the physical state of a chromatin domain.
The retinoblastoma tumour suppressor protein pRB, and the closely related p i07 and 
p i30 proteins play important roles in many stages of differentiation process, including 
regulation of clonal expansion, cell cycle exit, induction of tissue specific gene 
expression and maintenance of the post mitotic state. pRB appears to regulate terminal 
exit from mitosis through at least two distinct mechanisms. The first follows directly 
from its role in regulating of the cell cycle and involves the repression of E2F 
transcriptional activity. The second is unique to the differentiation process and results 
from interaction with, for instance, HMG box containing protein 1 (HBPl), a factor 
that plays a role in cell cycle exit.
Mechanisms that inhibit cell cycle progression and establish growth arrest are 
fundamental to tumour suppression and to normal cell differentiation. This thesis will 
focus on the role of HBPl in development, differentiation and cell cycle progression 
using a mouse model.
The introduction of this thesis will follow the same lines as described above. In the 
first part of this thesis, the haematopoietic development will be described as model for 
differentiation. The next part focuses on the molecular events underlying 
differentiation, such as the regulation of gene activation and repression. The cell cycle 
will be briefly described, followed by a description of the retinoblastoma tumour 
suppressor family and their function in the control of cell cycle progression and
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differentiation. Finally, the introduction will focus on HBPl and associated partners 
and their roles and gene expression, cell cycle regulation and differentiation. A brief 
description on the gene targeting tools used for the work on HBPl will also be given.
Development o f the immune system
Haematopoietic stem cells (HSCs) are cells, which possess the properties of both self­
renewal and multi-lineage potential for giving rise to all types of mature blood cells 
(see figure 1). Early HSC development displays a hierarchical arrangement starting 
with HSCs, which have extensive self-renewal capability. Next is the expansion stage, 
corresponding to proliferative multi-potent progenitor (MPP) or short term HSCs. 
MPP is also a stage of priming or preparation for differentiation. MPP then commits 
to either common lymphoid progenitor cells (CLP), which give rise to all the 
lymphoid lineages, or common myeloid progenitor cells (CMP), which produce all the 
myeloid and erythroid lineages. It is controversial whether this is the only pathway for 
lymphocyte development. Lineage determination of a differentiating stem cell may 
not be as rigidly defined as the above model predicts and committed progenitors may 
trans-differentiate when subjected to variety of micro-environmental regenerative 
cues (Blau et al., 2001).
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Figure 1: Model of major haematopoietic maturation pathways from HSC.
Long Term Haematopoietic Stem Cell (LT-HSC) gives rise to Multi-Potent 
Progenitor (MPP) or short term HSCs. The MPP give rise to Common Lymphoid 
Progenitor (CLP), which can form all cells of the lymphoid lineage, and Common 
Myeloid Progenitor (CMP), which can differentiate in either Granulocyte Monocyte 
Progenitor (GMP) or Megakaryocyte Erythrocyte Progenitor (MEP), which form the 
cells of the granulocyte/macrophage or megakaryocyte/erythroid lineages, 
respectively. From the CMP both B and T cells can be derived. The figure shows the 
timing in both lineages of checkpoints at which the population undergoes rigorous 
selection that eliminates many or most of the developing cells (Checkpoints 1 & 2) 
based on properties of their antigen receptor gene products. In the T-cell pathway, 
Double Negative (DN) Pro-T cells turn on both CD4 and CD8 to become a double 
positive (DP) Pre-T cell but ultimately down regulate one or the other if they succeed 
in passing checkpoint 2. Expression of CD4 and CD8 is mutually exclusive and stable 
thereafter.
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The main difference between the CLP and the CMP is the expression of interleukin-7- 
receptor (DL-7R), CLPs express the IL7R on the cell surface while this receptor is 
absent on CMPs (Sudo et al., 1993). The exact mechanism of what makes a HSC 
commit to either CLPs or CMPs is still unknown. However, key transcription factors 
that regulate this process have been identified. CMPs have been shown to express 
important transcription factors, for instance GATA-1, while these genes are 
completely repressed in CLPs which in turn express other transcription factors such as 
Aiolos and GATA-3 (Akashi et al., 2000). Furthermore, the transcription factor 
IKAROS has been shown to be essential for the development of lymphocytes 
(Georgopoulos et al., 1992).
The commitment of CLPs to either the B or T cell lineage depends on the trans­
membrane receptor Notch-1. A model proposed by Bussinger et al. is based on the 
assumption that Notch-1 is expressed on all CLPs (Busslinger et al., 2000). The 
thymic environment contains Notch-1 ligands and upon migration to the thymus, the 
model proposes that CLPs will be subjected to Notch-1 activation, inducing the 
progenitors to develop along the T-cell lineage. However, there are no Notch-1 
ligands in the bone marrow and hence the CLPs cannot be activated through the 
Notch-1 receptor. The absence of Notch-1 therefore allows the CLPs to differentiate 
to the B cell lineage and up regulate B cell specific transcription factors E2A and EBF 
which in turn activate Pax5 which represses certain genes and thereby commits the 
cells to the B cell lineage (Busslinger et al., 2000).
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B and T lymphocytes undergo developmental pathways that resemble each other in 
many respects. Both B and T cells express clonally unique cell surface antigen 
receptors. These receptors are encoded by genes that are assembled by a 
developmentally programmed mechanism of DNA rearrangements. Antigen receptor 
(immonuglobin [Ig] for B cells or T cell receptor [TCR] for T cells) gene 
rearrangement process is controlled by expression of the recombinase genes RAG1 
and RAG2 on both T and B cells. During lymphocyte development the developing B 
or T cell is subjected to several checkpoints. At these checkpoints most cells are 
eliminated and the few successful will proliferate strongly. The rearrangement of the 
gene encoding for the first chain of the antigen receptor forms the first checkpoint. All 
the cells in which the rearrangement was successful will proliferate and pass to the 
next checkpoint. At this checkpoint the functionality of the antigen receptor is 
determined. Only cells with an antigen receptor with an appropriate recognition 
specificity to be useful for the immune system will be allowed to become functional T 
or B cells. The developmental stages of the developing lymphocytes can be measured 
by the expression of certain cell surface markers.
Gene regulation
From the above it is clear that during lymphocyte differentiation specific transitions in 
gene expression are necessary for full differentiation. Gene expression in eukaryotes 
is regulated primarily at the level of transcription (Latchman, 1997). The level of 
transcription for many genes important for cell proliferation and differentiation is 
regulated in turn at the chromatin level. In this chapter a description of chromatin will
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be given and how packaging by chromatin influences gene transcription. The key 
proteins and sequence motifs that facilitate in these transitions between chromatin 
states will also be described. In the last part of this chapter studies on the regulation of 
hCD2 locus will be described as an example of a gene expressed during 
haematopoiesis.
Chromatin
In eukaryotes, genomic DNA is packaged by histones and non-histone proteins into 
chromatin. The histone proteins fall into five major classes HI, H2A, H2B, H3 and 
H4. Each histone class includes some gene variants or subtypes and is likely to 
provide tissue specific and developmental stage specific variation of the chromatin 
structure (Doenecke et al., 1997). Histones are an essential part of the fundamental 
repeating unit of chromatin: the nucleosome. The nucleosome core contains about 147 
bp of DNA and two copies each of the histones H2A, H2B, H3 and H4. The 
additional linker DNA that connects the nucleosome cores is of variable length. The 
nucleosome core, linker DNA and histone HI make up the complete nucleosome that 
can be visualized with electron microscopy as the classic “beads on a string” 
appearance (figure 2). However, this is only the first step in the compaction process 
that the DNA undergoes to fit in the nucleus. The next step in higher order chromatin 
structure is the so called 30nm fibre which is made when the “beads on a string” 
winds into a regular coil (figure 2). Linker histones, non-histone proteins and potential 
interactions of core histone N-terminal tails with adjacent nucleosomes contribute to
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this compaction of nucleosomal DNA. In the interphase nucleus two types of higher 
order structures can be distinguished; the highly condensed regions referred to as 
heterochromatin and the less condensed/decondensed regions referred to as 
euchromatin. Finally, the highest level of packaging occurs in the M phase of the cell 
cycle when the fibre is organized in loops and domains that compact the DNA by 
more than 10,000 fold. These can be visualised as chromosomes (figure 2).
It is thought that dynamic changes in chromatin structure facilitate or prevent the 
access of transcription factors to nucleosomal DNA, which in turn affect the 
expression of genes. Inaccessibility of a region to the transcriptional machinery, will 
lead to silencing of the genes that lie within this region. For transcription to proceed 
the structure of chromatin has to be unfolded and inaccessibility be overcome. At least 
two mechanisms can be used to alter or remodel chromatin structure. One mechanism 
involves multi-subunit protein complexes that use ATP as a source of energy, which 
alter chromatin structure by changing the location or conformation of the nucleosome 
(Becker and Horz, 2002). These structural changes are accomplished without covalent 
modification, and can be involved in either activation or repression (Varga-Weisz,
2001). A second mechanism involves covalent modifications either of DNA (Bird and 
Wolffe, 1999) or of histone N-terminal tails that protrude from the core nucleosome 
(Zheng and Hayes, 2003). In the following paragraphs, both kinds of modification 
will be discussed. It has to be noted however that both types of modification appear to 
work in concert in order to establish or maintain chromatin in either an active or silent 
state.
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Figure 2: Chromatin structure
The eukaryotic chromosome exhibits many levels of chromatin compaction, starting 
with the repeating nucleosomal unit, which wraps DNA on the surface of the histone 
octamer, and ending with the highly condensed and folded structure that characterizes 
the mitotic chromosome. (Adapted from Alberts et al. (1998), Essential Cell Biology)
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ATP dependent chromatin remodeline
ATP dependent chromatin remodelling complexes can be involved in nearly every 
step of gene regulation. They can regulate key steps in transcriptional activation 
before, during, and after assembly of the pre-initiation complex (Fry and Peterson,
2002). The pre-initiation complex, containing RNA polymerase II and other general 
transcription factors, is assembled at the target gene promoter prior to transcription. 
Besides transcriptional activation ATP dependent chromatin complexes can also be 
involved transcriptional repression by setting up inaccessible chromatin structures at 
promoters.
Many different ATP-dependent chromatin remodelling complexes have been 
identified which alter nucleosome structure or positioning. These factors have been 
separated into two families that are defined by the different features of their ATPase 
subunits. The TSWI’ family of complexes all contain an ATPase related to 
Drosophila ISWI protein, whereas the “SWI/SNF’ family of complexes all contain a 
protein related to the yeast protein Swi2/Snf2 (Narlikar et al., 2002; Varga-Weisz, 
2001). These families of complexes both function as classic enzymes and use the 
energy of ATP hydrolysis to lower the activation barriers between different 
nucleosomal states (Varga-Weisz, 2001 2). These chromatin states might differ in 
either the position of nucleosomes and/or the conformation of the nucleosome. 
Whether the altered nucleosome structure is transcriptionally active or inactive 
depends on the transcription factors that target these ATP-dependent chromatin
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remodelling complexes to the DNA. If transcriptional repressors are involved, the 
remodelling complexes will change the chromatin conformation into a repressed state. 
Conversely, involvement of transcriptional activators will change the chromatin 
conformation to an active state.
Covalent chromatin modifications
Covalent modifications can take place on the DNA itself or on the histone tails. Both 
can have profound effects on gene expression and DNA modifications will be 
discussed first followed by the modifications on the histone tails.
DNA methylation
DNA can be methylated at position 5 of cytosine within CpG dinucleotides, a 
modification that is associated with transcriptional repression; this methylation 
influences chromatin structure and as a consequence gene activity (Bird and Wolffe,
1999). This modification is carried out by methyltransferases (DNMTs). Sequences 
that include methylcytosines are specifically recognized by Methylcytosine Binding 
Proteins (MBPs), such as MeCP2 and MBPs 1/2/3. These proteins have been shown 
to be transcriptional repressors (Bird and Wolffe, 1999). MECP2, the best studied 
MBP, will be described as an example of how MBPs can function. MECP2 contains 
two domains: the methyl-CpG binding domain, which recognizes a methylated-CpG 
dinucleotide through contacts in the major groove of the double helix and a
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transcriptional repression domain, which interacts with the SIN3 complex. The SIN3 
complex contains two histone de-acetylases and two histone-binding proteins 
(Ahringer, 2000). This led to a model that predicts that MeCP2 is recruited to 
methylated regions of the genome where its interactions with a protein complex 
containing Sin3 and histone de-acetylases lead to the establishment and maintenance 
of repressive chromatin architecture (Bird and Wolffe, 1999).
Histone tail modification
Histone tails can be modified in several ways, including acetylation, methylation 
ubiquitination and phosphorylation. In the following paragraphs, these modifications 
will be described briefly.
Acetylation
The acetylation status of lysine residues in the core histone tails is under control of 
nuclear Histone Acetyl-Transferases (HATs) and of Histone De-acetylases (HDACs). 
Several mammalian HATs and HDACs have been characterised to date. These 
enzymes frequently targeted the highly conserved histone H3 lysines at amino- 
terminal amino-acid positions 9, 14, 18 and 23, and H4 lysines 5, 8, 12 and 16 for 
modification (Roth et al., 2001). A general correlation between histone acetylation 
and gene activity in vivo is now well established, although there are some exceptions 
(Eberharter and Becker, 2002). Lysine acetylation results in an altered charge density
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of the tail domains. Neutralization of the positive charge of lysine residues by 
acetylation is thought to weaken the interactions between the histone tails and the 
negatively charged DNA backbone leading to a “looser” or more “open” chromatin 
configuration for the entry for transcription factors (Morales and Richard-Foy, 2000). 
It also provides a binding site for bromo domains that can recognize acetyl-lysine 
(Zeng and Zhou, 2002). Bromo domains are found in several eukaryotic transcription 
factors, including most nuclear histone HATs (Jeanmougin et al., 1997) and all known 
SWI/SNF-like complexes (Horn and Peterson, 2001). Thus, lysine acetylation in the 
tails of histones has been associated with actively transcribed or poised chromatin; the 
binding of bromo domains to the acetylated lysines allows the anchoring of HATs and 
other co-activators onto active chromatin.
Methylation
There are two types of histone methylation, targeting either arginine or lysine residues 
within the tails of histone H3 or H4. Methylation of histones by arginine 
methyltransferases has been known for some time, but has been validated only 
recently as a functional event involved in gene activation. A breakthrough came when 
arginine methyltransferase CARM1 was shown to activate transcription via 
methylation of Histone H3 (Chen et al., 2002). Furthermore, estrogen-responsive gene 
expression was aberrant in Carml7' fibroblasts and embryos, thus emphasizing the 
role of arginine methylation as a transcription activation tag (Yadav et al., 2003).
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Methylation of histones on lysine residues has also been implicated in gene 
regulation. The lysines at the fourth (K4) and ninth (K9) positions on the tail of the 
histone H3 can regulate gene expression when a methyl group is added to these two 
positions. Generally, the methylation of H3K4 correlates with gene expression but 
exceptions to this model have been described (Sun and Allis, 2002). Stretches of 
chromatin in which histone H3 is methylated on position nine (H3K9) correlates with 
transcriptional repression by establishing regions of transcriptionally inert 
heterochromatin (Lachner and Jenuwein, 2002). This idea is supported by several 
recent discoveries. Methyltransferases SUV39 (mammalian homologue of Drosophila 
Su(var)3-9), that specifically methylates histone H3K9, associates with the 
heterochromatin protein HP1. HP1 is a conserved chromosomal protein that 
participates in restrictive chromatin packaging and gene silencing (Kouzarides, 2002; 
Zhang and Reinberg, 2001). Based on these findings, mechanisms for 
heterochromatin spreading have been proposed, involving recruitment of SUV39 by 
HP1 and propagation of the methylated mark along the chromosome via methylation 
of histone H3K9.
Phosphorylation
Histone phosphorylation involving serine residue position 10 of histone H3 (H3S10) 
has also emerged as an important modification, both in transcriptional activation and 
in chromosome condensation during mitosis (Cheung et al., 2000). Further studies 
suggest that phosphorylation of H3S10 facilitates acetylation of H3K9 and/or H3K14
16
(Cheung et al., 2000) whereas H3S10 phosphorylation is suppressed if methylation of 
H3K9 occurs first (Rea et al., 2000).
Ubiquitination
Recent developments indicate that histone ubiquitination is another important 
modification. In yeast Saccharomyces cerevisiae, for example, addition of ubiquitin 
on H2BK123 is critical to mitotic and meiotic cell division (Shekhar et al., 2002). 
Moreover, recent studies in yeast show that ubiquitination of histone H2B controls the 
outcome of methylation of H3K4. The pathway described here results in 
transcriptional silencing (Sun and Allis, 2002), even though H3K4 methylation is 
generally regarded as an activation mark for chromatin remodelling.
Cis acting sequences
The above described chromosomal modifications do not happen randomly in the 
genome, but are targeted to certain regions which are determined by their nucleotide 
sequences. In the next paragraph, some of these cis acting sequences/regions will be 
described.
Eukaryotic genes are arranged into coding and non-coding DNA sequences, exons 
and introns respectively. In addition to the protein coding DNA, other important 
extra-genic DNA sequences are present which are involved in gene regulation. The
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three main types of regulatory sequences that have been defined are promoters, 
enhancers and silencers, but additional elements exist, such as boundary elements and 
Locus Control Regions (LCRs). All these elements mediate their function by binding 
protein factors that recognise specific DNA sequences. The presence of a factor 
combined with its specificity for certain regulatory elements ensures the differential 
expression of genes in different cell types and developmental stages.
The gene promoter
The core promoter is defined as the minimal stretch of contiguous DNA sequence that 
is sufficient to direct accurate initiation of transcription by the RNA polymerase II 
machinery (Butler and Kadonaga, 2002). Core promoters comprise DNA sequence 
motifs within 40 nucleotides upstream and downstream of the RNA start site that, in 
the appropriate combinations, are sufficient to direct transcription initiation by the 
basal RNA polymerase II transcriptional machinery (Butler and Kadonaga, 2002). 
RNA polymerase II is a multi-subunit enzyme that catalyzes the synthesis of mRNA 
from the DNA template (Butler and Kadonaga, 2002). Accurate and efficient 
transcription from the core promoter requires the polymerase along with auxiliary 
factors that include (TF)IIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH (Butler and 
Kadonaga, 2002). In the stepwise RNA polymerase II complex assembly TFIID and 
TFIIB are the first two factors that interact with the core promoter (Butler and 
Kadonaga, 2002).
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Enhancers and Silencers
Transcriptional enhancers are DNA sequences that control expression of nearby genes 
in a positive manner (Blackwood and Kadonaga, 1998). The general mode of action 
of these sequences is that they associate with specific activator proteins; this 
association of enhancer and activator facilitates transcription initiation at the target 
gene’s promoter. Enhancers facilitate in the initiation of transcription through direct 
contact between the enhancer and promoter. Proof is this came when it was found that 
the DNase I hypersensitive sites of the p-globin locus (these contain the enhancers of 
the p-globin locus) and an active globin promoter are held in close physical proximity 
when the gene is transcribed (Carter et al., 2002). As yet, it is unclear how these loops 
are formed. It is possible that enhancer and promoter create a loop without interacting 
with the intervening DNA. It is also possible that components bound to the enhancer 
track along the chromatin towards a promoter that eventually results in a loop 
formation.
Enhancers might be located upstream, downstream or even within the transcription 
unit that they control and their action appears to be orientation independent 
(Blackwood and Kadonaga, 1998). Under the influence of one or more enhancers, a 
gene can be abundantly expressed in certain tissues of the organism (i.e., cells in 
which the activator protein is found) and weakly or not at all expressed in other 
tissues (Blackwood and Kadonaga, 1998).
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Silencers act similarly to enhancers in that they affect gene promoters from a distance 
in a position and orientation independent manner. However, the function of the 
silencer, as its name implies, is to down-regulate gene expression.
Boundary elements
Boundary elements or insulators are thought to separate chromatin into distinct units 
or domains with differential gene regulation (Bell and Felsenfeld, 1999). Boundary 
elements, when inserted between an enhancer and a promoter, can inhibit the 
enhancer from activating a promoter. The enhancer-blocking activity of boundary 
elements is clearly distinct from silencing, because it is strictly dependent on its 
position and occurs without repressing either the enhancer or the promoter (Bell and 
Felsenfeld, 1999). Furthermore, boundary elements have been described to insulate a 
transgene from position effects (Bell and Felsenfeld, 1999).
Factors affecting gene expression levels: Position effect variegation
The effects of the chromatin environment on gene expression is best seen when genes 
are translocated from their own normal location to a different chromosomal location. 
This is most often seen when transgenic animals are made (Kioussis and Festenstein, 
1997). Several factors conspire to make the expression patterns of transgenes highly 
unpredictable when transgenic animals are made. It is thought that these unpredictable 
expression patterns are caused by variations in the site of integration, the so called
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position effects, and that these variations are, at least in part, due to differences in the 
nature of the surrounding chromatin (Kioussis and Festenstein, 1997). These effects 
are exemplified by a phenomenon called Position Effect Variegation (PEV).
PEV can be defined as a position-dependent inactivation of gene expression in a 
fraction of a cell population of the same lineage (Henikoff, 1990). One of the best 
studied instances of PEV is a chromosomal rearrangement in Drosophila in which an 
allele of the white gene is transferred to a site close to the centromere (Wallrath and 
Elgin, 1995). After this translocation its previously uniform expression becomes 
“variegated,” producing patches of pigmented and unpigmented cells in the eye 
(Wallrath and Elgin, 1995). It is thought that a peri-centromeric location renders the 
gene susceptible to the variable spreading of heterochromatic condensation (Wallrath 
and Elgin, 1995). PEV has also been demonstrated in yeast (Allshire et al., 1994) and 
in mammals (Festenstein et al., 1996) for genes located within or near centromeres or 
telomeres.
Variegated expression has been observed in transgenes as well as in endogenous 
genes (Kleinjan and van Heyningen, 1998). As the expression level of a transgene is 
highly dependent on its integration site, which is not predetermined when transgenic 
animals are made, the forces leading to PEV can cause large and unpredictable 
variations in expression levels. In the case of mice, it has been reported that transgene 
integration into peri-centromeric regions is the most frequent inactivating process 
(Festenstein et al., 1996).
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Locus Control Region
In some remarkable cases transgenes are expressed in an integration-site independent 
manner (Grosveld et al., 1987). Attempts to identify the responsible elements for this 
protective effect have let to the discovery of locus control regions (LCR) (Grosveld et 
al., 1987). LCRs are operationally defined by their ability to enhance the expression 
of linked genes to physiological levels in a tissue-specific and copy-number 
dependent manner at ectopic chromatin sites (Grosveld et al., 1987). The components 
of an LCR commonly co-localize with sites of DNase I hypersensitivity (HS) in the 
chromatin of expressing cells (Li et al., 2002). The core determinants at individual 
HSs are composed of arrays of multiple ubiquitous and lineage-specific transcription 
factor-binding sites.
The existence of LCRs was first identified in the human P-globin locus (Grosveld et 
al., 1987). Evidence for the presence of an LCR came from transgenic mouse studies. 
Linkage of this region to a p-globin gene resulted in expression of the gene at a level 
comparable to the endogenous mouse P-globin genes in a position-independent, copy 
number-dependent manner (Grosveld et al., 1987). LCRs have been described in a 
broad spectrum of mammalian gene systems, suggesting that they play an important 
role in the control of eukaryotic gene expression (Li et al., 2002). In the following 
chapter, the studies on the hCD2 LCR will be described as a model of LCR function.
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Human CD2 Locus
The human CD2 molecule is expressed on virtually all T cells and thymocytes as well 
as NK cells. Human CD2 binds to the ubiquitous CD58 (LFA-3) cell surface 
glycoprotein, and through this receptor interaction, promotes the initial stages of T 
cell contact with antigen presenting cells (Springer, 1990) providing a mechanism for 
sustained TCR engagement and signalling and thereby optimizing T cell activation 
(Bierer et al., 1988). Indeed, CD2 is essential for the immune response against weak 
agonistic ligands (Sasada and Reinherz, 2001). Thus, CD2 sets a quantitative 
threshold for T cell activation. It has to be noted that the CD2 gene is diverged during 
evolution to recognize CD58 in humans and CD48 in rodents. The interaction with 
human CD2 and murine CD48 have not been demonstrated (van der Merwe et al., 
1994) indicating that human CD2 is inactive in a mouse model.
To study the mechanisms underlying CD2 expression transgenic animals were made 
with a 29.4 kb Kpn I fragment containing the human CD2 locus (figure 3A). This 
fragment contains 5.3 kb of DNA upstream from the 5’ end of the gene and 9.3 kb 
downstream from the second poly(A) addition site. Analysis of transgenic mice 
carrying the human CD2 29.4 kb Kpn I fragment showed that the levels of expression 
of the transgene was dependent on the copy number of the genes integrated into the 
mouse genome (Lang et al., 1988). These experiments showed that the hCD2 locus 
contains an element, which is capable of dominantly inducing changes in chromatin 
structure that are required for the expression of the genes, or alternatively, protect the 
gene from hetero-chromatinisation. As mentioned before locus control regions are 
functionally defined in transgenic mouse experiments as elements that give rise to full
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levels of expression of a linked transgene independent of the site of integration in the 
host genome (Grosveld et al., 1987). From this, it was concluded that the hCD2 locus 
contains a locus control region.
To identify further the sequences responsible for the copy number dependent 
expression, deletions were made in the 29.4 kb Kpn I fragment. Removal of sequences 
downstream of the second poly-adenylation site of the CD2, which left the promoter 
and gene intact, resulted in gene silencing. It was concluded that this 3’ region was 
necessary for the appropriate regulation of the expression of the CD2 gene (Greaves et 
al., 1989).
The 3’flanking sequences were further characterized by a range of deletions. 
Fragments covering 0.2,0.5, 1.1, 1.3, 1.5 and 2.1 kb of 3’ flanking sequences were 
made and linked to a hCD2 mini gene. This showed that the minimum sequences 
needed for copy number dependent and position independent expression are 2kb of 3’ 
flanking sequence (figure 3B) (Festenstein et al., 1996; Lang et al., 1991). It is 
reasonable to hypothesize that a number of regulatory proteins would bind to this 2kb 
fragment and that interactions between these regulatory proteins, leading to the 
formation of multi-molecular complexes, insures copy number dependent and position 
independent expression of the hCD2 locus. Thus, in order to characterize how an LCR 
functions it is of interest to identify the necessary regulatory proteins that would bind 
to this 2kb fragment.
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Figure 3: Human CD2 locus
A) The human CD2 locus is contained in a 29.4 kb Kpn I (K) fragment. This fragment 
contains 5.3 kb of DNA upstream from the 5’ end of the gene and 9.3 kb downstream 
from the second poly(A) addition site. Three identified HSS 3’ of the gene are 
indicated. The exons are indicated as black bars.
B) The hCD2 mini gene contains 5.5kb of the promoter region, the human CD2 gene 
with all but the first intron deleted and the minimal LCR, a 2.1 kb Hindlll (H) 
fragment 3’ of the poly (A) site). The LCR region contains a classical enhancer 
(HSS1) and a region without enhancer capacity but necessary for LCR function 
(HSS3).
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It is thought that multi-molecular complexes formed at the enhancer or promoter 
sequences result in the remodelling of chromatin at these points and in the formation 
of nuclease hypersensitive sites (HSS). Three clusters of such sites were identified 
within 2 kb of 3’flanking region of the hCD2 gene. Clusters HSS1 and HSS3 are 
shown in figure 3B (Festenstein et al., 1996; Greaves et al., 1989; Lang et al., 1991).
Within the 2kb of 3’flanking region the upstream HSS cluster of strong hypersensitive 
sites (HSS1) coincides with the region that functions as a classical enhancer, whereas 
the weak HSS2 and HSS3 have no activity in transient transfection assays (Lake et al., 
1990). The role of HSS3 was further investigated by generating transgenic mice 
carrying constructs lacking HSS3 (Festenstein et al., 1996). Removal of HSS3 
resulted in loss of position independence and led to mosaic expression rather than a 
general lower expression (Festenstein et al., 1996). This mosaic expression is thought 
to be the result of a stochastic process and once the decision is made to express or to 
silence the human CD2 transgene, it is maintained through subsequent cell divisions 
(Festenstein et al., 1996). The phenomenon is a typical example of position effect 
variegation (PEV) and is characterised by the ‘stochastic’ silencing of the hCD2 
transgene in a proportion of cells within the T cell lineage that would normally be 
expected to express it (Festenstein et al., 1996; Henikoff, 1990).
Non expressing cells show a closed chromatin configuration of the transgenic CD2 
locus as illustrated by a lack of DNase I hypersensitivity compared to cells that still 
express the human CD2 gene (Festenstein et al., 1996). Subsequently, it was shown 
that PEV of the disabled LCR constructs is sensitive to chromatin modifiers, like 
HPl-p, in a dose dependent manner. Thus, increased levels of HP1-P led to an
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increase in the proportion of cells that silence the variegating transgene. On the other 
hand, the expression of a hCD2 transgene containing the full LCR was not affected by 
different levels of HPl-p (Festenstein et al., 1999).
In summary, the hCD2 LCR consists of at least two distinct elements: a 
transcriptional enhancer and a region without enhancer activity necessary for 
preventing heterochromatin induced position effect variegation. The latter region is 
thought to prevent PEV by ensuring an open chromatin configuration, so that other 
factors can bind to the rest of the LCR and the promoter of the human CD2.
In order to identify components that participate in the chromatin structures formed in 
this region, protein bindings sites within HSS3 were mapped using DNase I footprint 
analysis (Zhuma et al., 1999). Using one of the identified HSS3 footprints (FT1) as a 
bait in a yeast one hybrid assay led to the isolation of HMG Box containing Protein 1 
(HBP1) (Zhuma et al., 1999). It was shown subsequently that HBP1 binds FT1 in a 
sequence specific manner (Zhuma et al., 1999). Deletion of the binding site of HBP1 
(FT1) from the hCD2 transgene results in its variegated expression when the 
transgene is integrated close to heterochromatic areas (Zhuma et al., 1999). Thus, it 
was concluded that HBP1 contributes to the hCD2 LCR function in preventing PEV. 
The contribution of HBP1 to the establishment of an active chromatin structure was 
confirmed by over-expression of a transgenic HBP1 in developing thymocytes. Thus, 
over-expressing HBP1 mice were crossed to a hCD2 variegating mouse line that has 
1.5 kb of the LCR. The 1.5 kb of the LCR still has the binding site for HBP1 (FT1), 
but is missing the rest of HSS3 and, thus, exhibits PEV. Over-expression of HBP1 in 
these hCD2 transgenic mice increases the number of cells that express hCD2
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compared to the transgenic mice with only endogenous levels of HBP1. Furthermore 
the variegation seen in transgenic mice lacking the FT 1 sequences was unaffected by 
HBP1 over expression. These results suggest that HBP1 activates the CD2 locus (B. 
Sekkali submitted for publication). It is unclear at the moment how HBP1 activates 
the hCD2 locus. HBP1 may promote an active hCD2 locus by binding to and bending 
the DNA, thus allowing DNA-protein and/or protein-protein interactions. It is also 
possible that the phenotype seen is through the recruitment of chromatin remodelling 
complexes by HBP1. HBP1 can interact with the retinoblastoma that, in turn, can 
interact with a SWI/SNF complex (van der Merwe et al., 1994). Thus, the initial 
binding of HBP1 to hCD2 LCR may result in the recruitment of RB and subsequently 
chromatin remodelling complexes to the locus to activate transcription.
The cell cycle
Co-ordination and balance between proliferation and differentiation is required for 
normal development and for the maintenance of homeostasis in the adult.
All somatic cells proliferate using a fundamentally similar mechanism. This cell 
division cycle comprises a set of processes that allows the cell to produce a pair of 
genetically identical daughter cells. This involves a complicated control system that 
has been conserved across evolution. Many of the proteins, which regulate the cell 
cycle in a human cell, are able to function when transferred to yeast. A eukaryotic cell 
cycle is traditionally divided into several distinct phases (figure 4A). During G1 cells
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make the necessary preparations for DNA synthesis, which occurs during S phase. 
Likewise, during G2 cells prepare for mitosis (M phase), during which replicated 
genetic material is segregated into daughter cells. Before the cells enter the mitotic 
cell cycle, they are in a state of quiescence. This state is often referred to as GO. 
Quiescent cells remain competent to respond to growth factors by progressing through 
G1 (Cook et al., 2000).
To maintain homeostasis, a tight control of the cell cycle process is required. Failure 
of cell cycle regulation can have a wide variety of consequences, such as incorrect 
number of cells produced during development or deregulated growth of terminally 
differentiated cells. Regulation of cell division is dependent upon various extra 
cellular signals, which include growth and differentiation factors, survival factors and 
cellular stresses (Cook et al., 2000). These extra cellular cues activate signal 
transduction pathways which induce programmes of gene expression and ultimately 
determine whether the cell enters the cell cycle and divides, leaves the cell cycle and 
differentiates, or undergoes apoptotic cell death (Cook et al., 2000).
Upon mitogenic stimulation, cells enter the G1 phase. Progression through G1 is the 
major growth-factor-responsive cell cycle transition; once the cell reaches a point late 
in Gl, termed the ‘restriction point’, it becomes committed to proceed through S 
phase as far as G2/M.
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Figure 4: The eukaryotic cell cycle
A) The successive phases of a standard eukaryotic cell cycle. See text for details.
B) Gl/S transition. This model represents key steps in the initiation of the Gl/S cell 
cycle transition by cyclin D1 CDK4/6 complex and the subsequent activation of 
cyclin E by Retinoblastoma. PI6, P21 and P27 are negative regulators of the Gl/S 
transition. The restriction point is indicated with R.
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An intricate control system oversees the timely and ordered succession of the various 
phases. After DNA replication, there is another major checkpoint to ensure the 
genome has been properly replicated before entering the M phase. The control system 
that oversees the cell cycle is based primarily on two key protein families. The first is 
the family of cyclin-dependent kinases (Cdk) which regulate downstream proteins 
through phosphorylation of target serines and threonines (reviewed in MacLachlan et 
al, 1995). Cdks are regulated by activation and inhibitory phosphorylation, and by 
interaction with a second family of proteins known as cyclins (Morgan, 1995).
Cyclins function as regulatory subunits by binding to their specific Cdk molecule and 
contribute to the activation of the kinase. Once activated, the complexes are able to 
phosphorylate specific nuclear targets. Regulation is achieved through synthesis and 
degradation of the cyclin molecules, as the cyclical assembly, activation and 
dismantling of these Cyclin-Cdk complexes are pivotal events during the cell cycle. 
Different cyclins contribute to the different substrate specificities of the complexes, 
e.g. Cdk2-CyclinA complexes phosphorylate different substrates to Cdk2-CyclinE 
complexes (Morgan, 1995). Therefore, the transient appearances of the varied Cyclin- 
Cdk complexes drive critical points in each phase of the cell cycle. In mammalian 
cells, aside from variations in cyclin concentrations and regulation of Cdks by 
phosphorylation, there is an additional control imposed by the action of cyclin- 
dependent kinase inhibitors (CDI) (Nakayama, 1998). This family of small proteins 
inhibit Cdk activity usually at a point just after the kinase has acted on its target. 
Elevated expression of CDIs is able to block cell proliferation and drive the cell into 
quiescence. In addition, CDIs are also involved in promoting differentiation, 
maintenance of the post-mitotic state in terminally differentiated cells and response of 
the cell cycle machinery to genotoxic stress. The CDIs are divided into two classes,
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based on their sequence similarity and specificity of action. One is the Cip-Kip 
family, which are capable of all of the kinases relating to the G1 phase (Cdk2, Cdk3, 
Cdk4 and Cdk6). Members of this family include p21, p27 and p57. The other class 
comprises the INK4 family and the main targets of these CDIs are Cdk4 and Cdk6. 
This family is composed of pl5, pl6, pl8 and pl9. In the following chapter, the 
mechanisms of the regulation of Cyclin/Cdk expression and activation during the G1 
to S phase will be described in more detail.
G l-S  transition
As shown before, cell cycle checkpoints are controlled by cyclin dependent kinases 
(CDKs). The CDKs act at key steps in the mammalian cell cycle to effect an orderly 
transition between stages. CDKs are activated by binding to cyclins (Cook et al., 
2000).
Following mitogen stimulation of quiescent cells, genes encoding D-type cyclins are 
expressed at the beginning of the G1 phase. Cyclin D then binds CDK4 or CDK6 
(figure 4B). The binding of cyclin D with CDK4/6 creates an active complex. This 
active cyclin D:CDK complex initiates cell cycle progression towards S phase. Cyclin 
D:CDK4/6 complex phosphorylates the retinoblastoma tumour suppressor protein 
(pRB) which results in its inactivation leading to progression from G1 to the S phase 
of the cell cycle. The growth-suppressive function of pRB lies in its ability to bind 
and sequester the sequence-specific transcription factor E2F (Harbour and Dean,
2000). Inactivation of pRB after phosphorylation by cyclin D:CDK releases E2F
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(Coqueret, 2002). Subsequently, E2F promotes the expression of a variety of genes 
required for transit through late G1 and entry into S phase, including cyclin E, which 
is needed for the next step in the cell cycle (Coqueret, 2002) (figure 3).
The active cyclin-CDK complexes are inhibited by CDK inhibitor proteins (CDKIs) 
(Harper and Elledge, 1996). CDKIs are expressed in response to a variety of anti­
proliferative signals, including DNA damage and differentiation signals (Harper and 
Elledge, 1996). Three of the most prominent CDKIs (pi6, p27 and p21) will be 
briefly described. pl6 serves as a selective inhibitor of cyclin D1:CDK4, thereby 
acting to prevent phosphorylation and inactivation of pRB (Lee and Yang, 2001) 
(figure 3B). Cyclin E:CDK2 activity is repressed by the CDKI p27 (figure 3B). p27 
accumulates to high levels in quiescent cells and must be inactivated for cells to enter 
S phase. In turn, inactivation of p27 is catalysed by cyclin E:CDK2, thereby ensuring 
fine control of cell cycle re-entry (Lee and Yang, 2001). Induction of p21 leads to 
inactivation of multiple cyclin/cdk complexes and allows pRB to remain hypo- 
phosphorylated. Hypo-phosphorylated pRB is capable of binding and inactivating of 
E2F causing cell to exit the cell cycle. pRB also activates tissue specific transcription 
factors which in turn up regulate p21 resulting in a regulatory loop. Studies on the 
expression of p21 found that the transcription factor HBP1 has a repressive effect on 
the p21 promoter (Gartel et al., 1998). It is unclear at the moment, to what extent the 
regulation of p21 by HBP1 is biologically relevant. Down regulating the cdk- 
inhibitory protein p21 has been linked to G1 progression while over expressing of 
HBP1 in a transgenic mice model leads to a delayed G1 phase of the cell cycle (Shih 
et al., 2001).
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Retinoblastoma
Products of the mammalian retinoblastoma (Rb) tumour suppressor gene family are 
important regulators of cell cycle, differentiation and apoptosis. Studies of 
retinoblastoma patients led to the current Knudson "two- hit" hypothesis for 
tumourigenesis (Knudson, 1971). The first tumour-suppressor gene to be cloned was 
the Rb gene. In familial cases of retinoblastoma, a germline mutation in the Rb gene is 
inherited and affected individuals develop retinal tumours in which the loss of the 
second Rb allele is the rate-limiting step (Weinberg, 1991).
Human pRB is a nuclear phosphoprotein with a relatively long half- life (>8hrs). pRB 
is synthesized throughout the cell cycle and its activity is regulated by cell cycle- 
dependent phosphorylation. pRB is broadly expressed, but the levels of the protein are 
variable between cell types. pRB is a member of a family of three closely related 
mammalian proteins that includes pl07 and pl30 (Mulligan and Jacks, 1998). 
Together, these proteins are referred to as the 'pocket proteins' because their main 
sequence similarity resides in a domain (the pocket domain) that mediates interactions 
with viral proteins (Mulligan and Jacks, 1998). These interactions are important for 
the transforming properties of viral products and are thought to inactivate pRB. 
Although there are several ways that protein association might disrupt pRB function, 
the most widely held view is that either the viral proteins prevent pRB from 
interacting with its normal partners by directly competing for binding sites on pRB, or 
inducing pRB degradation (Dyson, 1994). Mutagenesis of several viral proteins 
demonstrated that a small conserved domain within these proteins, containing the 
amino acids LXCXE, is essential for the binding of these proteins to pRB. In contrast,
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a relatively large portion of pRB, the so-called pocket domain, is required for this 
interaction and is essential for the growth suppression functions of pRB. It is 
indicative that most of the naturally occurring, tumour-derived mutations in Rb affect 
this region. However, regions outside of the pRB pocket are also likely to be 
important for its interaction with its partners (Dyson, 1994). The Rb family appears to 
be able to regulate cell cycle exit through at least two distinct mechanisms. One 
mechanism was described above; this involved repression of E2F transcriptional 
activity. The second mechanism is unique to differentiation process. During the 
differentiation process, pRB interacts and augments the activity of transcription 
factors necessary for differentiation. One of the identified interacting proteins is 
HBP1 and this interaction will be discussed in more detail below.
During differentiation in muscles (muscle cells represent the best characterized in 
vitro differentiation system), Rb and p i30 expression is markedly increased. During 
differentiation of C2C12 myogenic cell line HBP1 is induced with approximately the 
same kinetics as pRB and p i30. Forced over expression of HBP1 in the presence of 
pRB and p i30 leads to cell cycle arrest suggesting that alongside pRB HBP1 might 
play a role in initiation and establishment of cell cycle exit by repressing transcription 
of cell cycle genes (see discussion on HBP1). Expression of HBP1 not only causes a 
cell cycle exit but also blocks muscle differentiation of the C2C12 cell line (Shih et 
al., 1998) Myf5, the first of the MyoD family of transcription factors expressed in 
differentiation muscle cells, up regulation is not affected by the forced HBP1 
expression. HBP1 disrupts the transcriptional activity of Myf5 in a manner that is 
dependent on pRB or p i39. This prevents the expression of later members of the 
MyoD family, under which myogenin and MyoD itself. This differentiation block can
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be overcome by expression of the muscle specific transcription factors myogenin or 
MyoD. Furthermore, over expression of pRB also release the cells from the HBP1 
imposed differentiation bock. The authors suggested that the relative ratio between 
pRB and HBP1 determines whether only cell cycle exit or full differentiation occurs. 
At low ratios of pRB/HBPl, cell cycle exit occurs but pRB mediated expression of 
muscle specific genes is blocked. When the ratio between pRB and HBP1 increases 
MyoD family is activated and full differentiation occurs. M. Lipinski and T Jacks 
(Lipinski and Jacks, 1999 156) suggested a possible model that integrates E2F and 
HBP1 regulation by pRB. During the early stages of differentiation, hypo- 
phosphorylated pRB accumulates. The hypo-phosphorylated pRB binds and 
inactivates E2F family factors, leading to decreased transcription of cell cycle genes. 
As HBP1 protein levels also increase, HBPl/pRB complexes can bind to and further 
inactivate promoters of these genes. This complementary action of E2F/pRB and 
HBPl/pRB complexes eventually would lead to transcriptional repression of mitotic 
genes and cell cycle exit followed by differentiation. Besides, in muscle 
differentiation HBP1 may be actively involved in the differentiation process during 
haematopoiesis. In these experiments, induction of maturation in myeloid cell lines 
(HL-60 and K562) resulted in an initial rapid decline in the level of HBP1 RNA, 
followed by a marked (20 fold) increase upon final maturation (Lin et al., 2001a). 
These results are compatible with the model described above and might indicate that 
different cell types utilize HBP1 and pRB to achieve a post mitotic state and full 
differentiation.
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In the next chapter, HBP1 will be described in more detail. These descriptions include 
the structural properties, regulation of expression and the known target genes of 
HBP1.
HMG box containing protein 1
HBP1 is an ubiquitously expressed protein (Zhuma et al., 1999) that can potentially 
interact with retinoblastoma through two motifs (LXCXE and IXCXE) which are high 
and low binding sites respectively, for the pocket domain of retinoblastoma and p i30 
(RBI and RB2 in figure 5A). These interactions were confirmed by co- 
immunoprecipitation of HBP1 with retinoblastoma in experiments where these 
proteins were co-expressed in cells by transient transfection (Lavender et al., 1997; 
Tevosian et al., 1997). HBP1 contains a masked activation domain. Deletion of two 
independent N- and C-terminal inhibitor domains unmasks the activation. The 
released activation capacity is repressed by retinoblastoma or its family members 
(Lavender et al., 1997).
Structural domains o f HBP1
HBP1 is 513 amino acids long and contains two distinguishable structural domains, 
an HMG box and an Ataxin domain called AXH (figure 5).
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The High Mobility Group
High Mobility Group (HMG) proteins were identified as a class of non-histone 
chromosomal species, which share the common property of rapid migration in SDS- 
PAGE gels. Represented in all four eukaryotic kingdoms and ubiquitous in 
mammalian cells, HMG proteins were first isolated from calf thymus chromatin and 
characterized in 1973 (Goodwin and Johns, 1973). Numerous HMG box proteins have 
since been identified. An evolutionary study of the HMG box proteins has led to the 
notion that two types of HMG box proteins can be distinguished (Soullier et al.,
1999).
The first type usually contains multiple HMG boxes that bind non-specifically to 
DNA, recognizing distinct structural features such as pre-bent or cruciform DNA 
rather than specific sequences. These proteins are relatively abundant in all cells, on 
average one molecule per 10 to 15 nucleosomes in the nucleus (Soullier et al., 1999). 
These non-histone proteins probably play both a structural and a functional role in 
maintaining the overall chromatin structure.
The second type of protein contains a single HMG box that can bind to DNA in a 
sequence specific fashion (Soullier et al., 1999). This part of the HMG box family 
contains transcription factors which bind to specific DNA sequences, such as the T- 
cell transcription factors TCF1 and LEF1, the mammalian male sex determining 
factor SRY, numerous SOX factors and HBP1 (Soullier et al., 1999). Circular 
permutation assays indicated that these proteins can induce a strong bend of 
approximately 70-130° in the DNA helix (Bewley et al., 1998).
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Figure 5: Schematic representation of the architecture of HBP1 and ATX1
A) The positions of the high and low affinity retinoblastoma binding sites (RB 1 and 
RB2 respectively) and of the HMG and AXH motifs are indicated for HBP1.
B) The polyQ tract, the nuclear localization signal (NLS) and the AXH module are 
marked for ATX1.
C) Multiple alignment of the AXH sequences of HBP1 and ATX1 families and two 
hypothetical proteins from C. elegans and D. melanogaster. Secondary structure 
prediction for the multiple alignment as obtained by the PHD programme is reported 
in the first line (E = p sheet, H= a  helix).
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Compared to classical transcription factors the sequence specificity of the HMG box 
containing protein is fairly low (Weiss, 2001). For instance, HBP1 is able to bind 
AGAATGGG, TCAATGGG and AAAATGGG in the N-MYC promoter (Tevosian et 
al., 1997) and TTCATTCATTCA in the human CD2 LCR (Zhuma et al., 1999), but 
binding is inhibited when mutations are made in these sequences. The fact that these 
proteins seem “not precise” in recognizing a consensus sequence should not come as a 
surprise. It is remarkable that they can recognize a specific sequence at all. The 
interaction of sequence specific HMG boxes with linear DNA has been shown to 
proceed mainly through the minor groove, as revealed by methylation interference 
experiments and substitution of hydrogen bond donors and acceptors in the major and 
minor grooves (Bewley et al., 1998). Such a mode of interaction is unusual for 
sequence specific DNA binding proteins and is probably responsible for the modest 
specificity of HMG boxes for their binding sites. The minor groove provides little 
opportunity for base specific contacts, since hydrogen bonding cannot distinguish AT 
pairs from TA pairs. However, hydrogen bonding in the minor groove appears well 
suited for structure-directed recognition, since the phosphates will be spaced at 
favourable distances for selective interactions.
The AXH domain
A  small motif (ca. 130 amino acids long), named AXH module, was identified in 
HBP1 and in the apparently unrelated transcription factor ATX1 whose aberrant 
regulation leads to spinocerebellar ataxia type-1 (SCA1) (Mushegian et al., 1997) 
(figure 5B). The AXH module is highly conserved within members of each of the two
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protein species sharing ca. 78-80% identity. However, between the ATX1 and the 
HBP1 the identity is much lower (-28%) but still showing -54% similarity (figure 
5C).
The AXH of HBP1 coincides with the repression domain of HBP1. The repression 
activity is intrinsic to the domain but can be modulated by Rb and p i30 (Tevosian et 
al., 1997).(Yue et al., 2001) Besides the interaction with Rb and pl30 the AXH 
domain can also interact with Sin3 (Swanson et al., 2004) and TCF4 (Sampson et al., 
2001). SIN3 is a multi-protein complex that represses the transcription of many 
eukaryotic genes. The SIN3 complex does not directly bind DNA but is targeted to 
specific genes through proteimprotein interactions between SIN3 and DNA-binding 
proteins in this case HBP1 (Swanson et al., 2004). The mammalian SIN3 complex 
contains chromatin-modifying enzymes such as HDACs. The interaction between 
TCF and AXH can suppress the Wnt signalling (Sampson et al., 2001) and this 
interaction will be discussed further on.
The AXH of ATX1 partially overlaps with a protein interaction domain, causing 
dimerization of the protein (Burright et al., 1997) and is contained in a region 
involved in RNA binding. No ATX1 gene targets haven yet been reported.
Controlling HBP1 levels
The concentrations of transcription factors, as of intracellular proteins in general, may 
be regulated at any of the steps leading from DNA to protein, including transcription,
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RNA processing, mRNA degradation and translation. The activity of a transcription 
factor is often regulated by phosphorylation, which may affect different functions. In 
the following paragraph, an overview of different modes of regulation of HBP1 will 
be described.
The promoter activity of HBP1 has been studied in a promyelocytic cell line (Austin 
and Lin, 2002; Lin et al., 2001b). In these cells, the proximal 1.1 kb segment of the 5’ 
flanking region of the HBP1 gene exhibited strong promoter activity. Six hours after 
induction of differentiation, the promoter activity decreased to almost zero. This is 
followed by a dramatic increase of up to 50 times the pre-treatment levels after 24 
hours (Austin and Lin, 2002; Lin et al., 2001b).
The dramatic increase in HBP1 RNA levels, which accompanies myeloid 
differentiation, is due to an increase in HBP1 promoter activity. Transcription of the 
HBP1 gene appears to be regulated by API and c-myb, which enhance HBP1 
promoter activity, whereas GM-CSF and/or PE A3 inhibit HBP1 promoter activity 
(Austin and Lin, 2002; Lin et al., 2001b).
Naturally occurring antisense transcripts have been documented in prokaryotes and 
viruses, where they are found to regulate gene expression by affecting mRNA 
transcription, processing and translation. A growing number of endogenous antisense 
RNA transcripts have also been reported during the last several years in a variety of 
eukaryotic organisms. The effects that these eukaryotic antisense RNAs have on the 
corresponding sense RNAs has not been clearly established (Good, 2003).
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Recently, Rodrigo Yelin et al.(Yelin et al., 2003) identified transcripts that derive 
from both strands of the HBP1 locus. Thus, it is possible that antisense mediated gene 
regulation plays a role in HBP1 expression.
HBP1 is also regulated post-transcriptionally. It was found that p38 MAP kinase both 
binds and specifically phosphorylates HBP1 at serine 401(Xiu et al., 2003). As a 
result, HBP1 stability is increased. Only recently, the p38 MAP kinase pathway has 
been implied in the regulation of the cell cycle. p38 has to be inactivated to exit from 
the quiescent state as well as to elude mitotic arrest. Moreover, activation of p38 MAP 
kinases during the Gl/S transition can either inhibit or promote cell cycle progression 
depending on the stimulus and the cell type (Ambrosino and Nebreda, 2001). Thus, 
increasing the levels of HBP1 by p38 MAP kinase may contribute to the cell cycle 
regulation (figure 6).
Targets o f HBP1
HBP1 encodes a transcription factor that is up regulated during differentiation and 
regulates a specific set of target-genes. In the following chapter a brief description of 
the some of the target genes that of HBP1 will be given.
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Figure 6: Overview of HBP1 regulation and its targets
Levels of HBP1 proteins in the cell are post-translational regulated by p38 
phosphorylation. Phosphorylation by the p38 MAPK increases the protein stability of 
HBP1 resulting in increased protein concentration.
HBP1 can repress the Wnt signalling pathway. Binding of Wnt ligands to their cell 
surface receptors Frizzled activates cytoplasmic Dishevelled (Dsh) which interferes 
with the function of the destruction complex consisting of GSK-3, APC, and Axin. 
This prevents p-catenin degradation. As a consequence, p-catenin is allowed to enter 
the nucleus where it binds to TCF transcription factors and functions as a 
transcriptional activator to induce expression of specific Wnt target genes. HBP1 can 
compete with p-catenin for binding to TCF transcription factors and inhibits the 
expression of specific Wnt target genes.
HBP1 can bind to the regulatory elements of target genes and can either activate or 
repress transcription. It can influence expression levels directly or indirectly through 
the binding to pRB and/or the SIN3 complex.
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Wnt signalling
Several proteins, starting with interaction of Wnt with its receptor Frizzled (Fzd), 
participate in the Wnt signalling cascade (Novak and Dedhar, 1999). Frizzled interacts 
with and activates Dishevelled (Dsh) leading to the down-regulation of the activity of 
the GSK3p and the stabilization of cytoplasmic p-catenin (figure 4) (Novak and 
Dedhar, 1999). Cytoplasmic P-catenin becomes available for active transport to the 
nucleus by an importin-p-dependent mechanism (Novak and Dedhar, 1999). There p- 
catenin participates in transcription regulation through its interaction with the TCFs 
(Brantjes et al., 2002). The latter constitute a family of HMG box containing 
transcription factors originally identified for their ability to bind the T cell receptor 
enhancer (Brantjes et al., 2002). Expression of TCFs (TCF1, LEF1, TCF3 and TCF4) 
is not restricted to lymphoid tissue and they have now been implicated in a variety of 
developmental processes (Brantjes et al., 2002) and in cancer (Giles et al., 2003). A 
functional TCF transcription complex requires the assembly of the TCF protein with 
P-catenin. p-catenin provides the transcriptional activation domains while TCF 
provides the DNA binding domain (Brantjes et al., 2002). Several known 
transcriptional targets get up regulated through binding of TCF: p-catenin complex to 
their promoters, such as c-MYC and Cyclin D1 whose promoters contain TCF 
binding sites and appear to be constitutively active in several cancers (Giles et al., 
2003).
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HBP1 can suppress the Wnt signalling pathway (Sampson et al., 2001). It was shown 
that both Cyclin D1 and c-MYC expression was extinguished upon HBP1 over 
expression. HBP1 targets the transcriptional activators TCF4, which results in the loss 
of activity of TCF4. HBP1-DNA binding is not required for inhibition of Wnt-B- 
catenin transcriptional activation. Within HBP1, the necessary functional region for 
interacting with TCF4 is defined to amino acids 192-400, which is contained within 
the, previously described, AXH module (Sampson et al., 2001). While DNA binding 
was not necessary for down regulation of Cyclin D1 and c-MYC, these promoters do 
contain weak HBP1 binding sites (Yee et al., 2004). Further studies will be required to 
address what the effect is of direct binding to these promoters by HBPl(Tevosian et 
al., 1997).
N-Myc
The transcription factors encoded by the myc genes are implicated in the control of 
several aspects of cellular differentiation including cell proliferation and apoptosis 
(Grandori et al., 2000). Lack of N-myc expression causes severe effects of embryonic 
development while over expression of N-myc is associated with the development of 
several types of childhood tumours. HBP1 repressed the rat N-myc promoter in 
transient assays, it was speculated that HBP1 and E2F binding sites allow for the 
integration of opposing signals at the N-myc promoter via HBP1 or E2F in 
conjunction with pRB (Tevosian et al., 1997). There is no evidence yet to support this 
regulation of endogenous N-myc by HBP1.
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Histone H I0
The replacement linker histone HI is associated with terminal differentiation in many 
mammalian cell types, and its accumulation in chromatin may contribute to 
transcriptional repression occurring during terminal differentiation. HBP1 was 
identified as a target of histone HI0 in a yeast one hybrid using the element that 
regulates HI0 expression pattern as bait (Lemercier et al., 2000). HBP1 can up 
regulate histone HI0. Furthermore, it was shown that Rb could stimulate the DNA 
binding activity of HBP1 to the histone HI0 binding site. Through modulating the 
expression of specific chromatin-associated proteins such as HI0, HBP1 can play a 
vital role in chromatin remodelling events during arrest of cell proliferation in 
differentiating cells.
Myeloperoxidase
Myeloperoxidase (MPO) is a human enzyme in the azurophilic granules of 
neutrophils and in the lysosomes of monocytes. Its major role is to aid in microbial 
killing. HBP1 binds to Myeloperoxidase promoter and enhances MPO promoter 
activity (Lin et al., 2001a). However, high levels of HBP1 expression are not 
associated with high levels of Myeloperoxidase mRNA. At the moment, it is unclear 
what the cause of this discrepancy is.
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Summary o f HBP1
In summary, HBP1 appears to be an important regulator in the cell cycle and 
differentiation. Studies have shown that HBP1 can act as both a transcriptional 
activator and repressor. In vivo, it was shown that transgenic mice expressing HBP1 
had a delayed G1 phase of the cell cycle (Shih et al., 2001). Possible mechanisms 
through which HBP1 can repress the cell cycle was suggested by experiments which 
showed that HBP1 can repress the N-myc (Tevosian et al., 1997) and cyclin Dl. 
Specific gene activation of N-myc and cyclin Dl have been identified as the cause of 
some cases of leukaemia (de Boer et al., 1997; Mirro, 1992). The stoichiometry of Rb 
and HBP1 contributes to differentiation (Shih et al., 1998). HBP1 up regulates histone 
HI0, a linker histone variant that is expressed in terminally differentiated cells 
concomitant with the arrest of cell proliferation.
Gene targeting 
Embryonic mouse stem cells
The ability to generate a mouse with a targeted mutation in a desired gene has been 
one of the most important technological advances in our efforts to understand the 
function of gene products. Not only can gene disruption demonstrate the function of 
genes, but by disrupting development or survival of particular cells, it can also
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demonstrate the function of particular cells in the whole animal. Some knockout mice 
proved to be murine models of human genetic diseases and have shown that a single 
gene defect is capable of causing disease. In genetic terms, targeted gene disruption is 
complementary to using mutant strains of mice with a known phenotype to map and 
identify the disease causing genes.
Gene targeting is the term used to describe the predetermined mutation of an 
endogenous gene that results from a homologous recombination event between a 
mutated version of the gene carried on a targeting vector and the endogenous locus. 
When performed in embryonic stem (ES) cells, gene targeting is a powerful means for 
generating mice carrying specific genetic mutations.
Homologous recombination between the targeting vector and the endogenous locus in 
ES cells is a rare event, but gene targeting vectors incorporate marker genes for drug 
selection schemes to enrich for the recovery of homologous recombinant ES cells. 
Gene targeting experiments can employ different strategies to obtain a functional 
knockout. Basically, targeting vectors can disrupt gene expression by deleting certain 
sequences and replacing them with substitute DNA, usually a drug selection gene or a 
reporter gene to analyze target gene expression (Thomas and Capecchi, 1987). 
Alternatively, targeting vectors can introduce loxP sites for inducible or tissue specific 
deletions of the target gene or they can introduce new gene segments without deleting 
parts of the endogenous locus.
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Cre LoxP system
Conventional gene knockout technology by homologous recombination can provide 
important information toward elucidating the function of genes; however, the role of 
many genes cannot be investigated due to early embryonic lethality. Alternatively, the 
role of a particular gene in adult tissues may be masked by developmental 
abnormalities in any knockout animal generated. It is also possible that a phenotype 
can only be seen shortly after deletion, before compensatory mechanisms are 
activated, and take over the function of the inactivated gene. The implementation of 
site-specific recombinases, such as the bacteriophage PI loxP/CRE system, enables 
the development of conditional knockouts that lack a particular gene or domain of a 
gene only in a specific tissue or after a specific stage of development. This system can 
also be used to facilitate transgene activation/inactivation in vivo, deletions of large 
stretches of chromosomal DNA, chromosome translocations and subtle alterations to 
genes and/or their regulatory elements.
The CRE enzyme is a 35-kDa protein isolated from bacteriophage PI, which acts as a 
site specific recombinase (Rossant and Nagy, 1995). The sequence recognized by 
CRE, termed loxP, consists of two 13 base pair inverted repeats (CRE recognition 
sites) separated by an 8bp spacer. The 8-bp spacer region is asymmetrical and is 
responsible for the directional nature of the LoxP site. Two loxP sequences in the 
same orientation will result in excision of the intervening DNA by CRE leaving one 
loxP site. In contrast, where two loxP sites are in opposite orientation, CRE will invert 
the intervening piece of DNA. This method can also be adopted to translocate, delete, 
or invert large pieces of DNA only where and when required by the investigator. The
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latter is limited only by the availability of suitable regulators of CRE recombinase 
expression.
The success of the CRE/LoxP system relies on the targeted gene to function normally 
until recombination occurs. As mentioned earlier resistance genes are included in the 
targeting vector. Resistance genes included for selection of correctly targeted clones 
usually include > lkb of foreign DNA, which has the potential to influence the 
expression of the targeted gene prior to recombination (Meyers et al., 1998; Nagy et 
al., 1998). There is also some evidence that resistance genes located in introns can be 
spliced to upstream exons, effectively generating a truncated or mutant protein. To 
minimize this potential influence on gene expression, it is necessary to splice out the 
resistance gene from the correctly targeted embryonic stem cell. To remove the 
resistance gene, an additional loxP must be included to flank the resistance gene. The 
modified genomic DNA would thus include three loxP sites, two flanking the 
resistance gene and a third located so that it can cause the desired mutation when 
recombination occurs.
55
Rationale
The aim of this study is to determine the function of HBP1 in development and 
physiological processes in vivo. Structure provides the link between sequence and 
function, and therefore is central to unravelling the function of HBP1. HBP1 contains 
two recognisable domains: The well-characterised HMG box and a novel domain 
called AXH. We therefore set out to define the structural properties of this novel 
domain in collaboration with the department of Molecular Structure here at the 
National Institute for Medical Research.
A significant limitation of the structural approach is that it downplays the role of 
context (i.e. when, where and how the genetic information is utilized) in protein 
function. It would therefore be impossible and at times even misleading to predict its 
function, because a purely structural description ignores the context in which proteins 
operate. Initial analysis was performed to define the subcellular distribution of the 
HBP1 protein in order to determine how HBP1 behaves in the context of a single cell. 
Furthermore, these subcellular distribution studies identified which regions of the 
HBP1 protein are necessary for the correct distribution within the cell.
In complex organisms, gene function is defined by the temporal, developmental and 
physiological patterns in which a gene is expressed. In these organisms, tissue or 
whole animal context alone determines the final functionality, and all types of 
regulation of the activity of protein (gene expression, subcellular localization, post-
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translational modifications) are functional attributes. Therefore, we set out to generate 
mice in which HBP1 is inactivated. Studying the development and physiology of such 
mice would allow us to determine the function of the HBP1 gene in the context of the 
whole organism.
HBP1 is a ubiquitously expressed protein and given that there are no close 
homologues that could replace its function in its absence, there was the possibility that 
mice deficient in HBP1 may be embryonic lethal. To avoid this, it would be desirable 
to delete the gene in a tissue specific manner. The ability to inactivate an endogenous 
gene in the mouse in a temporally and spatially controlled manner is not only useful 
for circumventing early lethal phenotypes, but also allows biological questions to be 
addressed with exquisite accuracy. To achieve this, an essential region of HBP1 was 
flanked by loxP sites (floxed), so that this domain could be deleted specifically at will 
by directing the expression of Cre in a tissue specific manner. For this purpose, 
expression of the Cre recombinase was directed in the haematopoietic compartment.
In order to achieve Cre expression in the entire haematopoietic compartment or only 
in lymphocytes, we have chosen to express Cre under the control of VAV regulatory 
elements and the human CD2 regulatory elements, respectively.
In order to generate mice in which an essential region of the HBP1 gene is floxed a 
targeting vector was transfected into mouse ES cells. LoxP sites and drug resistance 
markers were assigned to introns, so that their location would not affect transcription 
of the targeted allele. As drug resistance gene insertion sometimes affects the 
expression of the target gene this unit was also flanked by loxP sites. Thus, the 
targeting vector has three loxP sites, positioned such that neo and the essential region
57
of the gene of interest were floxed. In this case, a partial Cre mediated recombination 
event would result in genomic deletions, one of which removes neo, leaving the 
essential region floxed.
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Materials and Methods
General 
Chemicals and reagents
Restriction endonucleases, T4 DNA ligase, Klenow DNA polymerase, Proteinase K, 
DNase I, alkaline phosphatase and RNase A were obtained from Boehringer 
Mannheim and New England Biolabs. Hybond nylon membranes were purchased 
from Amersham. Chemicals were obtained from BDH, Sigma Chemical Company 
and Pharmacia Biotech. Antibodies were purchased from Pharmingen and Caltech. 
Tissue culture plastics were obtained from Coming-Costar, Becton Dickinson and 
Nalgene Nunc International. Foetal calf serum (FCS) and other media supplements 
were purchased from Globepharm limited, GIBCO-BRL and Sigma Chemical 
Company.
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Molecular biology
Bacteriological cultures
Liquid cultures were grown in L-Broth supplemented with 100jAg/ml ampicillin. For 
agar plates, L-Broth was supplemented with 1.5% (w/v) bactoagar. Bacteria were 
frozen in 1 ml aliquots of L-Broth supplemented with 1/10 volume of lOx Hogness. 
L-Broth:
1% (w/v) bactotryptone; 0.5% (w/v) yeast extract; 1% (w/v) NaCl in ddH20. 
Hogness (lOx):
36mM KH2P04; 13mM K2HP04; 20mM NaCitrate; lOmM MgS04; 40%
(w/v) Glycerol.
Competent bacteria and cell transformation
For competent bacteria, a single colony of Escherichia coli (E.coli) DH5a bacteria 
was picked from agar plates and grown (250rpm in a New Branswicki Model G25 
orbital shaker) overnight to stationary phase at 37°C in 2.5ml of L-Broth. 250ml of L- 
Broth with 20mM Magnesium sulphate was inoculated with 2.5 ml of the overnight 
culture and grown with shaking at 37°C until an optical density of 0.5 at 600nm was 
reached. Bacteria were then pelleted in 50ml falcon tubes (Falcon, Beckton 
Dickinson) at 1285g, 4°C for 20 minutes and gently resuspended in 100ml of ice cold 
TFB1. Cells were left on ice for 5 minutes. Bacteria were then pelleted at 1285g, 4°C 
for 20 minutes and then re-suspended in 10 ml of ice cold TFB2. Cells were incubated
for 45 minutes on ice and then frozen in 100|xl aliquots in sterile Eppendorf tubes in a 
dry ice/methanol bath and stored at -70°C.
For transformation of bacteria, a ligation reaction containing lOOng of DNA was 
mixed with lOOpl of competent cells. Following incubation on ice for 30 minutes, the 
cells were heated to 42°C for 30 seconds and placed back on ice for another 2 
minutes. 1 ml of L-Broth was added and cells were grown for 45 minutes at 37°C. 
lOOpl of this culture was then plated out onto L-agar plates supplemented with the 
correct antibiotics.
TFB1:
30mM potassium acetate, lOmM CaCL, 50mM MnCl2, lOOmM RbCl 15% 
glycerol. pH adjusted to 5.8 with 1M acetic acid.
TFB2:
lOmM MOPS (pH 6.5), 75mM CaCl2, lOmM RbCl 15% glycerol. pH adjusted 
to 6.5 with 1M KOH.
Small scale plasmid DNA isolation
1.5 ml of a 5ml overnight culture of L-Broth supplemented with antibiotics was 
transferred to an Eppendorf tube and pelleted by centrifugation at 13000xg for 1 
minute. The bacterial pellet was resuspended in 200pi STET and 20 pi lOmg/ml 
lysozyme. The mixture was heated to 100°C for 1 minute. Debris was pelleted for 10 
minutes at 13000xg in a bench top centrifuge. The pellet was removed and the 
plasmid DNA was precipitated from the supernatant with 600pl of 100% ethanol at
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4°C and collected by centrifugation at 13000xg. The DNA pellet was resuspended in 
lOOpl ddH20 and stored at -20°C.
STET buffer:
0.1 M NaCl; 10 mM Tris-Cl, pH 8.0; 1 mM EDTA, pH 8.0; 5% Triton X-100 
Large scale plasmid DNA isolation
Bacteria were harvested from 1 litre over night culture by centrifugation at 4000rpm 
for 30 minutes, at 4°C. The pellet was resuspended by vortexing in 40ml lx glucomix 
and incubated for 5 minutes at RT. Bacteria were then lysed with 80ml of Lysis Mix 
for 10 minutes and chromosomal DNA and protein was precipitated for 10 minutes on 
ice by the addition of 40ml 5M KOAc. Debris was removed by centrifugation for 20 
minutes at 4000rpm. The supernatant was filtered through two layers of cheesecloth 
and plasmid DNA was precipitated at RT by the addition of 0.6 volumes of 
isopropanol and harvested by centrifugation for 20 minutes at 5000rpm. The pellet 
was dissolved in 9ml of ddH20. lOg of CsCl and 0.5ml of lOmg/ml ethidium bromide 
were added to the DNA solution. Samples were then transferred into Quickseal 
Ultracentrifuge Tubes (Beckman) and centrifuged at 55000 rpm for 15 hours in a 
Beckman VTi65.2 rotor. Banded plasmid DNA was recovered using a hypodermic 
needle and syringe and ethidium bromide was removed by repeated extraction using 
butanol saturated with ddH20. The DNA solution was then diluted with 3 volumes of 
ddH20 and DNA was precipitated with 2.5 volumes of ethanol. After centrifugation at 
8000rpm the DNA pellet was resuspended in 1ml ddH20. RNase A was added to the 
DNA to a final concentration of 20mg/ml and it was incubated at 37°C for 30 
minutes. The DNA was then extracted once with equal volume of
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phenol:chloroform:isoamylalcohol 25:24:1 and precipitated by adding 3M NaOAc to 
0.3M final concentration and 2.5 volumes of ethanol. The DNA pellet was washed 
with 70% ethanol, resuspended in 1ml ddfLO and stored at -20°C.
Glucomix (lOx):
250mM Tris-HCl, pH8.0; 500mM Glucose; lOOmM EDTA.
Lysis Mix:
200mM NaOH; 1% (w/v) SDS.
5M KOAc, pH4.8:
3M with respect to potassium; 5M to acetate; adjusted to pH4.8 with glacial 
acetic acid.
Lambda DNA preparation
A  single colony of XL1 blue MRA strain was inoculated in 50 ml of LB broth 
supplemented with 0.2% of maltose and lOmM MgS0 4  and grown overnight shaking 
at 30°C. Bacteria were then pelleted in a sterile conical tube at 1285g for 10 minutes 
and gently resuspended in 10 mM MgSC>4 in the volume so that a OD600 of 0.5 was 
reached. 600pl of this mixture was combined with ~ 5xl04 pfu of bacteriophage. This 
mixture was incubated for 15 minutes at 37°C. 6.5 ml of melted (48°C) LB agar was 
added and spread evenly onto 150-mm bottom LB agar plate. The plate was incubated 
at 37°C for 6-8 hours. The plates were overlaid with 10 ml of SM buffer and 
incubated overnight at 4°C while rocking. The SM buffer was collected from the 
plates chloroform was added to a final concentration of 2%, vortexed and spun down
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for 10 minutes to remove residual agarose. The lambda DNA was isolated using 
Qiagen lambda kit according to manufacturers’ instructions.
SM (suspension medium)
50mM TRIS C1, pH8.0; 0.1M NaCl; 8mM MgS04; 0.01% gelatin
DNA isolation from PAC clones
A single colony was inoculated into 2 ml LB media supplemented with 25 pg/ml 
kanamycin. The cultures were grown overnight (up to 16 h) shaking at 225-300 rpm at 
37°C. The bacteria were pelleted by centrifugation at 3500rpm for 10 minutes at 4°C. 
The bacterial pellet was then resuspended in 200pi lx glucomix supplemented with 
Rnase, transferred to an Eppendorf tube and incubated at room temperature (RT) for 5 
minutes. Bacteria were then lysed with 400pl of Lysis Mix and incubated on ice for 
10 minutes. This was followed by the addition of 200pi 5x KOAc pH4.8 and gentle 
mixing. Debris was pelleted for 10 minutes at 13000rpm in a bench top centrifuge and 
plasmid DNA was precipitated from the supernatant with 0.6 volumes of isopropanol 
at RT and collected by centrifugation at 13000rpm. The DNA pellet was then 
resuspended in lOOpl ddtbO and stored at -20°C.
Genomic DNA preparation
Five mm of tail tissue was incubated at 55°C overnight in 500pl tail mix 
supplemented with 200pg/ml of proteinase K in a shaking water bath. The DNA was 
then extracted twice by shaking for 10 minutes with equal amount of
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phenol:chloroform:isoamylalcohol 25:24:1 followed by centrifugation at 13000rpm in 
a bench top centrifuge for a further 10 minutes. This was followed by a similar 
extraction with chloroform. DNA was then precipitated with equal volume of 
isopropanol. The DNA was immediately spooled out using a Pasteur pipette which 
had previously been sealed in a Bunsen burner. The DNA was washed with 70% 
ethanol, air dried briefly and then resuspended in ddHbO overnight at 4°C. DNA 
concentration was then determined by spectrophotometry.
Tail mix:
50mM Tris-HCl, pH8.0; lOmM EDTA; 1% (w/v) SDS.
Phenol: Chloroform:
Phenol:Chloroform:Isoamylalcohol (25:24:1 v/v) equilibrated with lOmM 
Tris-HCl, pH7.5.
DNA restriction digests
Restriction digests were carried out according to the manufacturers’ directions. DNA 
was incubated under the appropriate conditions for the restriction enzyme used. For 
digests with more than one enzyme, which had not the same buffer requirements, 
DNA was digested in consecutive single digests. The DNA was phenol:chloroform 
extracted and ethanol precipitated between these digests. For enzymes that required 
the same restriction buffer, both enzymes were used simultaneously in the same 
reaction.
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Agarose gel electrophoresis
Agarose gels were prepared in lx TAE and run horizontally and submerged in lx 
TAE buffer. This buffer was supplemented with 5 mg/ml of ethidium bromide and run 
at 4V/cm. DNA was visualized and photographed under short wave UV light.
50x TAE:
2M Tris-Acetate; lOOmM EDTA; pH8.0.
Extraction o f DNA from agarose gels
DNA digests were run in agarose gels prepared in lx TAE and bands were visualized 
under long wave UV light. The DNA was extracted from the gel using a GeneCleanll 
kit (Anachem) following the manufacturers instructions.
Southern blot
lOpg of genomic DNA was digested in a final volume of 50pl overnight in the 
appropriate conditions for the restriction enzyme using 40 units of enzyme. To check 
completion of digestion, 3pi of this reaction was mixed with 0.5pg of lambda DNA in 
a second Eppendorf tube and incubated in parallel. The next morning the lambda 
DNA samples were run on a 0.8% agarose gel to determine the extend of digestion. 
Digests were then electrophoresed slowly (2V/cm) overnight in a 0.7% agarose gel
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followed by photography under short wave UV light. The gel was then prepared for 
blotting by submerging it for 40 minutes in Blot I solution. The gel was then 
incubated for a further 50 minutes in Blot II solution. It was then set up for overnight 
blotting similar to Southern (Southern, 1975). DNA was then fixed onto the 
membrane using an optimized UV cross-linking protocol.
Blot I solution:
0.5M NaOH; 1.5M NaCl.
Blot II solution:
0.5M Tris-HCl, pH7.5; 3M NaCl.
RNA preparation
Total RNA was prepared from tissues. Total RNA isolation was carried out using 
RNeasy Maxi Kit (Qiagen) following the protocol as specified by the manufacturer. 
Integrity of RNA was determined by loading lOpg of RNA on a 1.2% agarose gel.
The samples were electrophoresed at 10-15V/cm for 1 hour. Only samples with a 2:1 
ratio between 28S and 18S ribosomal bands where used for downstream applications.
Northern Analysis
lOpg of total RNA was loaded per lane on a 6% (v/v) formaldehyde gel and samples 
were electrophoresed at 5-7V/cm for 3.5 hours. The gel was then prepared for blotting 
by submerging it in double distilled H2O for 2 times 15 minutes and in 20x SSC for
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30 minutes. The RNA was transferred overnight on to a Hybond N+ nylon membrane 
similar to Southern (Southern, 1975). The RNA was fixed on to the membrane by 
using an optimized UV cross-linking protocol.
DNA probe labelling
DNA probes were radioactively labelled by random priming using a random priming 
kit (Pharmacia). 50ng of DNA resuspended in ddfUO was denatured at 100°C for 5 
minutes, cooled immediately on ice for 5 minutes and incubated in a final volume of 
50pl with 5pi of [a32P]-dCTP (370MBq/ml, Amersham) and one Ready To Go™ 
DNA labelling bead (-dCTP) at 37°C for 15 minutes. Unincorporated nucleotides 
were removed using a Pharmacia 50G nick column according to the manufacturers’ 
instructions. The collected probe was denatured by boiling at 100°C for 5 minutes 
before use in hybridisation reactions.
Filter hybridization
Filter membranes were pre-hybridised at 65°C for at least 30 minutes in 25ml of 
hybridisation buffer in either Hybaid bottles placed in a rotating Hybaid oven or in 
Perspex boxes submerged in a shaking water bath. 50ng of labelled probe was added 
to the hybridisation buffer and left to hybridise overnight at 65°C. Following 
hybridisation, nylon filters (Hybond XL, Amersham) were washed in a final
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stringency of O.lx SSC; 0.1% (w/v) SDS at 65°C changing wash solutions every 20 
minutes. Filters were then prepared for autoradiography.
SSC (20x):
3M NaCl; 0.3M NaCitrate.
Hybridisation buffer:
lOx Denhardts; 3x SSC; 0.1% (w/v) SDS; 10% (w/v) Dextran Sulphate; 
50mg/ml denatured salmon sperm DNA. 
lOOx Denhardts:
2% (w/v) BSA; 2% (w/v) Ficoll 400; 2% (w/v) Polyvinyl pyrollidone. 
Autoradiography
Washed nylon membranes from hybridizations were wrapped in Saran Wrap and 
exposed to Kodak Biomax photographic film at -70°C using intensifying screens.
Membrane stripping
Radioactive probe was removed from hybridisation membranes by immersion of the 
membrane into a boiling solution of O.lx SSC; 0.1% (w/v) SDS and letting the 
solution cool to RT. Complete removal of probe was confirmed by exposure of the 
membrane to photographic film.
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Mouse genomic PAC library RPCI21 screening
The mouse PAC library RPCI21 provided by the HGMP Resource Centre was 
constructed by Kazutoyo Osoegawa working in Pieter de Jongs' laboratory at the 
Roswell Park Cancer Institute, Buffalo (Osoegawa et al., 2000). Filters were 
hybridized with (32)P-labelled (random-primed) probe (lx l06cpm/ml hybridization 
solution) using standard conditions. After washing to remove unbound probe, filters 
are wrapped in plastic film (Saran) and exposed to X-ray film (Kodak Biomax) for 24 
hrs. Complete documentation on interpretation of hybridization results (location of 
positive clone plate coordinates) was included with the filter sets.
Sequencing
50 ng of purified plasmid DNA was sequenced with 3.2 pmoles of the appropriate 
primers and 8 pi of Perkin Elmer ABI Prism Big Dye Terminator cycling reaction in a 
final volume of 20 pi according to manufacturer’s instructions. Cycle sequencing was 
carried out using a Hybaid MBS PCR machine with the following parameters: 96°C 
for 30 seconds, 50°C for 15 seconds, 60°C for 4 minutes for 25 cycles. Extension 
products were precipitated and simultaneously purified from unincorporated Dye- 
terminators by ethanol precipitation at room temperature for 15 minutes followed by 
centrifugation at 13.000xg for 20 minutes. Pelleted extension products were washed
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with 70% ethanol and spun for 5 minutes. The pellets were air dried and resuspended 
in 5 pi of loading buffer.
Sequence data was acquired on an Applied Biosystems (ABI) Model 377 Automated 
DNA sequencer with 36 cm well to read plates and 5% poly-acrylamide gels using 
standard running conditions with a 9 hour collection time. Sequence data was 
analyzed and edited with ABI Sequence Analysis. Edited DNA sequence was further 
analyzed using a Contig Assembly Program from www.tigem.it, Redasoft visual 
cloning and Blast software form NCBI.
5% Polyacrylamide gel:
5 ml lOx TBE; 5ml Long ranger acrylamide solution, FMC Bioproducts; 18 g 
of urea; ddtLO to 50ml; 250pl of 10% (w/v) APS; 25pl TEMED 
Loading buffer:
5 parts deionized formamide; 1 part 25 mM EDTA (pH 8.0) containing 50 
mg/ml Blue dextran.
Genotyping by PCR
lOOng DNA were added to a mixture containing: lx Taq Polymerase buffer (Perkin- 
Elmer), 20nM dNTP’s (Amersham), 2mM MgCL, 40pM appropriate primers, 3 units 
Taq polymerase (Perkin-Elmer) in a final volume of 20pi. The PCR was carried out in 
a Hybaid PCR machine and the products analysed on an agarose gel.
Primers:
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PI TTAATATGGTGGTGGCTTGATT 
P2 GGCC AGCC AA AAT AT AATGC
P3 TAGCTGAAGAATGCCCCAAG 
P4 CAGAAGCCTGCAAGGATGTT
PCR conditions:
94°C 1 min.
Then for 35 cycles: 94°C for 30 sec
56°C for 45 sec 
72°C for 45 sec
72°C 2 min 
4°C hold
Cellular biology 
Expansion and trypsinisation o f ES cells
PC3 (OGorman et al., 1997) embryonic stem cells from 129/Sv mice were maintained 
in the undifferentiated state by growth on a feeder layer of y-irradiated primary 
embryonic fibroblasts using culture medium supplemented with leukaemia inhibitory 
factor (LIF) (Mansour, 1988). The ES cells were grown to confluency on 6cm culture
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dishes in 5ml of ES medium. The culture dishes were pre-coated with 3 ml of 0.1% 
Gelatine for 30 minutes and contained a monolayer of 2xl06 embryonic fibroblasts. 
The culture medium was changed every day and when the cells reached confluency, 
they were washed with 5 ml of PBS and 0.5 ml of trypsin was added to them. The 
cells were put in 37°C for 3 minutes and they were pipetted up and down vigorously 
with a Pasteur pipette ensuring that a single cell suspension was obtained. The cells 
were spun out through medium, resuspended in 5 ml of ES medium and 1/10 of them 
were transferred to a fresh 6  cm culture dish with a feeder layer.
ES Medium:
450ml Dulbecco's Modified Eagle's Medium (DMEM) with 0.11G/L 
NaPyruvate, pyridoxine; 75ml Foetal calf serum (FCS); 5ml Glutamine lOOx
stock at 200mM; 2.5ml Penicillin/ Streptomycin 200x stock at 10^ units 
penicillin and lOmg/ml streptomycin; 5ml Non essential amino acid (MEM) 
lOOx stock; 3.5|xl p-mercaptoethanol; 50|xl Leukaemia inhibitory factor (LIF) 
107 units/ml.
Phosphate buffered saline (PBS):
1.4M NaCl; 27mM KC1; 81mM Na2 HPC>4 ; 15mM KH2 PO4 ; adjusted to pH 
7.5 with HCL 
Trypsin:
To 1 litre of ddH20 add: 2.5gr Trypsin powder; 0.4gr EDTA; 7.0gr NaCl; 
0.3gr Na2HP04- 12H20 or 0.22gr Na2 HPC>4 . 7H20; 0.24gr KH2 PO4 ; 0.37gr 
KC1; l.Ogr D-glucose; 3.0gr Tris; 1ml Phenol Red 0.5%; adjusted to pH7.6 
and filtered.
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HEK-293 cells
The eukaryotic cells HEK293 were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10 % foetal bovine serum (FBS), supplemented 
with glutamine. Cells were incubated at 37°C in a 5 % C02 atmosphere and passaged 
when cells reached confluence of 70-80 %.
Preparation o f embryonic fibroblasts
To make G418 resistant embryonic fibroblasts (EFneo), a P2m-/- or an IL3-/- male 
mouse was mated to a wild-type female. The pregnant female was sacrificed at day 13 
or 14 of gestation and the embryos were dissected out free of extra-embryonic 
membranes in sterile conditions. Each embryo was washed in 70% ethanol and 
subsequently in PBS and soft organs and viscera (liver, gut, and brain) were dissected 
out. The remaining carcass was cut in small pieces and was placed into 2ml/embryo of 
trypsin in 15ml tube (FALCON). The tube was left at 4°C for 2-18 hours and then at 
37°C for 10 minutes. The embryonic tissue was pipetted up and down every 5 minutes 
and equal volume of EF medium was added. The big pieces of embryonic tissue were 
left to settle for 2 minutes, the supernatant was removed and plated out in one 162cm2 
tissue culture flask in 50ml of EF medium. The flask was incubated at 37°C and 5% 
CO2 . The medium was changed the next day and the fibroblasts were left to grow for 
2 further days until they reached extreme confluency. The fibroblasts from one flask 
were split 1/5 and passed into 5 new 162cm2 flasks. When they reached confluency 
after 3 days, the fibroblasts from each flask were split 1/5 and were passed into five
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162cm2 flasks again. They were left to grow for further 3 days and then the fibroblasts 
from all 25 flasks were collected, y-irradiated (3500 rads) and were frozen in EF 
medium containing 12% DMSO at 4xl06 cells/vial or 20x106 cells/vial. The total yield 
of fibroblasts is 400-600x106 irradiated EFs/embryo. The irradiated EFs were used to 
form a monolayer on the culture dish in which the ES cells were grown. One vial of 
4xl06 cells is enough for 1x10cm plate or 2x6cm plates.
EF Medium:
450ml Dulbecco's Modified Eagle's Medium (DMEM) with 0.1 lg/1 
NaPyruvate, pyridoxine; 50 ml Foetal calf serum (FCS); 5ml Glutamine lOOx
stock at 200mM; 2.5ml Penicillin/ Streptomycin 200x stock at 10^ units 
penicillin and lOmg/ml streptomycin.
Transfection and selection o f ES cells
The ES cells were grown to 50-100% confluency. The DNA used for the transfection 
was a CsCl2 banded plasmid, linearised, ethanol precipitated and redisolved in sterile
TE at concentration 2mg/ml. 10cm and 6cm culture dishes with 4x10^ and 2x10^ 
embryonic fibroblasts respectively were prepared in advance to receive the 
electroporated cells. The ES cells were trypsinised, spun out through medium and 
resuspended in Hepes buffered saline (HBS) containing 0.0007% 2-mercaptoethanol
(2-ME) at a concentration of 10^cells/ml. The linearised targeting construct was 
added to the stock of cells at a final concentration of 45fig/ml or 50^ig/ml and 0.8ml 
of this mix was used for each electroporation. The electroporations were done with a 
BIORAD Gene Pulser at 400Volts and 25|iF using 0.4cm electrode gap micro-
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cuvettes (BIORAD). The cells were transferred then to a 15 ml Falcon tube containing
3.4 ml medium and plated out onto 4x1 Ocm plates (0.9ml/plate). Selection was 
initiated 24hrs later at a concentration of 250pg/ml or 300pg/ml G418.
The selective medium was changed every 3 days and 576 resistant colonies were 
picked after 10 days onto 96-well plates, in 20pl PBS using P-200 Gilson pipette and 
tip. 6 days later the clones were transferred to 24-well plates and expanded for another 
5 days. At confluency, half of each well was frozen in ES medium containing 12% 
DMSO and the other half was used to make DNA.
Hepes buffered saline (HBS):
137mM NaCl; 5mM KC1; 0.7mM Na2HP04; 6mM dextrose; 21mM Hepes, 
pH7.1.
G418 stock:
50mg/ml in PBS stored up to a month at 4°Q 
Gancyclovir stock:
1 mg/ml in PBS stored frozen.
Karyotyping o f ES cells
The cells were grown to 50-75% confluency, the medium was changed and 2 hours 
later Demecolcine (Sigma) was added at a final concentration of 20ng/ml to arrest the 
cells in metaphase. Two hours later the cells were trypsinised for 3 minutes at 37°C, 
spun out through ES medium for 5 minutes at 1200rpm and washed one more time in 
PBS. They were then resuspended in 5ml KC10.56% (Hypotonic solution) and let
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stand at room temperature for 6 minutes following centrifugation at 750rpm for 5 
minutes. The pellet was resuspended carefully in 5ml fixative by adding it drop wise, 
flicking thoroughly, left at room temperature for 5 minutes, and spun down for a 
further 5 minutes. The fixing procedure was done another 3 times and finally the cells 
were resuspended in 1ml fixative and dropped from 30cm height on a microscope 
slide that was washed before in 5% Acetic Acid in ethanol. The metaphase spreads 
were stained with 10% Giemsa's (DBH) for 20 minutes and chromosomes were count 
on a high power microscope.
Fixative:
Methanol: Acetic Acid 3:1
Preparation o f primary cells fo r  culture
Tissues were placed directly into cold air-buffered (AB) IMDM upon removal. Single 
cell suspensions were obtained either using a 0.2mm mesh (Becton-Dickinson) or by 
gentle teasing with forceps. The cells were centrifuged at 1200 rpm for 7 minutes at 
room temperature and resuspended in appropriate medium.
Complete RPMI medium:
450ml RPMI 1640 (GibcoBRL); 10% FCS; 200jaM  L-Glutamine; 2.5ml lOOx 
stock Streptomycin (lOmg/ml) / Penicillin (104 units); 50pM p- 
mercaptoethanol.
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Purification o f Peripheral T cells
A maximum of 3xl06 cells were loaded on to a T cell enrichment column (R&D 
Systems) following the protocol supplied by the manufacturer. The eluate containing 
the purified cells was centrifuged at 1200 rpm for 7 minutes at room temperature and 
resuspended in 2ml complete RPMI. Purity of the samples was determined by flow 
cytometry using anti CD4 and anti CD8 antibodies. Purity obtained was always 
>90%.
T cell proliferation assay
96well plates were pre-coated with serially diluted anti-CD3 (2c 11) in PBS, with a 
starting concentration of 25pg/ml. The plates were incubated overnight at 4°C. Prior 
to use, the plates were washed three times with PBS. Purified primary cells were 
incubated with CFSE (Sigma) for 10 minutes at room temperature. The prepared cells 
were then plated in complete RPMI at 2xl05 cells per well, in a total volume of 200pl, 
and incubated at 37°C for up to 72 hours. The samples were then analysed by FACS 
analysis. Proliferation was assessed by measuring the proportion of cells in each peak. 
The calculations used to analyse the proliferation were as follows. Data of the 
frequency of CFSE labelled cells (F) that had undergone proliferation rounds (d) were 
used to calculate the adjusted frequencies (AdF), this was achieved by dividing F by 
2d. The percentage of cells triggered to divide (percent divided) was calculated by 
using the equation (l-[AdFo / XAdF) x 100. The proliferation index was obtained from 
the calculation £(AdF x d) / IF  (ford>0 )-
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Animal work
Transgenesis
Before microinjection of a DNA construct, the prokaryotic sequences were removed 
by restriction enzyme digestion followed by a purification of the construct using 
agarose gel electrophoresis as described before. The purified DNA was further 
cleaned on a Schleicher and Schuell Elutip column according to manufacturer’s 
instructions.
Fertilized oocytes from (CBA/Ca X C57BL/10) FI mice were isolated, and pronuclei 
were injected with a solution of the isolated DNA fragment at a concentration of 2-4 
mg/ml in TE buffer. Eggs surviving microinjection were transferred into oviducts of 
recipient pseudo pregnant females. Microinjection of DNA constructs and transfers 
were carried out by Mauro Tolaini.
Injection o f ES cells into blastocysts and generation o f mutant mice
The cells were grown to 70-80% confluency, then trypsinised for 3 minutes at 37°C, 
spun out through 5ml ES medium at 1200rpm for 5 minutes and resuspended in 5ml 
Injection medium. 3.5-day blastocysts were collected from C57B1/6 females and kept 
in blastocyst medium. 15-20 ES cells were injected into each blastocyst and 10-12 
blastocysts were transferred into the uterus of each foster mother. Chimeric males 
were bred to C57B1/6 females and germline transmission was determined by agouti
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coat colour. Injection of blastocysts and transferring into the uterus were carried out 
by Mauro Tolaini and Dimitris Kioussis.
Injection medium:
Dulbecco's modification of Eagle's medium with 20mM Hepes, without 
glutamine and bicarbonate (ICN Biomedicals); 10% Foetal calf serum; 1.5% 
Penicillin/streptomycin/ glutamine.
Blastocyst medium:
Dulbecco's modification of Eagle's medium; 10% Foetal calf serum; 1.5% 
Penicillin/ streptomycin/ glutamine.
Fluorescent Microscopy 
Whole Mouse Microscopy
Photographs were taken using a Nikon coolpix 5000 digital camera mounted on a 
Leica MZ FLIII fluorescence stereomicroscope fitted with a GFP fluorescence filter.
Cell Microscopy
To perform the EYFP fluorescence experiment, HEK293 cells were grown on cover 
slips in DMEM medium. The cells were transfected with 1 pig of desired plasmids 
using Lipofectin (LifeTechnologies, Inc) according to manufacturer’s instruction. 24 
to 72 hours after transfection cells were fixed with 1.5 % Paraformaldehyde in PBS
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for 15 min. EYFP images were analysed using a Deltavision microscope and the 
standard system operating software provided with the Deltavision microscope.
Flow c\tometr\ 
FACS Analysis
Single cells suspensions were prepared from thymus, lymph node and femoral bone 
marrow. To enrich for DN thymocytes, CD4+ and CD8+ thymocytes were depleted by 
staining single cell suspensions with anti-CD4 (RL 172.4) and anti-CD8 (AD4(15)) 
followed by treatment with guinea pig complement (Life Technologies) and rabbit 
complement (Sigma). The resulting viable cells were recovered on a ficol gradient.
For flow cytometry 106 cells were stained in lOOpl ice-cold PBS supplemented with 
0.5% BSA and 0.02% sodium azide. Cells were incubated for 30 minutes on ice with 
Fc blocker to minimize non-specific binding prior to a 30 minutes incubation with the 
specific antibodies. After the staining cell were washed twice with lOOpl ice-cold 
PBS azide. Cells were again resuspended in lOOpl PBS azide before data acquisition 
using a FACSCalibur and CELLQUEST software. All antibodies were used at 
appropriate saturating concentrations. The antibodies used were as follows: Fc blocker 
(anti-CD 16/32), anti-Terl 19-Biotin (Pharmingen), anti-Macl-APC (Parmingen), anti- 
Grl-Biotin (Pharmingen), anti-CD3-Biotin (Caltag), anti-CD 19-APC (1D3), anti-IgD- 
Biotin (1.19), anti-CD4-PECY7 (Caltech), anti-CD8-APC (Caltech), anti-Thyl-PE 
(Pharmingen), anti-CD44-APC (Caltag), anti-CD25-Biotin (Pharmingen), anti-CD69- 
Biotin (Pharmingen), Streptavidin-PECY7 (Caltag).
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Apoptosis assay (PI staining)
5 x 105 cells were used per sample. The cells were centrifuged at 1200 rpm for 5 
minutes at room temperature, washed once with PBS and stained with propidium 
iodide (1 mg/ml) in a hypotonic buffer overnight at 4°C in the dark. Analysis was 
carried out by flow cytometry as described by F. Nicoletti (Nicoletti et al., 1991). 
Hypotonic buffer
0.85mM Na3Citrate; 0.1% Triton X-100
Electro Mobility Shift Assay
The shift assay was performed with a 36-mer double stranded oligonucleotide 
containing FT1 (5 ’ -CTATTCAATCAATCCTTCATCGTTCATTCATTCAAC-3 ’) or 
a double stranded oligonucleotide containing the binding site for OCT-1 (Promega). 
An aliquot of the single stranded oligonucleotides were annealed (94°C, 5 min; 58°C, 
5 min) in 100 pi of TE buffer and then slowly cooled. The double-stranded DNA was 
5’ end-labelled with [y32P] ATP (ICN Pharmaceuticals, Inc.) and T4 polynucleotide 
kinase (Promega). After the labelling reaction, the unincorporated nucleotides were 
separated from the labelled DNA using MicroSpin™ S-200 columns (Pharmacia 
Biotech). DNA-protein binding reaction was performed as follows: lpl of nuclear 
extracts (3pg/pl) was incubated with 9 pi Binding Buffer. In parallel, 0,5pi of probe 
(50,000 cpm of labelled, double stranded oligo) was incubated with 1 pi of poly dldC 
(200ng/pl) in a total volume of lOpl for 10 minutes. Subsequently, the two mixtures 
were added together and incubated for 20 minutes on ice. In a competition
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experiment, a hundred times excess of unlabelled specific oligo nucleotide was 
incubated for 10 minutes before adding the specific radioactive probe. The labelled 
probe was separated from DNA-protein complexes by electrophoresis on 6 % non­
denaturing polyacrylamide gels in 0.5 x Tris-borate/EDTA buffer pH 7.8 at RT. 
Autoradiography was carried out by exposure of the gel to intensifying screen for 6 to 
14h at -70°C.
Binding Buffer:
400mM HEPES, pH 7.9; 200mM KC1; lOmM MgCl; 0.4mM EDTA; ImM 
DTT; 30% glycerol
Proteins 
Protein expression and purification
The construct sequences used in the present study are summarised in Table 1. ATX1 
constructs were amplified from human ATX1 (EMBL/GenBank acc. no. P54253). 
HBP1 constructs were produced by PCR amplification of the M. musculus HBP1 
sequence (acc. no. Q8R316). All constructs were produced as his-tagged GST fusion 
proteins. To obtain carboxy-terminal His and GST tagged recombinant proteins, the 
E. coli BL21(DE3) was transformed with DNA constructs. The single colony was 
picked from a freshly streaked selective plate, inoculated in a starter culture 100 ml 
LB supplemented with 100 pg/ml ampicillin and incubated overnight at 37°C. The 
pre-culture was transferred to a 6 litre of LB medium (100 pg/ml ampicillin, 5 mg/ml 
tetracycline and 30 pg/ml chloramphenicol) and further incubated until the A6oo was
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equal to 0.5. The protein expression was induced by adding isopropyl-p-D- 
thiogalactoside (IPTG), to a final concentration of 1 mM and incubated for 4-6 h. 
After that time, cells were harvested by centrifugation at 4°C for 15 min at 5000 rpm. 
The bacterial pellet from a 6 L culture was resuspended in BugBuster reagent by 
pipetting or gentle vortexing, using 5 ml reagent per gram of wet cell paste. 1 pi (25 
units) Benzonase Nuclease was added per 1 ml BugBuster reagent used for 
resuspension. The cell suspension was incubated on a rotating mixer at a slow setting 
for 10-20 min at room temperature. Insoluble cell debris was removed by 
centrifugation at 13,000xg for 20 min at 4°C. The supernatant was applied to a Ni- 
NTA agarose column (QIAGEN). Cleavage of the his-tagged GST was achieved 
overnight at room temperature using GIBCOBRL His-tagged TEV recombinant 
protease. Separation of GST and TEV from the proteins was performed using a Ni- 
NTA agarose column. The cleavage product was recovered by elution.
Preparation o f nuclear extracts
Nuclear extracts from mouse thymus were prepared as described (Dignam et al., 
1983). Briefly, the tissue was disrupted into smaller pieces and about 109 cells were 
spun down at 3,000 rpm, lOmin, Beckman J6 at 0°C. The pellet was resuspended in 
ice-cold homogenisation buffer in 5 times the volume of the pellet and homogenised 
with 10 strokes using a dounce tissue grinder (Wheaton). 3.5 ml of the homogenate 
were laid carefully on the top of the 1.5 ml pre-made cushions of homogenisation 
buffer in 5 ml tubes of the SW55 rotor. After centrifugation (100,000xg/30,000rpm, 
0°C, 1 hour) the supernatant was removed and the nuclear pellet was resuspended in
3.5 ml per tube nuclear lysis buffer. The nuclei were lysed adding 0.04 volumes of
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0.5% SDS and 0.1 volume of 4M (NH^SO* The lysate was spun in the SW55 rotor 
(150,000xg/40,000rpm, 0°C, lhr). The supernatant was transferred into a fresh tube 
and proteins were precipitated by adding solid (NHL^SCU to a concentration of 
0.33mg/ml. The protein pellet was collected by centrifugation in the SW55 rotor 
(100,000xg/30,000rpm, 0°C, 20 minutes). The pellet was resuspended in 1 ml of 
nuclear dialysis buffer and dialysed against >200 volumes of Dignam nuclear dialysis 
buffer for 2hr at 4°C. The concentration of protein extract was measured by a 
spectrophotometer at 590nm (against titrated BSA). Subsequently the extract was 
aliquoted into small samples, frozen and stored at -70°C.
Homogenisation buffer:
lOmM Hepes, pH 7.6; 15mM KC1; ImM EDTA; O.lmM EDTA; 2.2M 
Sucrose; lOmM NaF 
Nuclear Lysis Buffer:
lOmM Hepes, pH 7.6; lOOmM KC1; 3mM MgCl2; O.lmM EDTA; 10% 
Glycerol (v/v); lOmM NaF 
Dignam Dialysis buffer
20mM Hepes, pH7.6; lOOmM KC1; 0.2 mM EDTA; 20% Glycerol (v/v); 
0.5mM NaF
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Results
Structural analysis o f AXH module 
Properties o f the AXH module
As described in the introduction of this thesis a small motif of roughly 130 amino 
acids, named AXH module, was identified in the apparently unrelated factors HBP1 
and ATX1. Protein motifs are conserved sequences within several protein families. 
The conservation of the motif suggests that it participates in a common structural 
element and/or a common function that is critical for the proteins in which it was 
found. Thus, the homology found between ATX1 and HBP1 could provide insights 
into the function of both proteins. We, therefore, set up a collaboration with the 
department of Molecular Structure at the National Institute for Medical Research to 
characterize the structural properties and stability of this domain. My part of this work 
consisted of the cloning and expression of the protein domains.
Defining the domain boundaries
In order to determine the minimal length required to obtain a folded, soluble and 
highly expressed AXH from both ATX1 and HBP1, constructs for each of the two 
proteins were initially designed (ATX1 (568-689) and HBP1 (208-345)) which
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encompass the region of maximal homology (Table 1). Both proteins were expressed 
in good yields with final yields of around 20mg/litre of culture. The secondary and 
tertiary structures were checked by circular dichroism (CD) and nuclear magnetic 
resonance (NMR) respectively (The CD and NMR experiments were done by Cesira 
de Chiara and will not be further discussed in this thesis). To check whether the AXH 
module could still fold properly if cut further, constructs ATX1 (574-689) and HBP1 
(208-335) were designed, omitting an N-terminal and a C-terminal proline rich stretch 
respectively (Table 1). The rationale for this choice was that both stretches are not 
conserved and their sequences do not suggest secondary structure elements. ATX1 
(574-689) was isolated from the soluble fraction but the yields of the recombinant 
protein were extremely low yields (less than 1 mg/litre of culture). Both the CD and 
ID NMR spectra of the protein showed that the fragment retains some 3D fold but 
adopts a conformation different from that of the longer version (The CD and NMR 
experiments were done by Cesira de Chiara). In contrast, most of the expressed HBP1 
(208-335) formed inclusion bodies despite all attempts to shift the equilibrium 
towards the soluble form. To investigate a possible role of the flanking residues in 
domain stability, one more construct was designed for each of the two proteins by 
extending the boundaries both N- and C-terminally. In the absence of other 
indications, we selected the new boundaries to include predicted secondary structure 
elements. The NMR spectra of HBP1 (200-343) and ATX1 (556-700) are those of 
folded species and reminiscent of those of HBP1 (208-345) and ATX1 (568-689). 
However, the spectrum of ATX1 (556-700) changes with time, leading to a major line 
broadening indicating that the protein tends to aggregate. These results show that the 
stability of AXH domain is mostly independent from flanking regions but depends on
87
the domain integrity. Importantly, mutants excluding residues within the domain 
boundaries defined here lead to unfolded proteins.
The AXH module o f ATX1 but not o f HBPI forms dimers
The ATX1 and HBP1 constructs were then probed for their association state by 
analytical ultracentrifugation (The analytical ultracentrifugation experiments were 
done by Cesira de Chiara and only the final result will be described). The apparent 
molecular weight of 18.0 kDa derived for HBP1 (208-345) AXH domain 
approximates within experimental error the monomer value (16,410). Sedimentation 
equilibrium curves of ATX1 (568-689) AXH domain can be fit either as a dimer (at 
200 mM NaCl) or as a mixture of a prevalent dimeric species in equilibrium with 
further aggregates (at 50 mM NaCl). A higher tendency to aggregate was observed for 
the extended ATX1 (556- 700) AXH domain which, depending on salt conditions, is 
either a tetramer or a multimer in solution, confirming that extension of AXH of 
ATX1 promotes further aggregation. In contrast, HBP1 (200-343) AXH domain 
remains monomeric. These results show that the AXH domain in isolation is in a 
different aggregative state in the two protein families: while the AXH of HBP1 exists 
as a monomer, the AXH of ATX1 exists in solution as a dimmer or aggregates.
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Table 1 Summary of the constructs used in the study
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Constructs Boundaries Behaviour
HBPl(208-335)................................... PSTVWHCFLK...... VCL Inclusion bodies
HBP 1(208-345).................................... PSTVWHCFLK.....VCLPPGHPDA1NF Folded, monomer
HBP 1(200-343)..........DLGWCNSWPSTVWHCFLK.....VCLPPGHPDAI Folded, monomer
ATX 1(556-700) PVVQSBASPAAAPPTLPPYFMK VC1SLTLKNLKNGSVKKGQ Aggregating
ATX 1(568-689) PPTLPPYFMK... VC1SLTLKNLK Folded, dimer
ATX 1(574-689) YFMK... VC1SLTLKNLK Low yield
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HBP1 intracellular localization.
To gain insight into those sequences in the HBP1 that mediate nuclear import, we 
performed sub-cellular localization studies on wild type and mutant proteins in living 
cultured cells. First, we determined the sub-cellular localization of wild type HBP1. 
For that purpose, the complete HBP1 coding sequence was fused to the C-terminus of 
EYFP using the pEYFP-Cl vector (BD bioscience) (figure 7A). This approach has the 
advantage that localization of fusion proteins can be monitored directly by 
fluorescence microscopy. These constructs were transfected transiently into human 
embryonic kidney cell line 293 and analyzed for EYFP expression 24 hours post­
transfection. As published previously (Stauber et al., 1995), EYFP alone localized in 
both the cell nucleus and the cytoplasm (figure 7B). This is because proteins smaller 
than 60 kDa are able to enter the nucleus passively by diffusion through the nuclear 
pores. In sharp contrast, however, expression of HBP1-EYFP fusion protein resulted 
in exclusively nuclear accumulation, highlighted by a significant concentration in 
nucleoplasmic speckles (figure 7B). Given its size (around 80 kDa), this fusion 
protein is not able to enter the nucleus passively by diffusion through the nuclear 
pores. This might indicate that active processes may be involved in the import of 
HBP1 into the nucleus.
In order to define the regions of the HBP1 protein that are essential for nuclear 
transport of HBP 1, fusion proteins consisting of EYFP and various HBP1 domains 
were constructed. It is common for nuclear proteins that their nuclear localisation
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domain co-localises with their DNA binding domain. Therefore, we constructed two 
different fusion proteins. The first construct consists of the HMG box, which is the 
DNA binding domain of HBP1, fused to EYFP from now on referred to as EYFP- 
HMG. The second construct consists of the entire N terminal region of HBP1 up to 
the HMG box fused to EYFP from now on referred to as EYFP-AHMG (figure 7A). 
Transfection of the constructs into human embryonic kidney cell line 293 cells led to 
expression of the respective recombinant proteins. Fluorescence microscopy of the 
various transfected cell-lines revealed that the EYFP-HMG fusion protein
was located exclusively in the nucleus (figure 7B), while the construct in which the 
HMG box was deleted (EYFP-AHMG), was found throughout the cell giving the 
same staining pattern as EYFP alone (figure 7B). The size of this fusion protein was 
around 60 kDa. This allows the fusion protein to enter the nucleus passively by 
diffusion through the nuclear pores. This might explain why the protein is not found 
exclusively in the cytoplasm.
It should also be noted that a nucleoplasmic speckle pattern was observed when the 
EYFP-HMG box fusion protein was transfected into the cells. However, this 
nucleoplasmic speckle pattern showed smaller speckles compared to the wild-type 
HBP1 (figure 7B).
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Figure 7: The subcellular localization of full length HBP1 and truncated HBP1 in 
HEK-293 cells
A) Schematic representation of the EYFP-HBP1, EYFP-AHMG and EYFP-HMG.
B) The fluorescence image of HEK293 cells transfected with each EYFP fusion 
protein. EYFP expression can be visualized directly by its intrinsic green 
fluorescence. Counterstaining is with the nuclear dye DAPI (red fluorescence).
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When the cells were analysed at 72 hours post transfection the distribution of EYFP- 
HMG and EYFP-AHMG was the same as at 24 hrs post transfection (figure 7B). For 
the full-length EYFP-HBP1 fusion protein at 72 hrs post transfection, no fluorescent 
living cells were detected. Time-lapse videos showed that cells expression the full- 
length EYFP-HBP1 fusion protein changed there morphology (cells became round) 
and detached from the cover slip (data not shown). Rounding up of the cell and 
detachment from the matrix are signs of apoptosis (Nakayama, 1998). This might 
indicate that over-expression of the EYFP-HBP1 protein induces cell death.
Taken together these results indicate and confirm that the FIMG box sequences 
contain a nuclear localization signal that leads to the import of the transfected protein 
into the nucleus.
Generation and analysis o f Cre transgenic mice. 
Establishing Cre transgenic mouse lines
In order to generate a system for conditional gene targeting within the myeloid and 
lymphoid lineages two different regulatory elements were chosen to direct expression 
of iCre in transgenic mice. The improved Cre (iCre) gene was chosen instead of the 
“normal” Cre because iCre contains a reduced CpG content (Shimshek et al., 2002). 
High CpG content of prokaryotic coding sequence has been associated with epigenetic 
silencing in mammals. This part of this thesis was done in collaboration with Adam 
Williams.
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To restrict the iCre expression to the haematopoietic compartment the vavl 
expression vector was used. The vavl expression vector (HS21/45 vav-hCD4) has 
been shown previously to drive expression of a hCD4 transgene throughout the entire 
haematopoietic compartment (Ogilvy et al., 1999). Vavl is a signal transducer protein 
expressed exclusively in the haematopoietic system, where it plays a pivotal role in 
growth factor-induced differentiation and proliferation. Vavl couples tyrosine kinase 
signals with the activation of the Rho/Rac GTPases, leading to cell differentiation 
and/or proliferation (Tybulewicz et al., 2003). Thus, to restrict conditional targeting to 
the haematopoietic system, the hCD4 gene was removed from the vavl expression 
vector and replaced with the iCre cDNA (done by Adam Williams) (figure 8). To 
restrict expression further to lymphocytes, the iCre cDNA was inserted into, the 
earlier described, hCD2 VA vector, which has previously been shown to drive high 
levels of transgene expression in T cells and occasionally in B cells, but not in other 
tissues (Lang et al., 1988). As a control, the GFP open reading frame was inserted 
directly into the hCD2 VA cassette (figure 8).
After linearization and removal of plasmid sequences each of the Vav-iCre, hCD2- 
iCre and hCD2-GFP constructs were injected into the pronuclei of fertilised oocytes 
(injections were done by Mauro Tolaini). The presence of the transgene in founders 
was determined by Southern blot analysis. After germ line transmission a minimum of 
four independent mouse lines were established for each construct. Of each of the Vav- 
iCre, hCD2-iCre and hCD2-GFP lines, one line of each which shows wildtype 
number of haematopoietic cells (table 2 on page 122) and good reporter gene 
expression (data not shown) was chosen for further analysis.
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Figure 8 Cre expression constructs
The iCre cDNA (Shimshek et al., 2002) was inserted into the HS21/45 vav-hCD4 
expression cassette (Vav-iCre) (Ogilvy et al., 1999). The untranslated portion of the 
Vavl exon 1 is represented by a light grey box. The SV40 splice sites and poly- 
adenylation signal (pA) are represented by dark grey boxes. The iCre and GFP 
cDNAs were inserted into the hCD2 VA cassette (Zhumabekov et al., 1995) (hCD2- 
iCre and hCD2-GFP, respectively). Exon 1, exon 2 and the hCD2 poly-adenylation 
signal (pA) are represented by black boxes.
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To determine the efficiency of iCre expression, Vav-iCre and hCD2-iCre transgenic 
mice were crossed to the homozygous R26R-EYFP reporter mouse (Srinivas et al., 
2001). The R26R-EYFP reporter line contains an EYFP transgene inserted into the 
ROSA26 locus by homologous recombination. EYFP is only expressed when a floxed 
transcriptional stop sequence that prevents transcription from the ROSA26 locus is 
excised by Cre mediated recombination (figure 9). Resulting EYFP expression can be 
detected by either fluorescence activated cell sorting (FACS) or by fluorescence 
microscopy.
Tissue restricted expression ofiCre.
In order to investigate iCre expression patterns in each of the selected lines, mice 
transgenic for both iCre and EYFP were dissected under a fluorescence microscope 
fitted with a GFP filter. Mice either transgenic only for EYFP or for hCD2-GFP were 
also dissected as negative and positive controls, respectively (figure 10).
In Vav-iCre/EYFP and hCD2-iCre/EYFP transgenic mice, superficial lymph nodes 
were obvious and appeared bright and uniform in colour and fluorescent intensity 
(figure 10). Other lymphoid tissues such as the thymus, spleen, Peyer's patches and 
intestinal crypto patches were also positive for EYFP expression (figure 10). Further 
dissection revealed that the mesenteric (figure 10) and inguinal lymph nodes (data not 
shown) were positive for EYFP expression. Analysis of hCD2-GFP transgenic mice 
showed an almost identical distribution of fluorescence, as observed in Vav- 
iCre/EYFP and hCD2-iCre/EYFP transgenic mice. In contrast, however, to the
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Figure 9 Fate mapping cells that have undergone recombination
A tissue-specific promoter (In our case hCD2 or VAV) controls the expression of iCre 
transgene. These mice were crossed to a reporter line, which has EYFP cDNA 
inserted into the ubiquitously expressed ROSA26 locus, preceded by a loxP-flanked 
stop sequence. In cells that do not express iCre no EYFP is detected because Cre 
mediated recombination is required to remove the floxed Stop sequences that separate 
the promoter from the reporter coding sequences. Cre activity results in the removal 
of the Stop sequence and reporter activation. Even cells that no longer express Cre, 
will express the reporter.
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Figure 10 Analysis of Cre expression patterns in tissues of transgenic mice by 
fluorescent microscopy
Vav-iCre R26R-EYFP double transgenic mice, hCD2-iCre R26R-EYFP double 
transgenic mice, hCD2-GFP mice were dissected under a fluorescent microscope 
fitted with a GFP filter. A R26R-EYFP single transgenic mouse is also shown as a 
negative control. Similar results were obtained in at least five independent 
experiments.
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uniform expression as seen in Vav-iCre/EYFP and hCD2-iCre/EYFP transgenic mice, 
the Peyer’s patches from hCD2-GFP mice exhibited areas of high and low 
fluorescence intensity (see below).
Surprisingly, expression of EYFP was noted in testis (figure 10) and ovaries (data not 
shown) of Vav-iCre/EYFP transgenic mice. Mosaic expression was also seen in testis 
of hCD2-iCre/EYFP transgenic males (figure 10), but not in ovaries of hCD2- 
iCre/EYFP females (data not shown). In both iCre expressing lines, all other tested 
tissues were negative for EYFP expression, indicating that, with the exception of 
testis and ovaries, expression of iCre was restricted to tissues of the haematopoietic 
and/or immune system. Interestingly, expression of GFP was not detected in testis or 
ovaries from hCD2-GFP mice (figure 10). No EYFP expression was detectable in any 
tissue analysed from EYFP single transgenic controls.
Cre expression in T cells
In order to identify the types of cells that have undergone Cre mediated recombination 
within the positive organs described above, cells isolated from lymph nodes were 
stained with anti-CD3 and anti-CD 19 and analysed by flow cytometry (figure 11 and 
table 2 and 3). Analysis of both Vav-iCre/EYFP and hCD2-iCre/EYFP transgenic 
mice revealed that all peripheral CD3+ T cells expressed EYFP. In addition, high 
levels of GFP expression were detected in all peripheral T cells from hCD2-GFP 
mice. Thymocytes were stained with anti-CD4 and anti-CD8 to distinguish the
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Figure 11 Flow cytometric analysis of EYFP and GFP expression in lymph node 
derived lymphocytes
Single cell suspensions from lymph nodes were prepared from Vav-iCre R26R-EYFP 
double transgenic mice, hCD2-iCre R26R-EYFP double transgenic mice, hCD2-GFP 
mice and wild type mice. These cells were stained with CD3 and CD 19 antibodies to 
allow differentiation of the T cell (CD3+/CD19-) and B cell populations (CD3- 
/CD19+). Levels of EYFP or GFP expression on T cells and B cells are shown as 
histograms. Bold line indicates EYFP or GFP expression in the transgenic animals 
while the dotted line shows the auto-fluorescence in non-transgenic controls. Each 
experiment was repeated at least three times with similar results.
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CD4+/CD8'or CD4"/CD8+ single positive (SP) thymocytes as well as CD4+/CD8+ 
double positive (DP) thymocytes (figure 12 and table 2 and 3). Detailed analysis 
revealed that Vav-iCre/EYFP and hCD2-iCre/EYFP transgenic mice exhibited high 
levels of EYFP expression on approximately 100% of both SP and DP thymocytes. 
This finding indicates that Cre was expressed in these cells or had been expressed at 
an earlier developmental time point. Identical analysis revealed a similar percentage 
of GFP expressing SP and DP thymocytes in the hCD2-GFP line. Importantly, no 
expression was seen on T cells derived from EYFP single transgenic controls (figure 
11 and 12 dotted line).
To determine precisely the time point at which Cre expression is initiated during 
thymocyte development in each of the lines, double negative (DN) thymocytes were 
stained with anti-CD44 and anti-CD25 in order to separate the four stages of DN 
thymocyte development (figure 13 and table 2 and 3). When thymocytes enter the 
thymus, they express high levels of CD44, but no CD25 (DN1 stage). As the 
thymocytes mature they up regulate CD25 to become CD44+/CD25+ cells (DN2 
stage); subsequent down regulation of CD44 gives rise to CD44low/CD25+ thymocytes 
(DN3 stage). After successful T cell receptor (3-chain rearrangement these cells down 
regulate CD25 to become CD447CD25’ (DN4 stage). Finally, these cells begin to 
express CD4 and CD8 to become DP thymocytes.
All four DN populations from the Vav-iCre/EYFP line showed high levels of EYFP 
expression in approximately 100% of cells, indicating that even the earliest T cell 
progenitors within the thymus had expressed Cre. Intriguingly, analysis of the hCD2- 
iCre/EYFP line revealed a slightly different pattern of EYFP expression. A population
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Figure 12 Row cytometric analysis of EYFP and GFP expression in thymocytes
Thymocytes from Vav-iCre R26R-EYFP double transgenic mice, hCD2-iCre R26R- 
EYFP double transgenic mice, hCD2-GFP mice and wild type mice were stained with 
CD4 and CD8 antibodies. Levels of EYFP or GFP expression on SP (CD4+/CD8- or 
CD4-/CD8+), DP (CD4+/CD8+) and DN populations (CD4-/CD8-) are shown as 
histograms. Bold line indicates EYFP or GFP expression in the transgenic animals 
while the dotted line shows the auto-fluorescence in non transgenic controls. Each 
experiment was repeated at least three times with similar results.
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Figure 13 Flow cytometric analysis of EYFP and GFP expression during DN 
thymocyte development
Single cell suspensions from thymocytes from Vav-iCre R26R-EYFP double 
transgenic mice, hCD2-iCre R26R-EYFP double transgenic mice, hCD2-GFP mice 
and wild type mice were depleted from CD4 and CD8 expressing cells by 
complement treatment (see materials and methods). Remaining DP and SP 
thymocytes were excluded from analysis by staining with CD4, and CD8 antibodies. 
Resulting DN thymocytes were stained with anti-CD25 and anti-CD44 antibodies. 
Levels of EYFP or GFP expression at each DN stage are shown as histograms. Bold 
line indicates EYFP or GFP expression in the transgenic animals while the dotted line 
shows the auto-fluorescence in non-transgenic controls. Each experiment was 
repeated at least three times with similar results.
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of EYFP negative cells were detected in DN1, DN2, and DN3 stages, which 
disappeared in the final DN4 stage. To determine if all the cells in DN2 were true 
immature T cells they were stained with a number of lineage markers (figure 14). The 
EYFP negative cells did not express the CD3/T-cell receptor complex as measured by 
anti CD3 as is true for DN thymocytes before they rearrange the TCR genes. They 
were negative for markers, which are characteristic for B cells (B220), Natural Killer 
cells (DX5), monocytes (Macl), red blood cells (Terl 19) and dendritic cells (CD1 lc). 
They were positive for the haematopoietic marker CD45 and expressed intermediate 
levels of the T cell marker Thy. 1. Altogether, these data suggest that the negative cells 
in DN2 are true immature T cells that had not initiated Cre expression yet. Analysis of 
GFP expression in DN thymocytes from hCD2-GFP transgenic mice showed yet a 
different expression profile. A significant proportion of DN 1 thymocytes did not 
express detectable amounts of GFP. As the thymocytes proceeded through to the DN2 
stage the proportion of GFP expressing cells increased until the DN3 and DN4 stages, 
where 100% of the cells expressed GFP. These data suggest that the hCD2 transgenes 
start expressing sometime between the DN1 and DN3 stage and that expression is 
universal in all thymocytes by DN4 stage.
Cre expression in B cells
To analyse iCre expression in B lymphocytes, cells isolated from lymph nodes of 
Vav-iCre/EYFP and hCD2-iCre/EYFP transgenic mice were stained with anti-CD3 
and anti-CD 19 in order to distinguish the B cell and T cell populations (figure 11 and 
table 2 and 3). Analysis of EYFP expression revealed that almost all peripheral
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Figure 14 Flow cytometric analysis of EYFP negative cells in DN2
Single cell suspension from thymocytes from hCD2-iCre R26R-EYFP double 
transgenic mice was depleted from CD4 and CD8 expressing cells by complement 
treatment (see materials and methods). The remaining DN thymocytes were stained 
with CD25 and CD44 antibodies and one of the following lineage markers anti-CD3, 
anti-B220, anti-DX5, anti-Mac-1, anti-Terl 19 anti-CDl lc, anti-CD45 or anti-Thy-1. 
The bold line in the histograms shows the expression profile for each marker on the 
EYFP negative cells in the DN2 compartment. The dotted line shows the staining 
profile of the used lineage markers on splenocytes.
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CD19+ B cells in these transgenic mice had expressed iCre. In contrast, only low 
levels of GFP expression were detected in peripheral B cells from hCD2-GFP mice. 
To determine the stage of B cell development at which expression of iCre was 
initiated in this lineage, bone marrow was isolated and stained with anti-CD 19 and 
anti-IgD antibodies (figure 15 and table 2 and 3). CD19+/IgD+bone marrow cells are 
mature recirculating B cells, whereas CD19+/IgD'bone marrow cells represent stages 
of B cell development prior to migration into the periphery. All mature CD19+/IgD+ 
and CD19+/IgD'bone marrow derived B cells in Vav-iCre/EYFP and hCD2- 
iCre/EYFP transgenic mice were positive for EYFP expression, indicating that even 
the earliest B cell progenitors had undergone iCre mediated recombination. In 
contrast, recirculating CD19+/IgD+ bone marrow B cells from hCD2-GFP mice 
expressed lower levels of GFP, comparable to those found in the peripheral lymph 
node B cells of these mice. Interestingly, the more immature CD19+/IgD' bone 
marrow B cells expressed high levels of GFP. These data suggest that the Vav-iCre 
and hCD2-iCre constructs have been active in all B cell and T cell progenitors. The 
pattern of expression of hCD2-GFP that does not detect the history of expression, but 
current expression, indicates that the transgenic construct is active in early stages of B 
cell development, but its expression is diminished as the B cells mature leading to a 
picture resembling PEV in this cell lineage.
Cre expression in other lineages
As the Vavl regulatory elements have previously been shown to direct transgene 
expression in all haematopoietic cells we decided to check for Cre expression in the 
myeloid and erythroid lineages.
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Figure 15 Row cytometric analysis of EYFP and GFP expression in bone marrow
derived B cells
Single cell suspensions from bone marrow from Vav-iCre R26R-EYFP double 
transgenic mice, hCD2-iCre R26R-EYFP double transgenic mice, hCD2-GFP mice 
and wild type mice were stained with CD19 and IgD antibodies. Levels of EYFP or 
GFP expression on mature recirculating CD19+/IgD+ B cells and CD19+/IgD- 
immature B cells are shown as histograms. Bold line indicates EYFP or GFP 
expression in the transgenic animals while the dotted line shows the auto-fluorescence 
in non transgenic controls. Each experiment was repeated at least three times with 
similar results.
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Firstly, bone marrow cells were stained with anti-Gr-1 and anti-Mac-1 to identify 
granulocytes and monocytes (figure 16 and table 2 and 3). Granulocytes (Gr-1+/Mac- 
1+) from the bone marrow of Vav-iCre/EYFP transgenic mice showed high levels of 
EYFP expression in all cells. In contrast, no expression of EYFP or GFP was seen in 
granulocytes of hCD2-iCre/EYFP or hCD2-GFP transgenic mice, respectively. All 
monocytes (Gr-l+/Mac-llow) from Vav-iCre/EYFP transgenic mice showed high 
levels of EYFP. No substantial EYFP or GFP expression was seen in monocytes from 
either hCD2-iCre/EYFP or hCD2-GFP transgenic mice, respectively. However, a 
small population of EYFP positive Gr-l+/Mac-llow cells were observed in hCD2- 
iCre/EYFP transgenic mice.
Finally, to analyse EYFP expression in the erythroid lineage, bone marrow was 
stained with anti-Terl 19 (figure 16 and table 3). Erythrocytes from Vav-iCre/EYFP 
transgenic mice were seen to express EYFP, although the levels of expression varied 
significantly between cells. No EYFP or GFP expression was seen in erythrocytes 
from hCD2-iCre/EYFP or hCD2-GFP transgenic mice, respectively.
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Figure 16 Row cytometric analysis of EYFP and GFP expression in bone marrow
derived myeloid and erythroid cells
Single cell suspensions from bone marrow from Vav-iCre R26R-EYFP double 
transgenic mice, hCD2-iCre R26R-EYFP double transgenic mice, hCD2-GFP mice 
and wild type mice were stained with Gr-1 and Mac-1 or Terl 19 antibodies. Levels of 
EYFP or GFP expression on granulocytes Gr-1+/Mac-1+, monocytes Gr-l+/Mac-l,ow 
or erythrocytes are shown as histograms. Bold line indicates EYFP or GFP expression 
in the transgenic animals while the dotted line shows the auto-fluorescence in non 
transgenic controls. Each experiment was repeated at least three times with similar 
results.
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Table 2: Summary of iCre mice: Cellularity
The table shows the Absolute number of cells (ABS) and the percentage of cells for 
different cell types in haematopoietic organs. The mean of triplicates ± one standard 
deviation is shown.
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Vav-iCre hCD2-iCre hCD2-GFP Non transgenic
ABS 
(x 1,000,000)
%
ABS 
(x 1,000,000)
%
ABS 
(x 1,000,000)
%
ABS 
(x 1,000,000)
%
Lymph node*
Peripheral T cells 6.1±2.6 45%±3 7.1±3.6 45%±3 4.2±3.0 46%±3 4.5±3.3 44%±3
Peripheral B cells 5.4±2.3 40%±3 6.5±3.3 41%±3 3.5±2.5 38%±3 3.8±3.0 40%±3
Thymus
Double Negative 6.2±0.7 4%±1 4.9±0.4 3%±1 4.3±0.4 4%±1 6.6±0.4 5%±1
Double Positive 130±15 84%±1 140±9.9 85%±1 93±9.0 86%±1 110±6.2 84%±1
Single CD4 Pos. 14±1.6 9%±1 16±1.2 10%±1 9.8±1.0 9%±1 12±0.7 9%±1
Single CD8 Pos. 4.7±0.5 3%±1 4.9±3.5 3%±1 4.3±0.5 4%±1 4.0±0.2 3%±1
Double Negative Stages
DN1 N.D. 20%±2 N.D. 22%±2 N.D. 19%±2 N.D. 20%±2
DN2 N.D. 6%±3 N.D. 5%±3 N.D. 6%±3 N.D. 8%±3
DN3 N.D. 43%±2 N.D. 42%±2 N.D. 41%±2 N.D. 44%±2
DN4 N.D. 31%±3 N.D. 33%±3 N.D. 30%±3 N.D. 32%±3
Bone marrow**
Maturing B cells 1.0±0.31 20%±4 1.0±0.51 24%±4 0.76±0.15 20%±4 0.82±0.29 19%±4
Recirculating B cells 0.1 ±0.02 2%±1 0.09±0.03 2%±1 0.08±0.02 2%±1 0.09±0.03 2%±1
Granulocytes 1.2±0.32 25%±4 1.3±0.54 30%±4 0.80±0.15 21%±4 0.95±0.34 22%±4
Monocytes 0.25±0.06 5%±2 0.17±0.07 4%±2 0.19±0.04 5%±2 0.22±0.08 5%±2
Erythroid N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D.
* The cells are isolated from the following lymph nodes: Axillary, Brachial,
Mesenteric and Inguinal lymph nodes.
** Cells are isolated from the bones of one back leg.
N.D. Not Done
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Table 3: Summary of iCre mice: Reporter expression in analysed cells.
The table shows the percentage of EYFP positive cells for the analysed cell types. The 
mean of triplicates ± one standard deviation is shown.
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Vav-iCre hCD2-iCre hCD2-GFP Non transgenic
% EYFP Positive % EYFP Positive % EYFP Positive % EYFP Positive
Lymph node
Peripheral T cells 99%±1 98%±2 98%±2 0%
Peripheral B cells 99%±1 99%±1 Variegated 0%
Thymus
Double Negative 97%±1 93%±1 90%±1 0%
Double Positive 100%±1 99%±1 99%±1 0%
Single CD4 Pos. 99%±1 99%±1 98%±1 0%
Single CD8 Pos. 98%±1 97%±2 95%±2 0%
Double Negative Stages
DN1 100%±1 99%±1 43%±3 0%
DN2 93%±2 41%±21 52%±4 0%
DN3 99%±1 98%±1 98%±1 0%
DN4 100%±1 99%±1 98%±1 0%
Bone marrow
Maturing B cells 99%±1 100%±1 99%±1 0%
Recirculating B cells 99%±1 99%±1 65%±4 0%
Granulocytes 99%±1 1%±0 0% 0%
Monocytes 99%±1 2%±1 0% 0%
Erythroid Variegated 0% 0% 0%
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Generation o f mice with targeted HBP1 allele.
Screening o f mouse genomic PAC library RPCI21
The first step in generating mice with a targeted HBP1 allele was to obtain a genomic 
clone, which contains the HBP1 locus. Previously in our laboratory a mouse genomic 
phage library was screened to obtain the HBP1 genomic locus. Initial mapping of 
these clones let to the identification of two types of clones (data not shown). Clones 
containing the HBP1 gene as one fragment without an intron and exon structure and 
clones with an intron and exon structure. Intronless copies of genes are termed 
processed pseudo genes and are non-functional. Processed pseudo genes are created 
through a process called retro-transposition during this process mRNA transcript gets 
reverse transcribed with subsequent re-integration of the cDNA into the genome 
(Zhang et al., 2004). The clones containing the pseudo gene were not further 
characterised. The isolated clones contained only part of the HBP1 locus. In order to 
obtain the entire HBP1 locus a PAC library was screened. The mouse PAC library 
RPCI21 was provided by the MRC gene service and was constructed by Kazutoyo 
Osoegawa (Osoegawa et al., 2000). The source for the library is mouse spleen 
genomic DNA from a female 129/SvevTACfBr. The average insert size is 147 kb and 
the library consists of approx. 123,000 clones. The library has been gridded on 
Hybond N nylon membranes (Amersham). The filters were hybridized with a 2.4 kb 
genomic fragment of HBP1 isolated from a mouse genomic phage library (Stratagene) 
that should not cross hybridize with the pseudo-gene. Eleven positive clones were
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obtained from the Resource Centre. The analysis of one of these clones, N621-G6 is 
briefly described. The DNA of clone N621-G6 was digested with Notl, EcoRI and 
SacI and analysed by southern analysis. Figure 17 shows the hybridization pattern 
using the open reading frame of the HBP1 cDNA. The open reading frame was used 
as a probe to ensure that the entire HBP1 locus will be present in the PAC clone. The 
drawback of using this probe is the high sequence similarity with the pseudo-gene. 
Pseudo-genes often interfere with PCR or hybridization experiments that are intended 
for the “real” genes. The hybridisation fragments are identical in size between clone 
N621-G6 and genomic mouse DNA, although the genomic DNA shows extra bands 
(extra lkb band with EcoRI digest and extra lOkb band with SacI digest) 
corresponding to the pseudo gene. Because the bands are identical in size between the 
PAC and genomic DNA we conclude that clone N621-G6 encompasses the entire 
HBP1 genomic locus.
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Figure 17 Southern blot analysis of Pac clone N621-G6
DNA from PAC clone N621-G6 and mouse genomic DNA (129/Sv origin) was 
digested with Notl, EcoRI or SacI respectively. The blot is probed with the open 
reading frame of HBP1.
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Sequencing and mapping o f HBP1 locus
To design a targeting vector and to gain insights in the genomic structure of the mouse 
HBP1 locus a sequencing project was started. Different genomic fragments of the 
HBP1 were sub cloned in pBluescript. The cloned inserts were sequenced from 
“universal” primer binding sites in the flanking vector DNA. The next step was to 
design a walking primer using the most distant, reliable sequence data obtained from 
the first sequencing reaction with the universal primer. This walking primer was then 
used to sequence the next unknown section of the DNA template. The last step was 
repeated until the entire locus was sequenced. The resulting sequence information was 
compiled by computer, using CAP3 Sequence Assembly Program (program available 
at http://fenice.tigem.it/bioprg/interfaces/cap3.html), into a contiguous sequence in 
order to reassemble the mouse HBP1 genomic locus. By comparing the sequence of 
our mouse HBP1 cDNA clone with that of the genomic sequence data we were able to 
define the intron / exon structure of the mouse HBP1 gene, which is shown in figure 
18. The mRNA of HBP1 gene spans ten exons and nine introns. The HBP1 protein is 
encoded by exons 1-9 plus a small segment at the 5’-end of exon 10. Most of exon 
10, which is the largest exon, does not code for protein sequences (figure 18). The 
generated map of the mouse HBP1 locus was used to design the targeting vector.
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Figure 18 Overview of HBP1 locus
Intron-exon organization of the mouse HBP1 gene: black boxes correspond to coding 
exons and white boxes represent non-coding exons. The grey boxes indicate the repeat 
elements as identified by RepeatMasker.
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Determination o f the location o f  repetitive DNA
Gene targeting vectors require long regions of target homology and will often include 
intron sequences or other untranslated segments of the endogenous gene. Untranslated 
portions of genes can be problematic for the constructions of a targeting vector. These 
regions can contain stretches of interspersed repetitive DNA that, if located within 
several hundred base pairs of linearised end of the vector, will drive the vector to 
target homologous repetitive sequences in the genome. This leads to homologous 
recombination in other places than the target gene. To determine any major stretches 
of repetitive DNA the sequenced fragments from the mouse HBP1 locus were 
analysed using RepeatMasker. RepeatMasker is a program that screens DNA 
sequences for interspersed repeats known to exist in mammalian genomes as well as 
for low complexity DNA sequences (program available at: 
http://ftp.genome.washington.edu/cgi-bin/RepeatMasker). The mouse HBP1 locus 
contains about 20% of repetitive sequences (figure 18). The longest identified repeat 
is an Alu repeat of 153bp. The targeting vector was designed so that at least 0.5 kb of 
non-repetitive DNA was present at the 5’ and 3’ end of the homologous DNA 
sequence.
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Generation o f mice with targeted allele.
We chose to flox the exons 8 and 9 of the HBP1 locus by homologous recombination 
because they encode the HMG box, which provides the DNA binding domain for the 
HBP1 protein. We reasoned that without a DNA binding domain some functions of 
HBP1 will be abolished. Furthermore, in the nuclear localisation studies described 
above we had shown that the HMG box contains important sequences for 
translocation of the protein into the nucleus.
In order to flox the HMG box of HBP1 in the mouse genome, a targeting construct 
with floxed HMG box encoding exons was introduced into embryonic stem cells.
In order to generate the targeting construct (figure 19) the following steps were taken; 
pBSneo, which contains a loxP-flanked neomycin gene cloned into the Smal site of 
pBluescript IISK, was digested with BamHI and Spel. A 3.5 kb BamHI Spel genomic 
fragment containing the HMG box encoding exons was inserted in the BamHI Spel 
digested pBSneo to generate construct B (figure 19). A double stranded oligo 
nucleotide containing a loxP site and an EcoRI site was synthesised and cloned into 
the Spel and Notl site of construct B to generate construct C (figure 19). Construct C 
was cut open with Spel and Aatll and a 1.8 kb Spel-Aatll genomic fragment 
consisting of 3’ homology was cloned into Spel Aatll digested construct C to generate 
construct D (figure 19). Finally, construct D was digested with Clal, blunted and then 
cut with Sail. A 5.8 kb XhoI-BamHI (blunt) genomic fragment consisting of the 
5’homology of the targeting construct was cloned into Sail Clal (blunt) to generate the 
final targeting construct (figure 19). The target construct was designed so that when
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Figure 19 Schematic representation of the cloning strategy 
See text for details. The diagram is not to scale.
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replacement of the endogenous sequence by the exogenous one occurred via 
homologous recombination, the HMG box encoding sequences of the HBP1 gene 
would become floxed. The Neo gene would also be transferred into the targeted site. 
Thus, cells in which the homologous recombination occurred would be neo resistant.
In order to generate embryonic stem cells carrying one allele of the HBP1 gene with 
floxed HMG box encoding exons, the construct was linearised with Sacl and 
introduced into PC3 embryonic stem cells of 129/Sv origin (O'Gorman et al., 1997) 
by electroporation. 0.8xl07 ES cells were transfected by electroporation with a final 
DNA concentration of 45pg/ml. Selection was initiated 24hrs later at a concentration 
of 250 or 300pg/ml G418. The targeting event inserts the floxed neomycin resistance 
gene 5’ of the HMG box encoding exons and a loxP site 3’ of the HMG box encoding 
exons. The homologous recombination event is shown in figure 20. Because of the 
artificially introduced EcoRI site in the end of the 3’ loxP site, the 4.4 kb wild type 
EcoRI fragment is converted to a smaller 1.9 kb mutant fragment, as detected by a 
400bp NcoI-EcoRl probe. This probe is located downstream of the targeted region, 3’ 
of the homology of the targeting vector (figure 20). 576 resistant clones were screened 
by Southern blot analysis, using the 400bp Ncol EcoRI probe, six clones that showed 
the 1.9kb mutant band were picked (for an example see figure 20D). On the southern 
blots the probe gives, besides the 4.4 kb wildtype and the 1.9 kb band of the targeted 
allele, a 3.5 kb band (* in figure 20). This band probably represents the pseudo gene 
of HBP1, which is present in the mouse genome. The integrity of the locus was 
verified with a Sacl digest using the Neo probe. The Sacl digest with the Neo probe 
resulted in a 21kb fragment (for an example see figure 20D). Besides an 21 kb
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Figure 20 Targeting of HBP1 locus
A) Schematic representation of the mouse HBP1 locus. Map of the HBP1 gene locus 
showing the location of the HMG box (black boxes: coding exons white box: 
untranslated region). Restriction enzyme sites are indicated by vertical bars (Rl: 
EcoRI, S: Spel, Sa: Sacl).
B) The targeting construct. LoxP sites are indicated by grey arrows. The neomycin 
gene is indicated.
C) The targeted locus. Map of the targeted HBP1 locus after homologues 
recombination with the targeting vector.
D) Southern analysis of targeted clones. The insertion of the floxed Neomycin and 
loxP with EcoRI site results in the reduction of a wild-type 4.4 kb EcoRI fragment to 
a mutant 1.9 kb EcoRI fragment as detected with a 0.4 kb Ncol EcoRI genomic probe 
(grey box) as shown in the southern blot analysis. The probe also detects a 3.5kb 
fragment (indicated with *) corresponding to the pseudo-gene of HBP1. The insertion 
of the floxed Neomycin and loxP result in a 21 kb Sacl fragment. The Southern blot 
was labelled with the NEO probe. The probe also cross hybridizes with a 21 kb Sacl 
fragment (indicated with **).
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fragment for the targeted locus the probe used also cross hybridizes with a 23 kb Sacl 
fragment (** in figure 20). The 23 kb fragment is probably due to homologues 
sequences between the Protamine Cre transgene, which is present in the used ES, and 
the NEO probe as it is not present in wildtype 129 DNA (data not shown). This digest 
also confirms that there is no additional random integration in the genome. An 
additional integration would have shown extra bands besides the 21 kb targeted band 
and the 23kb cross-hybridizing band. These results indicated that ES cells in which 
the HMG box encoding exons of HBP1 are floxed have been generated.
In order to generate chimeric mice, three of the six clones were karyotyped (number 
10, 35 and 126); all the three clones had a euploid karyotype (40 chromosomes). 
These cells were injected into 3.5-day blastocysts derived from C57B1/6 females. 
These injected blastocysts were subsequently transferred into the uteri of foster 
mothers. Chimeric males were bom as determined by agouti coat colour. The 
chimeric mice that carried the targeted HBP1 allele with the floxed HMG box 
encoding exons of HBP1 were bred to establish mouse lines with this allele. Germline 
transmission was determined by agouti coat colour of the FI offspring.
The ES cells (PC3) used contain a transgene comprised of the mouse Protamine 1 
promoter and the Cre recombinase coding sequence (O'Gorman et al., 1997). These 
ES cells can mediate the efficient recombination of a Cre target in the male germ line, 
but not in other tissues (O'Gorman et al., 1997). Cre recombinase expression in the 
male germ line would mean that the progeny of ES cell chimeras can carry 
recombinant targets. Cre recombinase deletes the DNA sequences between loxP sites 
when the loxP sites are in the same orientation. Because there were three loxP sites in
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the targeted HBP1 allele, there were three possible Cre-mediated recombination 
events (figure 22): deletion of the neo alone (generating HBPl+/flHMG mice), deletion 
of the HMG box of the HBP1 gene but not the neo (generating HBPl+/neo mice), and 
deletion of both the HMG box and the neo (generating HBP1+/ahmg mice). The last 
possibility is that Cre is not active and no recombination between the loxP sites occurs 
(generating HBPl+/flHMGneo mice). To establish which of these recombination events 
has occurred in the progeny of ES cell chimera tail DNA was isolated and analysed by 
Southern blot or PCR analysis.
Progeny of ES cell chimeras were tested by Southern analysis using EcoRV digestion 
followed by hybridization with a probe specific for the region between the third loxP 
sites and the EcoRV recognition sequence (figure 21). A 7.0 kb EcoRV fragment 
represents the wild type locus. Mice carrying the targeted HBP1 locus can show the 
following additional fragments depending on which loxP sites recombined. If Cre was 
inactive in the germline the EcoRV fragment from the targeted locus will be 6kb 
(figure 21). Deletion of the neo alone (generating HBPl+/flHMG mice) will generate a 
4.7 kb fragment. Deletion of the HMG box of the HBP1 gene, but not the neo 
(generating HBPl+/neo mice), will generate a 2.5 kb fragment. Finally, deletion of both 
the HMG box and the neo (generating HBP1+/ahmg mice) will generate a 1.2 kb 
fragment (figure 21). Southern blot analysis of the progeny revealed, in addition to 
wild type 7.0 kb band, either a 4.7 kb fragment (corresponding to HBPl+/flHMG mice) 
or a 1.2 kb fragment (corresponding to HBP1+/ahmg mice). For an example of these 
deletions see figure 22A. Deletion of only the floxed HMG box (without deleting 
NEO) was not observed in the mice analysed. This indicated that mice with a
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Figure 21 Schematic overview of partial Cre recombination
Schematic representations of HBP1, showing the targeted and Cre-mediated 
recombinant alleles. For consistency with the text and figures, each allele is named. 
Also shown are schematic representations of the probe (grey) and of the primers (Pl- 
P4) used to determine the HBP1 genotype.
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Figure 22 Cre-mediated recombination of the HBP1 allele
A) Southern blot analysis was performed on tail DNA from wildtype, heterozygous 
and homozygous mice. The probe is indicated in figure 21.
B) The Southern blots were confirmed by PCR analysis. The primers are indicated in 
figure 21. Primer pair PI and P2 is shown in lane 1, primer pair P3 and P4 is shown in 
lane two, and finally primer pair PI and P4 is shown in lane three.
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constitutive deleted HMG box of HBP1 gene and mice with a floxed HMG box of the 
HBP1 gene for inducible deletion have been generated. Heterozygous mice with the 
HBP1+/ahmg or HBPl+/flHMG genotype were bred to generate the homozygous mutant 
mice. Mice homozygous for the mutations are designated HBP1AHMG/AHMG or 
HBPlflHMG/flHMG respectively. Figure 22 shows the Southern blot analysis of wild type 
129/Sv, heterozygous and homozygous mutant mice of the H B P l^ 1^0 and HBPlnHMG 
mice. To confirm the Southern analysis the mice were screened by polymerase chain 
reaction (PCR) using four different primers called PI to P4 (figure 21) Primer pair PI 
and P2 amplifies the region in which the NEO is cloned (figure 21). For the wild-type 
allele this region should generate a band of 170bp, while the same region after Neo 
deletion, but leaving a loxP site and the HMG box, should generate a band of 300bp 
(figure 21). If the HMG box is deleted, the recognition site for P2 is deleted and the 
PCR should generate no product. Primer pair P3 and P4 amplifies the region in which 
the 3’ loxP site is cloned. For the wild-type allele, this region should generate a band 
of 200 bp while the same region with the loxP site and the HMG box not deleted 
generates a band of 250 bp (figure 21). If the HMG box is deleted, the recognition site 
for P3 is deleted and the PCR should generate no product. Primer pair PI and P4 
amplifies the region between the 5’ and 3’ loxP sites (figure 21). For the wildtype 
allele, this region is too big to amplify. The same is valid for all other possible 
recombination events excepts when all intervening sequences between the loxP sites 
are deleted in this case you should get a band of 350 bp (figure 21). Using the above 
PCR strategy the southern blots were confirmed as shown in figure 22B.
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Northern Analysis
To confirm that the HMG box was removed from the HBP1 gene mRNA from 
wildtype and knockout was analyzed by Northern analysis. Northern analysis provides 
a direct relative comparison of message abundance and transcript size between 
samples on a single membrane. RNA was isolated from the thymus of HBP1+/+, 
HBP1+/ahmg and HBP1ahmg/ahmg mice. RNA samples were separated by size via 
electrophoresis in an agarose gel under denaturing conditions. The RNA was 
transferred to an N+ membrane, cross-linked and hybridized with a labelled probe. 
Northern hybridization was performed with radiolabelled open reading frame cDNA 
of HBP1.
Figure 23 presents such northern blot analysis. Full length HBP1 was detected in 
HBP1+/+ mice as a single transcript of approximately 2.6 kb in size. In the 
HBP1 +/ahmg mjce5 a fuu iength HBP1 was detected as well as a smaller transcript of 
2.1 kb in size that corresponds to HBP1 without the HMG box (HBPl^**10). In the 
last lane, RNA from a mouse homozygous for the AHMG mutation shows a single 
transcript corresponding to HBP1 without the HMG box (HBP1ahmg). This confirms 
that the HMG box from HBP1 has been deleted.
The DNA mobility shift assay
The HMG box is a conserved DNA-binding domain found in a family of transcription 
factors that regulate growth and development. Therefore, we postulated that
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Figure 23 Northem-blot analysis of mRNA from HBP1ahmg mice
mRNA from wildtype, heterozygous and homozygous HBP1ahmg mice was probed 
with the HBP1 coding sequences. A 2.6 kb transcript was detected in the wildtype and 
heterozygous HBP1ahmg mice. A smaller transcript of 2.1 kb, corresponding to HBP1 
lacking the HMG box, was detected in heterozygous and homozygous HBP1ahmg 
mice. The membrane was subsequently incubated with GapDH to compare relative 
amounts of mRNA in each lane.
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sequences within the HMG box must be required to maintain the DNA binding 
capacities of the HBP1 protein. The DNA mobility shift assay provides a tool for the 
detection of factors binding to specific sequences. The method relies on the ability of 
a protein to bind to radiolabelled DNA fragment (probe) in vitro. This is followed by 
electrophoretic separation of DNA:protein complexes from the unbound DNA on 
non-denaturing poly-acrylamide gels.
HBP1 has been reported to bind to a footprint (named FT1) in the hCD2 LCR. To 
determine if the h b p iahmg/ahmg mice have lost the ability to bind to this footprint a 
24 bp synthetic oligo-nucleotide, representing the binding site of HBP1 (FT1), was 
used in the DNA mobility shift assay. Incubation of the radio labelled oligo­
nucleotide FT1 with the nuclear extracts from the wild-type mice yielded a specific 
DNA:protein binding complex and also a smaller non-specific complex (figure 24). 
The specificity of the binding was verified by competition with the same unlabeled 
oligo-nucleotides at 100 molar excess. The results showed that the binding complex 
was abolished and confirmed that the smaller band was non-specific (figure 24). The 
integrity of the thymus nuclear extracts was confirmed by using OCT1 probe. 
Incubation of the radio labelled oligo-nucleotide OCT-1 with the nuclear extracts 
from the wild-type mice yielded a specific DNA:protein binding complex (figure 24).
Incubation of the radio labelled oligo-nucleotide FT1 with the nuclear extracts from 
the mice yielded no specific DNA:protein binding complex, only the
smaller non-specific complex was detected (figure 24). The integrity of the thymus 
nuclear extracts was confirmed by using OCT1 probe. Incubation of the oligo­
nucleotide OCT-1 with the nuclear extracts from the H B Pl^ 1^0^™ 0 mice
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Figure 24 Electromobility shift assay (EMSA)
FT 1, the radiolabelled specific oligo-nucleotide, was incubated with thymus nuclear
extract from wild-type mice or HBP1AHMG/AHMG (lane 1 and 4 respectively). 100-fold
molar excess of unlabeled specific probe was used for competition with labelled
oligo-nucleotide (lane 2 and 5). Lanes 3 and 6, show OCT1, the radiolabelled specific
oligo-nucleotide, incubated with thymus nuclear extract from wild-type mice or 
h b p 1a h m g /a h m g  r e s p e c t i v e l y .
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yielded the normal specific DNA:protein binding complex (figure 24), indicating that 
the absence of the specific FT1 complex using h b P1ahmg/ahmg protein extracts is not 
due to protein degradation in the different samples.
These results confirm that thymocyte extracts from mice homozygous for the 
HBP1ahmg allele have lost the ability to bind specific DNA targets due to loss of the 
HMG box, the DNA binding domain of HBP1.
Morphological analysis o f HBP1 mice
In order to determine if the HBP1ahmg/ahmg mice show any gross defects they were 
followed through their development. Recovery of HBP1ahmg/ahmg offspring from the 
heterozygous breeding indicates that these mice do not exhibit an embryonic lethal 
phenotype. No obvious difference in litter size, male to female ratio and Mendelian 
inheritance of the mutant allele was observed. The homozygous mutant mice thrive 
like wild type mice. Even after weaning (after 3 weeks) no differences were observed 
indicating that the mice eat normally. From the above observations, we concluded that 
the mice are normal at weaning.
The next step was to see if they are reproductively normal. A male and female 
HBP1ahmg/ahmg were taken and set up for breeding. Normal size litters from these 
breedings were generated indicating that their reproductive capacity remains intact.
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Gross necropsy was performed which included an initial physical examination of 
external surfaces and all orifices as well as an internal examination of tissues and 
organs in situ. The following were examined: the external surfaces of the brain and 
spinal column, the nose and neck, with associated organs and tissues; the thoracic, 
abdominal, and pelvic cavities, with associated organs and tissues; and the 
musculoskeletal carcass. No obvious differences between wild type and 
HBP1ahmg/ahmg mice were observed.
Thus, as far as we can determine from these experiments we conclude that the 
development of j ib p iahmg/ahmg is normal and no gross abnormalities were detected.
Haematological analysis o f HBP1 mice
Haematopoiesis requires continuous cell proliferation, lineage commitment, 
differentiation, and maturation. Each step of haematopoietic development has been 
characterised by the expression of cell surface markers. HBP1 mediates a link 
between the cell cycle control machinery and cell differentiation signals. Furthermore, 
K.M. Lin et.al (Lin et al., 2001a) suggested that HBP1 is actively involved in the 
differentiation process during haematopoiesis. Therefore, the haematopoietic system 
provides an excellent model for studying the function of HBP1 in cell proliferation, 
lineage commitment, differentiation, and maturation.
To determine whether the loss of HBP1 had any effect on haematopoiesis, we 
analyzed primary and secondary lymphoid organs of wild-type, heterozygous and
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knockout mice. There was no obvious reduction or increase in the size of the thymus, 
spleen, and lymph nodes, and comparable cellularity was exhibited in HBP1+/+, 
HBP1+/ahmg and h b P1ahmg/ahmg littermates. Mice from 4 to 12 weeks old (at least 
three mice per time point) were analysed using flow cytometrical analysis. The flow 
cytometric analysis of mice of 6 weeks is shown in figure 25 as an example of the 
mice analysed and a summary of the analysis is given in table 4. Flow cytometry 
analysis of developing thymocytes revealed no difference in numbers and proportions 
of double-negative (CD4- CD8-), double-positive (CD4+ CD8+), and single-positive 
(CD4+ CD8- or CD4- CD8+) subsets (figure 25A), indicating that T-cell development 
is unaffected by HBP1 deficiency. Peripheral T-cell numbers, as measured by anti- 
Thy.l reactivity, were likewise unaffected by the absence of HBP1, as were the levels 
and ratio of CD4 or CD8 single-positive T cells (figure 25B and C). With regard to 
the B cell lineages we observed normal numbers of maturing B cells (CD 19+ IgD-), 
and mature B (CD 19+ IgD+) cells in the bone marrow of HBP1 deficient mice (figure 
25D). To assess whether the deletion of HBP1 affected mature B-cell development, 
we analyzed B-cell populations in the lymph nodes by flow cytometry using 
antibodies to CD 19. There was no significant difference in numbers of peripheral B 
cells between HBP1+/+ and h BP14HM0/4HM0 mice (figure 25C). The ratio of B to T 
cells in peripheral organs in HBP1 deficient mice is also unchanged (figure 25C). To 
assess the role of HBP1 in myeloid development bone marrow cells were stained with 
antibodies against Grl and Macl (figure 25E). No major differences in the 
percentages of these cells were detected. These results show that DNA binding and 
cellular distribution of HBP1 have no major function in development of the 
haematological compartment of the mice.
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Figure 25 Flow cytometric analysis of wildtype, j j b p i+/ahmg and jjBP1ahmg/ahmg 
mice
A) Thymocytes were stained with CD4 and CD8 antibodies. Percentage of cells 
within SP (CD4+/CD8- or CD4-/CD8+), DP (CD4+/CD8+) and DN populations 
(CD4-/CD8-) are shown.
B) Single cell suspensions from lymph nodes were stained with CD4 and CD8 
antibodies to allow differentiation of the T cell subpopulations. Percentages are 
shown.
C) Single cell suspensions from lymph nodes were stained with Thy.l and CD 19 
antibodies to allow differentiation of the T cell (Thy.l+/CD19-) and B cell 
populations (Thy.l-/CD 19+). Percentages are shown.
D) Bone marrow cells were stained with CD 19 and IgD antibodies. Percentage of 
cells within mature recirculating CD19+/IgD+ B cells and CD19+/IgD- immature B 
cells are shown.
E) Bone marrow derived cells were stained with Gr-1 and Mac-1 antibodies. 
Percentages of cells within gated populations are shown.
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Table 4: Summary of cellularity of HBPlAHMG/AHMGand wildtype mice.
The table shows absolute numbers cells of the different cell types of the organs at 4, 6 
and 12 weeks after birth. The mean of triplicates ± one standard deviation is shown.
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4 weeks 6 weeks 12 weeks
j _ j g p  j A H M G /A H M G
( X  1,000,000)
Wildtype 
(x 1,000,000)
j _ j g p  j  A H M G/AH M G
(x 1,000,000)
Wildtype 
(x 1,000,000)
j _ j j g p  j  A H M G /A H M G
(x 1,000,000)
Wildtype 
(x 1,000,000)
Lymph node*
Peripheral T cells 2.2±0.4 2.5±0.8 2.0±0.7 2.6±1.1 1.7±0.4 1.9±0.9
Peripheral CD4 T cells 1.5±0.3 1.7±0.5 1.3±0.4 1.7±0.7 1.1 ±0.2 1.3±0.6
Peripheral CD8 T cells 0.73±0.1 0.83±0.3 0.67±0.2 0.87±0.4 0.57±0.1 0.63±0.3
Peripheral B cells 1.9±0.4 2.2±0.7 1.8±0.6 2.4±0.9 1.5±0.3 1.7±0.8
Spleen
Peripheral T cells 15±0.6 20± 1.5 17± 1.8 15±0.6 15±0.9 15±0.2
Peripheral CD4 T cells 11 ±0.5 15± 1.1 13± 1.2 12±0.5 11±0.7 12±0.1
Peripheral CD8 T cells 3.7±0.2 5.0±0.4 3.9±0.4 3.6±1.3 3.4±0.2 3.6±0.05
Peripheral B cells 19±0.8 25±1.9 18± 1.9 17±0.6 18± 1.1 19±0.2
Thymus
Double Negative 9.1 ±0.4 8.9±0.7 4.9±0.4 5.4±0.2 4.7±0.4 5.6±0.2
Double Positive 190+7.6 190±14 140±11 150±4.7 130±9.5 160±4.9
Single CD4 Pos. 20±0.8 20±1.5 16±1.3 18±0.6 16±1.1 19±0.6
Single CD8 Pos. 6.8±0.3 6.7±0.5 4.9±0.4 5.4±0.2 4.7±0.4 5.6±1.7
Bone marrow**
Maturing B cells 2.0±0.8 2.5±0.5 3.2±1.2 2.8±0.4 2.3±1.3 2.9±0.8
Recirculating B cells 0.20±0.09 0.26±0.03 0.27±0.1 0.23±0.04 0.18±0.1 2.3±0.3
Granulocytes and 
Monocytes
2.5±1.0 3.1±0.7 4.0±1.5 3.5±0.4 2.4±1.3 3.0±0.4
**
Cells were taken from Mesenteric lymph nodes 
Cells were taken from the bones of one back leg
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Effect o f HBP1 expression on the apoptosis o f thymocytes
The transfection studies described earlier in this thesis suggested that HBP1 over 
expression might induce apoptosis. To study the potential role of HBP1 in apoptosis 
we measured the response of T cells from HBP1 wild type and targeted mice to 
apoptotic stimuli. Apoptotic cell death can occur via several distinct pathways, which 
are regulated by different molecules. In this study, the following apoptotic stimuli 
were used: y-irradiation, which causes DNA damage, and dexamethasone, which 
activates glucocorticoid receptors leading to cell death in thymocytes. Thymocytes 
from HBP1+/+, HBPl+/iHMG and HBPlAHMG,iHMG were treated with apoptotic stimuli, 
the samples harvested at various time points and the amount of apoptosis determined 
by propidium iodide staining of DNA followed by flow cytometry analysis (Nicoletti 
et al., 1991). It has to be noted that the experiment was done only once with each 
sample in triplicate, y-radiation induces p53 dependent apoptosis through DNA 
damage, and thymocytes in particular are highly sensitive to this form of damage. The 
level of apoptosis in the thymocytes of the HBP1 targeted mice was determined 
following treatment with 5Gy of y-radiation (figure 26A). No difference in the rate of 
cell death was seen in thymocytes of HBP1+/+ compared to HBPl^11^ 07^ 1^6. This 
indicates that absence of the HMG box from HBP1 does not affect the rate of 
apoptosis, which is induced through y-radiation. Thymocytes from the HBP1 targeted 
mice were also exposed to dexamethasone, which induces p53-independent apoptosis. 
Again, no difference in the rate of cell death was seen in thymocytes of HBP1+/+ 
compared to h b p jahmg/ahmg (figure 26B). This indicates that the absence of the
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HBP1 HMG box binding activity does not alter the rate of apoptosis, which is induced 
through dexamethasone. As a control, thymocytes from the HBP1 targeted mice were 
placed in culture without any apoptotic stimuli. The rate of survival of the thymocytes 
from all mice was equal (figure 26C).
These results indicate that the thymocytes from jjb p iahmg/ahmg mice are as 
sensitive/insensitive to apoptotic signals as wild type thymocytes. It was concluded 
that at least the DNA binding activity of HBP1 has no function in the activation of or 
protection against apoptosis.
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Figure 26 h b p iahmg/ahmg thymocytes show wildtype levels of apoptosis
Total thymocytes from HBP1+/+ (red line), h b p j+/ahmg (green line) and 
Hb p i ahmg/ahmg (blue line) were cultured in vitro for up to 24 hours. Charts show the 
percentage of surviving cells per time point. Studies were carried out following 
treatment with either (A) 5 Gy y-irradiation, (B) 5pM Dexamethasone or (C) 
untreated controls. Error bars indicate mean ± SD.
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HBP1mMGtmMG lymphocytes exhibit enhanced proliferative response to 
TCR stimuli.
To determine if HBP1 has a significant role in modulating mitogenic signalling of 
lymphocytes, we assessed T cell proliferation in response to CD3 stimulation. 
Lymphocytes from HBP1+/+, HBP1+/AHMG and h B P I ^ 07^ 0 were isolated. Cell 
suspensions from the isolated lymphocytes were loaded onto T Cell Enrichment 
Columns. The purity of the recovered T cells was around 90%.
To follow the fate of individual T cells throughout activation and clonal expansion, 
we have employed the fluorescent dye carboxyfluorescein succinimidyl ester (CFSE). 
The di-acetate form of CFSE is a non-toxic, non-fluorescent molecule that can 
passively diffuse into cells. Once inside the plasma membrane of live cells, cellular 
esterases cleave acetyl groups from the di-acetate form of CFSE to create the active 
fluorophore (CFSE) that absorbs and emits light at wavelengths characteristic to its 
fluorescein moiety. The highly amine-reactive succinimidyl ester then forms dye- 
protein adducts which are retained within the cells or at the cell surface. The result is 
the very bright labelling of cell populations that is stable over a span of weeks. This 
labelling is universal within the T cell compartment, as all CD4 or CD8 positive cells 
fluoresce brightly before proliferation (data not shown). CFSE segregates equally 
between daughter cells upon cell division, resulting in the sequential halving of 
cellular fluorescence intensity with each successive generation. When analyzed by 
flow cytometry, this sequential halving of fluorescence is visualized as reduced
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fluorescent intensity of populations of cells, and can be used to track cell division in 
populations of proliferating cells.
Figure 27 A shows a histogram of CFSE intensity from a representative experiment. 
Three days post-stimulation both CD4 and CD8 HBP1ahmg/ahmg lymphocytes 
exhibited a greater proliferation, as shown by increased CFSE dilution, compared to 
HBP1+/+ lymphocytes (figure 27A). This affect was more pronounced in the CD8 cells 
compared to the CD4 cells. The CFSE profile were used characterize two parameters; 
the percentage of cells that had been triggered to divide (percent divided) and the 
mean number of divisions among those cells that had divided at least once 
(proliferation index or burst size).
The percent divided, that is the percentage of the cells of the original sample that have 
divided, is shown in figure 27B. No differences between the h b P1ahmg/ahmg 
compared to wildtype were measured for the first 48 hours. However, after 72 hours 
of culture, a clear difference was measured. With greater proportion of CD4 and CD8 
cells from HBPl^^10^ 1^0 being triggered into division compared to wildtype cells. 
The difference seen was more significant for CD8 T cells compared to CD4 T cells. 
Thus, more lymphocytes from HBP1ahmg/ahmg mice are triggered into division 
compared to wildtype mice.
The proliferation index, or the average number of divisions that a dividing cell has 
undergone, was equal for CD4 HBP1ahmg/ahmg compared to wildtype CD4 
lymphocytes and may be slightly increased for CD8 HBP1ahmg/ahmg compared to
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wildtype CD8 lymphocytes (figure 27C). Thus, once a cell is triggered to go into the 
cell cycle they undergo about the same amount of divisions after 72 hours.
Taken the data together this indicates that both CD4 and CD8 h b P1ahmg/ahmg 
lymphocytes are more responsive to TCR signalling but once the cells are cycling, the 
cells undergo a similar amount of division (although this may be slightly increased for 
the CD8 lymphocytes). This might indicate that HBP1 regulates the
cell cycle entry of resting cells but once they are in cycle, other control mechanisms 
take over.
A plausible explanation why h b P 1 ahmg/ahmg lymphocytes respond with increased 
cell proliferation might be that hbP1ahmg/ahmg lymphocytes are in a "pre-activated" 
state and thus predisposed to immediate response. A few gene-targeting studies have 
described cases of pre-activated lymphocytes that have elevated CD69 and CD25 
levels (Grossman et al., 1999; Kuo et al., 1997). To explore this possibility, FACS 
analysis of HBP1+/+ and HBP1ahmg/ahmg lymphocytes was first performed for CD69, 
which is highly expressed on activated T cells. CD69 was absent on wild-type cells 
which did not get stimulated by CD3. Intermediate levels of CD69 expression was 
measured on non-stimulated HBP1ahmg/ahmg lymphocytes (figure 28). This indicates 
that these cells might be pre-activated. 24 h post-stimulation CD69 was up regulated 
in both HBP1AHMG/AHMG and wild type cells but the level of up-regulation was greater 
in hbP1ahmg/ahmg lymphocytes. Similar results were seen for the high affinity IL2 
receptor (CD25). Non-stimulated knockout lymphocytes show intermediate levels of 
CD25 while expression was absent on wild-type cells. 48 hours post activation CD25 
was up regulated in both HBP1ahmg/ahmg and wild type cells but again the increase of
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CD25 expression was greater in the knockout cells compared to wild-type cells 
(figure 28). Taken the results together this might indicate that HBP1ahmg/ahmg cells 
are more responsive to signalling through the TCR and this might be due to a pre­
activated phenotype.
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Figure 27 T cells from HBP1ahmg/ahmg are poised for activation
A) CFSE profile after 72 hours
Lymphocytes from h b P1ahmg/ahmg mice (single black line) and wild-type mice 
(filled grey area) were stained with CFSE prior to activation. Non-stimulated 
lymphocytes do not divide whereas anti CD3 activated h b p iahmg/ahmg lymphocytes 
exhibit enhanced entry into the cell cycle as shown by a greater decrease in CFSE.
B) Percent divided after stimulation
More cells underwent division for both CD4 and CD8 jjbP1ahmg/ahmg lymphocytes 
compared to wildtype as shown by increase in the % divided. Error bars indicate mean 
± SD.
C) Proliferation index after 72 hours
The average number of divisions that the cells, which divided, underwent is similar 
for the CD4 HBPIahmg/ahmg and wildtype lymphocytes. The CD8 HBPlaHMG/aHMG 
lymphocytes have a slight increased proliferation index compared to wildtype 
lymphocytes. Error bars indicate mean ± SD.
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Figure 28: jjB P lAHMG/AHMG lymphocytes have up regulated levels of CD69 and CD25
Lymphocytes from h b P1ahmg/ahmg (single black line) mice exhibit up regulated 
levels of CD69 and CD25 prior and after activation with ant-CD3 compared to 
wildtype littermates (filled grey area). After stimulation for 24 hours for CD69 or 48 
for CD25 h b P1ahmg/ahmg lymphocytes still exhibit higher levels of CD69 and CD25 
compared to wildtype.
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Discussion
Domains o f HBP1
Patterns of gene expression in cells are triggered by a variety of intracellular and extra 
cellular signals that mobilize specific transcriptional regulatory factors. Once 
marshalled, these transcription factors interact and recruit various cellular machines to 
govern directly the transcription of the specified genes, prescribing both the time and 
the scale of positive or negative control of transcription. Transcription factors 
typically bear at least two essential yet separable modules: the DNA-binding domain 
and a regulatory domain. The DNA binding domain imparts most of the specificity in 
targeting the regulatory module to a particular site in the genome. The regulatory 
modules typically play a less critical role in selecting a gene for regulation; instead, 
they mediate their effects directly or through interaction with other proteins on the 
gene to which they are delivered. The DNA-binding modules of transcriptional 
regulators consist of a wide variety of structural folds and many have been well 
characterized from both a structural and functional standpoint. By contrast, regulatory 
modules are less well defined and only a few have been characterized structurally. As 
described in the introduction of this thesis the transcription factor HBP1 contains two 
modules that are recognized by BLAST analysis, the AXH module and the HMG box. 
The AXH module is a novel regulatory element identified in HBP1 and in SCA1. The 
gained insights in the function and properties of this domain in terms of its structural
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properties and stability will be discussed in the following section. This is followed by 
a functional characterisation of the HMG box, the DNA binding domain of HBP1, and 
its function in sub-cellular localisation of the protein.
The AXH module ofH B P l
Expression of the AXH domain yields an independently folded polypeptide with the 
N and C termini juxtaposed in space. It was shown that deletion mutants that cut out 
even a few residues from the N and C termini adjacent to the AXH domain led to 
unfolded proteins. Thus, the stability of the AXH module is affected by the presence 
of interactions with adjacent poly-peptides. This implies that boundary selection is 
clearly important. Incorrect selection of the boundary of AXH by a couple of residues 
removes several interactions that contribute to the overall stability of the structure. 
This has local and global effects on the stability and alters related biophysical 
characteristics such as the unfolding rates.
This observation has direct implications for interpreting mapping studies of the 
interaction sites of HBP1 with other proteins. Only constructs that comprise the full- 
length AXH module are able to retain binding, whereas truncation of AXH abolishes 
binding as expected, if its tertiary structure is disrupted.
The AXH domain of HBP1 is monomeric. This is in stark contrast with the AXH 
domain of SCA1, which forms dimers in solution. A dimerization domain of ATX1 
falls within a region spanning residues 495-605 (Burright et al., 1997) and this region
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partially overlaps with the AXH domain of ATX1 (568-689). Thus, it is likely that 
the residues responsible for the dimerization of AXH of SCA1 fall within a 37 aa 
region (568-605). The dimerization is not an intrinsic feature of AXH, since the AXH 
of HBP1 is monomeric. It is conceivable that the non-conserved residues within the 
identified 37 aa dimerization domain are the residues involved in protein 
dimerization. Therefore, it is unlikely that the AXH domain of HBP1 interacts with 
the AXH domain of AXT1.
In conclusion, we have used the sequence similarity between regions of two otherwise 
unrelated proteins to obtain information about their domain architecture. The AXH 
motif is a novel protein-protein binding domain. The high degree of similarity 
between the domains of ATX1 and HBP1 may indicate that both proteins bind to 
similar targets. One of the targets the has been identified to bind to both ATX1 
(Femandez-Funez et al., 2000) and HBP1 (Swanson et al., 2004) is the Sin3 complex. 
Deacetylation of histones by the SIN3 complex is a major mechanism utilized in 
eukaryotic organisms to repress transcription. Thus, the interaction between Sin3 with 
AXH from both ATX1 and HBP1 implicates both genes in transcriptional repression.
Sub-cellular localisation o f HBP1: The HMG box and identification o f  
NLS
The DNA binding domain is necessary for the correct targeting of the transcription 
factor to a particular site in the genome. In eukaryotic cells, the nuclear envelope 
generates two distinct cellular compartments that separate transcription and genome 
(nuclear) from protein biosynthesis (cytoplasm). Thus, a given transcription factor has
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to be transported into the nucleus to ensure its function. Before we set out to define 
the region necessary for the nuclear transport, we confirmed that transcription factor 
HBP1 is a nuclear protein. To visualize the protein it was fused to the fluorescent 
protein EYFP that allows the protein to be detected by fluorescence microscopy. The 
fluorescence of the fusion protein was only detected in the nucleus. This confirmed 
that HBP1 is a nuclear protein.
The nuclear membrane of eukaryotic cells is freely permeable to solutes of up to 
about nine nm (e.g., 40- 60-kDa proteins). Transport of larger molecules through 
nuclear pores is signal-mediated, involves shuttle molecules, and requires energy. 
These larger molecules contain peptides composed of karyophilic clusters of arginines 
and lysines, which signal transcription factors to specialized transporter molecules in 
the pore complex of the cytoplasm. These karyophilic clusters are called nuclear 
localization signals (NLS). Two types of NLSs have been described in the literature, 
one contains four arginines and lysines within a hexa-peptide and the other comprise 
two clusters of basic amino acids separated by a non-basic peptide. Analyses of the 
sequence of the HBP1 gene lead to the identification of a bipartite NLS motif, 
consisting of two clusters of basic amino acids separated by a non-basic peptide, 
within the HMG box (435-KRPMNAFMLFAKKYRVE-451). These sequences are 
highly homologous with corresponding NLS motif in other HMG domain proteins. To 
confirm that the identified NLS was active as an NLS two mutants of HBP1 were 
fused to EYFP. One mutant consists of just the HMG box while the other mutant 
contained the rest of the protein (figure 7). Deletion of the HMG box resulted in 
accumulation in the cytoplasm. However, deletion of the HMG box did not prevent 
the fusion protein from entering the nucleus. This could be due to the size of the
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fusion protein that is around 60 kDa, small enough to enter the nucleus by diffusion 
through the nuclear pore. These results demonstrate that the HMG box is a critical 
determinant for nuclear localization.
Thus, the HMG box provides the DNA binding domain and the necessary signals for 
the transport of HBP1 from the cytoplasm to the nucleus. The co-localization of the 
DNA binding domain and the NLS to one part of the gene is not uncommon. A survey 
showed that the NLS of ~70% of nucleic acid-binding proteins are coincident with 
their nucleic-acid binding domain. It is not known why nuclear import and DNA 
binding are so closely localized on these molecules, but it has been speculated to be 
an evolutionary consequence of exon shuffling.
The location of a transcription factor within the nuclear space can be important for its 
function. The HMG box, the DNA binding domain of HBP1, is necessary for the 
targeting of HBP1 to particular sites in the genome. When the EYFP-HMG box was 
expressed, it was localized as fluorescent speckles in the nucleus. However, when the 
full length EYFP-HBP1 was expressed the protein seemed to show a different 
localization pattern. Unfortunately, due to the lack of antibodies against HBP1 we 
could not perform immuno-fluorescence staining on endogenous expressed HBP1. 
Therefore, we could not exclude that the observed fluorescent speckles are an artefact 
due to the formation of inclusion body like structures upon over expression of the 
EYFP fusion proteins. If the observed phenotype is not an artefact, the significance of 
this might be that the AXH, or other protein binding sites in the HBP1 gene, can form 
complexes with other proteins that affects the function of the gene and the spatial 
localization of HBP1 in the nucleus.
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Besides the difference in localization, there was also a functional difference between 
the full-length fusion protein and the two mutant fusion proteins. 72 hours post 
transfection no fluorescence was detected in the cells transfected with the full-length 
fusion protein. Furthermore, time-lapse experiments showed that the transfected cells 
rounded up and detached from the surrounding cells. This might indicate that over 
expression of the EYFP-HBP1 causes apoptosis or is at least toxic for the cells. At 
this moment in time, we do not know if this phenotype is due to HBP1 or EYFP. It 
has been reported that fluorescent fusion proteins can be harmful or even toxic to cells 
in transient transfection experiments. Although, when EYFP-HMG or even EYFP- 
AHMG was expressed high levels of fluorescence were detected in the cells after 72 
hours. This indicates that these mutants are not harmful for the cell.
From these experiments, we conclude that the HMG box provides the signals for the 
nuclear localisation and is necessary to target HBP1 to certain sites in the genome, 
while the rest of HBP1 mediates its effects directly or through interaction with other 
regulatory proteins. Furthermore, when both domains are uncoupled the resulting two 
proteins (HMG and AHMG) are not harmful to the cell.
Gene targeting
Conditional gene targeting is increasingly used to create loss-of-function mouse 
models, and a standard approach involves the Cre-loxP recombination system. This 
approach involves creating a floxed conditional allele, designed to remain functionally 
equivalent to the wildtype, and then inactivating it in vivo in a cell type-specific and
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temporally controlled fashion, using transgenes expressing Cre recombinase. First, the 
generation of two Cre recombinase mouse lines will be discussed. This is followed by 
a discussion of mice in which an essential part of the HBP1 is floxed.
Cre recombinase transgenic mice
The generation of conditional mutants is becoming increasingly important in 
determining the physiological role of specific gene products. To date, the Cre/loxP 
based approach has been the most successful method to generate defined mutations in 
a spatially and temporally controlled manner. Here two independent Cre/loxP based 
systems are described for the generation of conditional mutants within the 
haematopoietic system. The first places Cre expression under the control of the Vavl 
regulatory elements which drive expression in all haematopoietic lineages (Ogilvy et 
al., 1999), presumably including the haematopoietic stem cells, thus allowing pan- 
haematopoietic targeting. In the second system Cre expression is controlled by the 
hCD2 LCR and allows targeting to be restricted to lymphocytes only (Lang et al., 
1988).
Cre expression in transgenic mice
Cre activity in both the Vav-iCre and the hCD2-iCre transgenic mice was 
demonstrated by the subsequent mating of the established transgenic lines with the 
ROSA26-EYFP transgenic mouse line (Srinivas et al., 2001) creating double 
transgenic offspring. The ROSA26-EYFP mouse line carries the EYFP gene under the
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control of the ubiquitous and constitutive expressed ROSA26 promoter. Inserted amid 
the ROSA26 promoter and the EYFP gene are the loxP sequences flanking a strong 
transcriptional stop sequence to prevent transcriptional read-through. In the presence 
of the Cre-recombinase, the stop sequence is removed and the EYFP gene is 
expressed. Thus, fluorescence microscopy reveals if any Cre-mediated recombination 
events have occurred. The finding of EYFP expression demonstrates that the reporter 
gene chosen is functional. Measuring fluorescence is not without its pitfalls and one 
has to be careful to avoid false positive and false negative results.
One should generally show caution when measuring fluorescence because of auto 
fluorescence that can be interpreted as a positive signal. The included single 
transgenic ROSA26-EYFP mice therefore served as control that the fluorescence 
observed was indeed caused by EYFP expression and not background fluorescence.
Strebel et al. (Strebel et al., 2001) showed that GFP transfected haematopoietic cell 
lines undergoing apoptosis or necrosis have a decrease in fluorescence. Decreased 
EGFP fluorescence appears to be an early and very sensitive marker of cell death. 
This could lead to false negative cells when all the cells analysed are presumed to be 
alive. Indeed, when we took lymphocytes from our fluorescent mice expressing either 
GFP or EYFP and left these cells for couple of hours at room temperature to die, we 
detected, by flow cytometry, a significant proportion of GFP or EYFP negative cells, 
which were not present in the fresh sample (data not shown). T cells were more prone 
to loss of fluorescent signal compared to B cells and this may reflect the rate of death 
for these cells in vitro. Steff et al. (Steff et al., 2001) showed that the amount of 
fluorescent protein was similar in living and dying cells ruling out the possibility that
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fluorescent proteins can leak out of cells or are degraded. They suggested that 
fluorescent proteins are quenched by modifications in the intra-cellular milieu. Thus, 
dying cells expressing fluorescent proteins lose their fluorescence and can cause false 
negative results when not excluded from the analysis.
The results obtained by mating the iCre transgenic mice lines with the ROSA26- 
EYFP mouse line showed expression of EYFP in all lymphoid tissues. Except for 
expression of EYFP in the testis and ovaries for the Vav-iCre/EYFP mice and 
variegated expression in the testis for the hCD2-iCre mice, no EYFP expression was 
detected in other tissues.
The expression of EYFP in the testis of the iCre transgenic lines was unexpected.
The Vav-iCre transgenic mice used an expression vector that previously had been 
reported to be inactive in the testis. The testis from hCD2-iCre/EYFP mice displayed 
a variegated appearance indicating that Cre had been expressed in a proportion of the 
cells in this organ. It should be noted here that expression of hCD2 has never been 
noted in the testis of transgenic mice, nor has expression of GFP been detected in the 
testis of hCD2-GFP mice (de Boer et al., 2003).
It is not likely that this aberrant expression in testis is due to the site of integration of 
the transgene, as it is observed in two independent transgenic lines represented here, 
as well as in the other Vav-iCre lines that we have generated.
Prokaryotic sequences can have erratic performance in transgenic animals (Cui et al., 
1994). Those sequences contain numerous potential binding sites for mammalian
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transcription factors. These complexes formed between the prokaryotic DNA and the 
mammalian transcription factors could interfere with proper assembly on linked 
mammalian regulatory elements. Thus, it is likely that iCre contains DNA sequences 
that are able to activate transcription of the Vav-iCre and hCD2-iCre transgenes in the 
testis of these mice. Besides inappropriate expression in the testis, a number of other 
Vav-iCre lines that we generated exhibited mosaic expression of Cre in several non- 
haematopoietic tissues, including gut, brain, and muscle (data not shown). These 
results support the notion that some prokaryotic transgenes are able to cause aberrant 
transcriptional regulation of transgenes and neighbouring genes at the site of 
integration.
Besides inappropriate activation of loci prokaryotic sequences contain CG sequences, 
which are potential mammalian methylation sites, which can contribute to the creation 
of a silent state (Clark et al., 1997). The inactivation might be due to stable repressed 
complexes, hetero-chromatinisation, and/or methylation. Support that Cre can induce 
transcriptional silencing became evident in a number of hCD2-iCre transgenic lines 
that we have produced. The hCD2 LCR is able to direct tissue specific expression of 
mammalian transgenes in a position independent copy number dependent manner. 
However, in a number of hCD2-iCre lines, expression of Cre was either mosaic or not 
detectable (data not shown). In these mice, Cre was able to overcome the powerful 
regulatory elements of the hCD2 LCR and induce variegation, possibly by enforcing 
hetero-chromatinisation of the transgenic locus at the site of integration.
A transgenic line expressing Cre under the control of the hCD2 regulatory elements 
has been previously described, and according to expectation Cre activity was detected 
only in lymphoid organs (Wilson et al., 2002). However, the detection system used in
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this study did not allow the assessment of Cre expression in individual cells and 
therefore, the issue of variegation was not addressed.
In addition to the transcriptional deregulation, we also noted toxic effects of Cre 
expression. The Vav-iCre and hCD2-iCre transgenic lines presented in this report 
showed no detectable differences in thymic cellularity or development when 
compared to non-transgenic littermate controls. However, in a number of other hCD2- 
iCre lines and one Vav-iCre line the size of the thymus was decreased approximately 
ten fold when compared to non-transgenic littermates (unpublished data). High levels 
of Cre expression have been reported to be toxic in eukaryotic cells, possibly due to 
chromosomal rearrangements caused by recombination between cryptic ‘pseudo-loxP’ 
sites naturally found within the genome (Thyagarajan et al., 2000). Alternatively, 
integration of the transgene into the genome of these mice may have disrupted a gene 
important for thymic development. However, this possibility seems unlikely as the 
phenomenon was noted in a number of independently generated lines.
Pattern of Cre expression in T cells
EYFP expression in T cells from the R26R-EYFP and iCre double transgenic mice 
was analysed by flow cytometry. This showed that EYFP was expressed in all 
peripheral T cells of both Vav-iCre and hCD2-iCre double transgenic mice. T cell 
development is normally analysed by the expression of CD4 and CD8 on the 
thymocyte surface. When thymocytes were stained with these markers all phases from 
double negative to single positive showed close to hundred percent expression of
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EYFP in both Vav-iCre and hCD2-iCre double transgenic mice. Even though great 
care was taken to avoid dying cells from the analysis, a couple of cells were detected 
that have lost their fluorescence. These negative cells are most likely dying cells that 
are not longer fluorescent (Steff et al., 2001; Strebel et al., 2001).
It is possible to analyse further the double negative population by staining these cells 
with CD44 and CD25. This allows us to follow the development of the earliest T cells 
organised from DN1 to DN4. In both iCre transgenic lines, even the earliest 
progenitors to be found in the thymus express the EYFP reporter gene. However, 
analysis of hCD2-iCre mice revealed a small population of EYFP negative cells 
within the DN1, DN2 and DN3 gates. In hCD2-GFP mice, the amount of GFP 
negative cells decreased from the DN 1 stage until the DN4 stage were all cells were 
GFP positive. Less GFP negative cells were found in DN 1 from the hCD2-iCre 
R262R EYFP mice compared to hCD2-GFP mice. These differences could be due to a 
number of factors. The hCD2-iCre transgenic locus might be integrated in a more 
open chromosomal locus compared to the hCD2-GFP locus. This could allow earlier 
expression from the hCD2-iCre because it is more accessible to transcription factors. 
The differences could be in the mechanism used to report expression of each 
construct. Expression of Cre results in the deletion of the R26R-EYFP stop signal, 
which is a permanent modification that results in the expression of EYFP. All 
subsequent daughter cells therefore express EYFP and at levels determined by the 
ROSA26 locus. In contrast, expression of GFP is directly under the control of the 
hCD2 regulatory elements and will only be expressed when the hCD2-GFP transgene 
is actively being transcribed and at levels determined by the hCD2 regulatory 
elements.
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Pattern of Cre expression in B cells
All B cells analysed in the VAV-iCre and hCD2-iCre double transgenic mice 
expressed EYFP. This indicates that the deletion occurs early in B cell development.
Mosaic expression of GFP was seen in hCD2-GFP peripheral B cells, and this could 
account for the mosaic appearance in fluorescence within the Peyer’s patches of these 
mice. In contrast, all CD19+/IgD' immature B cells expressed GFP. The fact that all 
immature hCD2-GFP B cells express GFP while the expression mature B cells is 
variegated suggests that the hCD2-GFP construct is active in early stages of B cell 
differentiation, but gets turned off during later stages of B cell development.
Pattern of expression in other haematopoietic lineages
It has been reported previously that the Vavl regulatory elements were able to direct 
transgene expression in all haematopoietic cell types. Accordingly, expression of the 
EYFP reporter was noted in all granulocytes, monocytes and erythrocytes indicating 
that iCre had been expressed in all these cells and possibly their progenitors.
EYFP in erythrocytes showed a more varied profile in the Vav-iCre double transgenic 
mice. This can be due to the gradual loss of EYFP after the enucleation of these cells. 
This is because no new proteins are made in these cells and the half-life of
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erythrocytes is longer than the half-life of EYFP. In agreement with the known pattern 
of hCD2 expression in transgenic mice, no expression of EYFP or GFP was detected 
in these cell types in either hCD2-iCre/EYFP of hCD2-GFP transgenic lines, 
respectively.
Genomic organization o f HBP1
To gain better insights into the function of the HBP1 gene, we determined its genomic 
structure. These studies should provide valuable information for our gene knockout 
experiments aiming at dissecting the physiological roles of HBP1, and should 
facilitate our understanding on the transcriptional regulation of the HBP1 gene.
The initial strategy for obtaining HBP1 genomic locus depended on screening a 
lambda phage library. Phage clones containing the 5’ end of the HBP1 gene could not 
be obtained from critical phage clones, so a PAC clone, was used to obtain the HBP1 
genomic locus. Fragments from the PAC clone, were sub cloned to construct a 
sequencible contig. The sub clones were sequenced using a modified primer walking 
protocol. A map of the HBP1 gene was constructed utilizing the known mRNA 
sequence to establish the exon-intron organization of the gene (figure 18).
The mouse HBP1 gene is approximately 23 kb, coding for 10 exons and 9 introns. 
Exons 1 to 9 and a small portion of exon 10 code for the 514 amino acid HPB1 
protein.
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Different domains of the HBP1 protein have mapped to the cDNA sequence. 
Combining that information with the data about the gene’s organization, as shown 
here, reveals that the first RB binding domain of the protein falls within exon 2. While 
the second RB binding domain is within exon 6. The AXH domain of the protein is 
encoded by exons 5 to 7. Finally the HMG box of HBPlhas been mapped to exons 8 
and 9.
The role, if any, of the remainder of exon 10 remains to be determined. A comparison 
of human and mouse orthologs of HBP1 revealed that the 3’ untranslated region of the 
HBP1 gene is highly conserved (95% homology) between mouse and human. The 
significance of highly conserved 3’ UTR is not known. The HBP1 contains a 1.1 kb 
long 3' UTR which can be spliced. This alternative splicing alters the sequence of the 
five most C-terminal amino acids and includes or omits 1 kb of 3' untranslated region 
to the HBPl-encoding mRNAs. In general, 3' UTRs act in cis to regulate mRNA 
translation, stability, and localization through association with regulatory proteins or 
with antisense RNA. It is interesting that the identified antisense RNA by (Yelin et al., 
2003) aligns to the region that is alternatively spliced. It is possible that the 3’ 
untranslated region of HBP1 contains binding sites for regulatory proteins. The 
antisense RNA may enhance or abolish the establishment of complex protein 
interactions on the 3’ UTR that can affect HBP1 mRNA.
The genomic data provided in this thesis have been used to prepare the targeting 
construct for the generation of HBP1 knockout mice. This will be discussed in the 
following section.
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Floxing the HMG box o f HBP1
To inactivate the HBP1 gene in a temporal and positional manner an essential part of 
the gene one or several exons in general need to be flanked with loxP sites by 
homologous recombination. It is, however, necessary to ensure that the loxP sites do 
not interfere with the wild-type pattern of gene expression. Current technology for 
homologous recombination in ES cells requires the concomitant insertion of 
selectable markers into the target gene. These selectable markers are expression 
cassettes conferring antibiotic resistance, such as the Neomycin resistance gene.
These cassettes contain strong promoters and prokaryotic DNA and their presence can 
disturb the expression of the targeted and sometimes also surrounding genes in 
unpredictable ways (Meyers et al., 1998). To prevent the possibility of unwanted 
effects on target genes the removal of the selectable marker is recommended in gene 
knockout strategies.
For this reason, we decided to use tri-lox strategy. This strategy involves the use of 
three loxP sites, positioned such that neo, as well as the essential region of the gene of 
interest, is floxed. A partial Cre-mediated recombination event then removes neo, 
leaving the essential region floxed.
To circumvent the possible early embryonic lethality and to study the later functional 
significance of HBP1 in individual organs, a conditional knockout strategy involving 
the bacterial Cre/loxP recombinase system was chosen. A study comparing the 
recombination frequencies of loxP sites in different alleles in vivo found marked 
differences in recombination frequencies. The distance between LoxP sites in the
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various targets tested explained in part these differences. The construct with the 
smallest floxed region showed a higher percentage of deletion of the floxed allele 
compared to the alleles with larger floxed regions (Vooijs et al., 2001). To keep the 
loxP sites as close as possible to each other to ensure a higher degree of 
recombination, we put loxP sites around a crucial region of the HBP1 gene rather then 
around the entire HBP1 locus.
Transcription factors are defined as proteins that bind to regulatory regions in the 
genome and help control gene expression. As sown previously in this thesis, removal 
of the HMG box allows the protein to stay in the cytoplasm and stops it from binding 
to DNA. Thus, removal of the HMG box will stop HBP1 functioning as a 
transcription factor. Unfortunately, during the course of this work, it was reported that 
HBP1-DNA binding is not required for inhibition of Wnt-8-catenin transcriptional 
activation (Sampson et al., 2001). This means that removing the DNA binding domain 
will not abolish all the functions of HBP1. Thus, the results obtained only address the 
function of HBP1 as a transcription factor when its DNA binding activity is 
indispensable.
To flox the HMG box a floxed neo resistance marker, a necessary part of the initial 
floxed allele, was cloned 5’ of the HMG box and a single loxP site was cloned 3’ of 
the HMG box.
Regions containing multiple loxP sites can be partially eliminated by transient Cre- 
expression. As shown in figure 20, the HBP1 floxed allele contained three loxP sites. 
Cre mediated recombination could theoretically occur between any two of the three
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loxP sites, generating offspring with three possible genotypes. Mice with different 
genotypes were identified by southern analysis. This strategy yielded the complete 
HMG box knockout and a strain devoid of neo but containing the floxed HMG box. 
Deletion of the HMG box alone (without deleting the neo) or no recombination was 
not observed in the animals screened.
Although based on no more than circumstantial evidence, it seems that partial 
deletions of tri-lox alleles are biased towards one of the two possible forms. The 
analysis of the presented tri-lox allele indicates that the neo is preferentially deleted 
compared to the HMG box. It has to be noted that the distance of loxP sites 
surrounding the neo was smaller then the distance of loxP sites surrounding the HMG 
box. However, at least for the ranges used here, it seems unlikely that this will 
influence the partial Cre lox deletion. Furthermore, other studies using the tri-lox 
strategy have also seen a preferential deletion of the neo gene (Holzenberger et al., 
2000; Leneuve et al., 2003). It seems more likely that the proximity to prokaryotic 
DNA, the natural environment for loxP sites, the nucleotide sequences immediately 
surrounding the loxP sites, or the state of chromosomal structure may affect the 
likelihood of recombination.
In vivo and in vitro protocols have been established to remove the neo cassette from 
the targeted allele. In the first protocols the tri-lox configurations were converted into 
final floxed conditional alleles by the transient transfection of targeted ES cell clones 
in vitro with Cre-expressing plasmids, prior to chimera production(Gu et al., 1994). 
While this method has been used successfully in generating conditional knockouts, it 
does require additional manipulation of ES cells. This means additional
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electroporation and prolonged culture of already targeted ES cells. This may reduce 
ES cell totipotency and the probability of germ-line chimeras developing from a 
particular clone.
To circumvent the extra ES manipulation it is possible to eliminate the floxed marker 
fragment selectively in vivo. The established protocols use Cre transgenic mouse lines 
capable of inducing partial loxP recombination (Holzenberger et al., 2000; Leneuve et 
al., 2003). Heterozygous F0 tri-lox mice are bred to the Cre transgenic mouse line to 
obtain double transgenics in the FI generation, which should be mosaic for the Cre 
deletion. These mosaic mice are then crossed with wild-type mice. F2 animals are 
then screened for the desired recombination. Thus, an additional mouse generation (9- 
10 weeks) is required to accomplish selection cassette excision.
Here we explored an alternative strategy based on partial in vivo Cre recombination in 
the germline and allelic segregation in the next generation. We used ES cells that 
contain a Protamine Cre expression cassette for in vivo Cre expression. It was 
previously shown that these ES cells can mediate the efficient recombination of a Cre 
target transgene in the male germ line, but not in other tissues (O'Gorman et al.,
1997).
This has the advantage that the recombination occurs in the germ-line of F0 
(chimeras). FI animals are then screened for the desired recombination. This saves the 
need for an F2 generation to establish the mouse line. Thus, this method saves 9 to 10 
weeks in breeding time compared to the previous described method. Moreover, in the 
in vivo strategy, the initial ES cell clones, obtained by homologous recombination, are
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available for blastocyst injection at an earlier time-point, without additional in vitro 
manipulations, so that unexpected difficulties with the germ-line transmission of 
particular clones or mutations will be detected sooner.
HBP1 knockout mice
To our surprise homozygous HBP1 knockout mice were bom. This might be due to 
the fact that we only removed the DNA binding domain of HBP1. We have only 
abolished the function of HBP1 when the DNA binding is indispensable for its 
functioning. In all other cases, the HBP1 mutant without the HMG box might still be 
functioning as wildtype.
Although both HBPl4™0"™ 0 and HBP1nHMG/nHMG were obtained in this thesis 
efforts were concentrated on the HBP1ahmg,ahmg mice. Genomic southern blot and 
PCR analyses proved the proper homologous recombination. Northern blot 
hybridizations were performed to control for the presence of the right-truncated 
mRNA transcripts. In HBP1ahmg/ahmg mice, the expected truncated HBP1 transcript 
lacking the 470 nucleotides, corresponding to exons 8 and 9, was found. The 
combined Southern and Northern analyses proved that the targeting event had 
removed the portion of the gene encoding the HMG box domain.
It remains possible that the residual expressed N-terminal region of HBP1, containing 
the AXH domain, retains all the functional properties of the full-length protein. To 
dismiss the possibility we tested whether the truncated protein still can act as a
192
transcription factor. As said before transcription factors are defined by their ability to 
bind DNA. Furthermore, it was shown previously that full length HBP1 interacts with 
the FT 1 region of the LCR in a sequence-specific manner and contributes to the 
regulation of LCR function (Zhuma et al., 1999). Thus, if we could show that the 
binding to FT1 by HBP1 was abolished in the knockout mice, we could conclude that 
truncated HBP1 was not longer acting as a transcription factor. To demonstrate that 
the truncated HBP1 has lost the ability to bind DNA, a band-shift experiment was 
performed using the thymus nuclear extract with an oligo-nucleotide containing the 
HBP1 HMG box-binding motif. The experiment revealed that HBP1ahmg/ahmg 
nuclear extracts have lost the ability to bind to the HBP1 recognition sequences in 
electrophoretic mobility shift assays (figure 24). Thus, the HBP1ahmg/ahmg mice lack 
the ability to bind to the hCD2 LCR. This confirms that deletion of the HMG box 
inactivates HBP1 whenever DNA binding is indispensable. We have to assume that 
HBP1 act as wild type in all cases where DNA binding is not necessary for its 
function.
Functional analysis o f T cells in HBP1mMG/AHMG mjce
We have demonstrated that HBP1 knockout mice are generally healthy and that they 
lack HBP1 function. These mice develop normally in utero, as the knockout allele is 
inherited in a ratio expected by Mendelian genetics. No clear phenotypic 
abnormalities were noted upon assessment of fresh tissues. Taken together, these 
findings indicate that the DNA binding activity and sub-cellular localisation of HBP1 
DNA binding is dispensable for development and function through early adulthood.
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K.M. Lin et al (Lin et al., 2001a) suggested that HBP1 is actively involved in the 
differentiation process during haematopoiesis. Furthermore, the haematopoietic 
system provides an excellent model for studying the function of HBP1 in cell 
proliferation, lineage commitment, differentiation, and maturation because each stage 
is well defined by the expression of cell surface molecules. Therefore, we decided to 
inspect the haematological compartment in greater detail. Preliminary FACS analysis 
of the T cell, B cell and myeloid lineages in homozygous and heterozygous HBP1 
knockout mice revealed no obvious abnormalities when compared with wild-type 
littermates. These results are preliminary, and we are currently carrying out further 
detailed analyses on larger numbers of mice of both sexes and different ages to detect 
whether there are more subtle effects. As no alterations in steady-state haematopoiesis 
were observed, we investigated how T cells from these mice react to apoptotic and 
proliferative stimuli.
HBP1 and apoptosis
Results from HBP1 transfection experiments suggest that the HBP1 protein may 
induce apoptosis. Thus, one would predict that inactivation of the endogenous HBP1 
should inhibit the apoptotic death process. This hypothesis was investigated by 
stimulating thymocytes from h b P1ahmg/ahmg mice with different apoptotic stimuli. 
Thymocytes from h b P1ahmg/ahmg mice exhibit roughly the same levels of apoptosis 
after treatment with low dose y-radiation or dexamethasone. These data indicate that 
even though multiple apoptotic pathways were activated no effect was seen on the rate
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of apoptosis in h b P1ahmg/ahmg thymocytes. These seemingly conflicting results 
might be due to a dosage effect of HBP1 on apoptosis and only when high levels of 
HBP1 are present an effect on apoptosis is seen. These results might also indicate that 
the results obtained with the EYFP fusion protein are an artificial artefact. More 
experiments need to be done to address these questions.
HBP1 and proliferation
HBP1 has been shown to be a negative regulator of the cell cycle. Accordingly, 
ablation of HBP1 might increase the proliferation potential of cells from these mice. 
To investigate the possible role of HBP1 in modulating mitogenic signalling of 
lymphocytes we assessed aspects of cellular proliferation of T cells of 
HBP1ahmg/ahmg and wild type mice subsequent to T-cell receptor stimulation. To 
follow the fate of individual T cells throughout activation and clonal expansion, we 
loaded the cells with the fluorescent dye carboxyfluorescein succinimidyl ester 
(CFSE) prior to stimulation. CFSE segregates equally between daughter cells upon 
cell division resulting in the sequential halving of cellular fluorescence intensity with 
each successive generation. When analyzed by flow cytometry, this sequential halving 
of fluorescence is visualized as reduced fluorescent intensity of cohorts of cells and, 
thus, can be used to track cell division in populations of proliferating cells. It was 
found that within 3 days of stimulation T cells from h bP1ahmg/ahmg mice respond 
more vigorously to the CD3 stimulation (as shown by increased CFSE dilution) 
compared to T cells from wild type littermates. This was true for both CD4 and CD8 
T cells from HBP1ahmg/ahmg mice although the difference seen was larger for CD8 T
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cells compared to CD4 T cells. CD8 cells are more responsive to anti-CD3 
stimulation in vitro compared to CD4 cells. Thus, it is unclear if HBP1 differentially 
affects CD4 and CD8 cells or if the difference is due to the assay used.
HBP1 may control either entry into cell cycle from resting cells or progression 
through the cell cycle. Analysis of cell division showed that the fraction of cells 
triggered through the TCR to divide (percent divided) but not the mean number of 
divisions of the dividing cells (proliferation index) was significantly increased in both 
CD4 and CD8 T cells. Together this might indicate that HBP1 prevents the cell from 
entering the cell cycle but does not affect the cell cycle once the cells are in cycle.
It is possible that HBP1ahmg/ahmg lymphocytes respond with increased cell 
proliferation because they are in a "poised for activation" state and, thus, predisposed 
for immediate response to stimulation. Previously, gene-targeting of LKF and JAK3 
(Grossman et al., 1999; Kuo et al., 1997) demonstrated the presence of such pre­
activated lymphocytes with elevated CD69 and/or CD25 levels. To explore this 
possibility, FACS analysis of h b P1ahmg/ahmg lymphocytes for CD69 and CD25 was 
performed. CD69 and CD25 were absent from non-stimulated wild-type T cells, while 
intermediate levels of CD69 and CD25 expression were found on non-stimulated 
HBP1ahmg/ahmg lymphocytes. This indicates that these cells might be in a pre­
activated state, even in non-stimulating conditions. Post-stimulation the differences in 
the amount of CD69 and CD25 expression were still observed. From these initial 
experiments, we conclude that T cells in H B PI^m07^ 1^0 mice are in a pre-activated 
state and are hyper-responsive to signals through the TCR.
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Possible roles fo r HBP1.
Our results with the mice, in which the HMG box of HBP1 has been
removed, support a role for HBP1 as a cell cycle inhibitor in differentiated tissues. 
HBP1 is constantly up regulated in differentiation and under conditions of cell cycle 
arrest in muscle, myeloid, erythroid, and other cell types while it is expressed at low 
levels in cycling cells. Consistent with this, we showed that lymphocytes from 
HBP1ahmg/ahmg mice are more likely to enter the cell cycle compared to wildtype 
mice while cycling cells underwent the same amount of mean divisions. Furthermore, 
over expression of HBP1 in transgenic animals resulted in a delayed G1 phase of the 
first cell cycle. The progression of G1 phase in the subsequent cell cycles was not 
determined (Shih et al., 2001). Thus, HBP1 blocks cell cycle entry but does not affect 
the cell cycle of cycling cells.
We propose that HBP1 sets the cellular threshold to mitogenic signals. In this model 
increased levels of HBP1 dampens the mitogenic response while cells with low levels 
of HBP1 have an increased mitogenic response. Consistent with this the lymphocytes 
lacking fully functional HBP1 are "poised for activation".
It is unclear at the moment how HBP1 regulates the threshold to mitogenic signals. 
HBP1 can form a complex with retinoblastoma and this complex can enforce a 
proliferation barrier in differentiated tissues (Tevosian et al., 1997). HBP1 alone or in 
complex with retinoblastoma can affect the expression of different target genes such 
as the cell cycle regulators cyclin D1 and N-myc and genes associated with terminal
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differentiation such as histone HI0. It is possible that the phenotype seen by HBP1 is 
through the regulation of expression of these target genes. Future experiments will 
address the question of target gene expression by a combination of western and 
northern blot analysis.
Clinical relevance
A major question for tumour suppression is how normal proliferation controls are lost 
in the early stages of certain cancers, in which there is a proliferation of differentiated 
cells. The phenotype observed in lymphocytes from HBP1ahmg/ahmg mice is clearly 
not leukaemia, the hyper-responsiveness of the cells indicates that certain pathways 
that regulate the cell cycle are affected and mis-regulation of the cell cycle might lead 
to cancer. The hyper-proliferative response in h bP1ahmg/ahmg mice suggests that 
HBPl could have a tumour suppressor function. Consistent with the notion of tumour 
suppression, the HBPl gene resides in human chromosome 7q31. Loss of 
chromosome 7 or deletions of its long arm (7q-) are recurring chromosome 
abnormalities in myeloid disorders. These aberrations are associated with 
myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML), in particular 
with therapy-related MDS/AML (t-MDS/t-AML) after therapy with alkylating agents 
or secondary MDS/AML after occupational exposure to chemical mutagens. A 
commonly deleted region was defined by the MDS/AML cases and was a genomic 
region of approximately 20 Mb encompassing the terminal part of band 7q22 and the 
entire band 7q31. Although the commonly deleted genomic region is still large, HBPl 
is a good candidate as a tumour-suppressing gene.
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Thus, a loss-of-function mutation in HBPl results in an enhanced cell cycle response 
in the lymphocytes and may be important in tumour onset. Future work will be 
directed at the importance of HBPl in tumour suppression and in signalling networks 
that govern proliferation.
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